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A major problem in chemotherapy is that many cancers are intrinsically drug resistant 
or later become resistant. Resistance to one drug is often accompanied by cross­
resistance to many unrelated drugs and this is known as multidrug resistance (MDR). 
MDR is commonly associated with a 170kDa glycoprotein called P-glycoprotein (P-gp), 
which is thought to act as an ATP-dependant drug efflux pump and which is encoded 
for by the MDRI gene in humans. MDRI transcription can be initiated by various 
mechanisms such as demethylation of MDRI promoter sequences or translocation of the 
MDRI gene. In cells already expressing P-gp this expression can be increased by 
mechanisms such as amplification of the MDRI gene copy number or an increase in the 
rate of mRNA translation or stability. However the focus of many studies is on the 
regulation of MDR! transcription through the binding of transcription factors to specific 
sequences in the MDR! promoter region, in particular an inverted CCAAT element 
known as the Y-box and the -55GC box.
The current study investigated the mechanisms for MDR in a series of K562 derived 
MDR cell lines demonstrating varying levels of low level MDR. Levels of resistance of 
each of the K562 MDR cell lines were all confirmed by performing vinblastine and 
paclitaxel cytotoxicity assays on the cell lines. Northern hybridisation of total RNA 
isolated from K562 MDR cells indicated a positive correlation existed between the level 
of MDRI mRNA expressed in the MDR cells and the level of MDR displayed by the 
cells. Southern blot hybridisation of DNA from the cells with an MDRI probe indicated 
that increase of MDRI mRNA in the K562 MDR cells was not due to amplification of 
the MDRI gene. Bisulphite genomic sequencing of K562 and MDR cell lines revealed 
the MDRI promoter in both cell lines to be almost completely unmethylated apart from 
two distinct sites of methylation in K562 cells at two CpG sites downstream of the 
transcription start at +421 and +423bp respectively.
xiii
Treatment of the K562 cells with the histone deacetylase inhibitor Trichostatin A (TSA) 
increased the cells resistance to epirubicin, however no effect was seen upon TSA 
treatment of the K562 MDR cells. This suggests there is a difference in the chromatin 
structure in the two cell lines.
It was further demonstrated that resistance levels of K562 derived MDR cell lines 
declined with increasing time in drug free culture, but could be restimulated by short 
term drug exposure to P-gp substrate drugs, in some cases in as little as after 4 hours 
exposure, suggesting a transcriptional mechanism of MDRI upregulation is likely to be 
responsible for the induction. Consistent with this, mRNA stability studies indicated 
that the drug induction of K562 MDR cells that resulted in increased MDR and MDRI 
mRNA levels was not mediated by an increase in the stability of MDRI mRNA, as the 
rate of mRNA decay was the same in treated and untreated control cells. However, 
electrophoretic mobility shift assays (EMSA) of the two major transcription factors 
involved in MDR! regulation, the Y-box binding protein (identified as NF-Y) and the - 
55GC box binding protein indicated no difference in nuclear levels of these two proteins 
in untreated and drug induced cells. Thus the mechanism for up-regulation of MDRI 
activity in K.562 MDR cell lines is most likely due to activation via alteration of other 






Cancer is a leading cause of death in industrialised society, resulting in over six million 
deaths per year (Ferley et al., 2001). The process of carcinogenesis is a multistage 
process, with the emergence of a cancerous cell population the result of the sequential 
accumulation of alterations in genes responsible for the control of cellular proliferation, 
cell death and the maintenance of genetic integrity (Vainio et al., 1992; Balmain and 
Harris, 2000).
Cancer is generally treated by surgery, radiotherapy, chemotherapy, or a combination of 
the three (Heilman and Vokes, 1996). Surgery is the oldest and most widely used 
treatment and with advances in new technology minimising invasive surgery it can be 
quick and effective (Bremers et al., 1999). However surgery is unable to treat cancers 
that have metastasised throughout the body and is also not appropriate to treatment for 
tumours that are attached to vital organs or for malignant disorders of the blood. 
Radiotherapy involves exposing dividing cancer cells to ionising radiation and aims at 
inflicting cellular damage sufficient to cause cell death (Price and Sikora, 2000). 
Although not always fully effective, radiotherapy is often safer for elderly patients who 
may be unable to recover from the trauma of surgery, and like surgery, is inappropriate 
for the treatment of metastatic tumours. Chemotherapy, another treatment strategy, 
involves the systemic administration of an anticancer drug with the aim of achieving 
selective toxicity to cancer cells by targeting differences between normal and cancer 
cells. Chemotherapy has the advantage of being effective against widely disseminated
Chapter 1: Introduction
tumour types (Heilman and Vokes, 1996). This treatment has been in use since the 
1940s and usually involves interference with tumour cell replication and/or transcription 
(Heilman and Vokes, 1996; Gottesman, 2002). During this time over one hundred 
cytotoxic agents have been approved for the treatment of cancer however the efficacy of 
chemotherapy has been hampered by the occurrence of dose limiting side effects and 
the development of drug resistance.
1.2 The Problem of Multidrug Resistance in Cancer
The aim of chemotherapy is to eliminate cancer cells. This has been successfully 
achieved in some cases by the use of various combinations of anti-neoplastic drugs 
(Ling, 1994). However a major problem of chemotherapy is that many forms of cancer 
are intrinsically refractory to drug treatment and others that initially respond, later 
become resistant (Ling 1994). Although there are many factors that may lead to the 
failure of chemotherapeutic treatment of cancer, it is thought that one of the main 
contributors is the development of drug resistance at the cellular level (Rischin and 
Ling, 1993). It has also been found that resistance to one drug is often accompanied by 
cross-resistance to a broad range of structurally and functionally unrelated agents, a 
phenomenon known as multidrug resistance (MDR) (Rischin and Ling, 1993). MDR 
was originally characterised by reduced drug cytotoxicity due to the decreased 
intracellular accumulation of several drugs (for review see Kane, 1996). MDR cells are 
typically resistant to small hydrophobic, natural product drugs such as anthracyclines 
(doxorubicin, daunorubicin, epirubicin and idorubicin), Vinca alkaloids (vincristine and 
vinblastine), epipodophylotoxins (etoposide and teniposide), taxanes (paclitaxel and 
taxotere) and amsacrine (Sonneveld, 2000; Kane, 1996). In some cancers an extended 
form of MDR may also be seen where cells are resistant to additional non-classical 
MDR drugs such as methotrexate and chlorambucil (Marks et al., 1996).
Many different drug resistant mechanisms have been attributed to the development of 
MDR and rather than operating singularly, it is most likely that many of these 
mechanisms operate concurrently. Much of MDR research has focused on the 
overexpression of drug transporter proteins, for example P-glycoprotein (P-gp) (for
Chapter 1: Introduction
review see Harrison, 1995; McKenna, 1997; Ross, 2000) and the multidrug resistance- 
associated protein (MRP) (for reviews see Borst, 1999; Ishikawa, 2000; Leslie, 2001). 
P-gp and MRP are both members of the ATP-binding cassette (ABC) superfamily of 
transporters and are involved in the extrusion of cytotoxic drugs from cells and thereby 
reducing intracellular drug accumulation and hence decreasing the cytotoxic effect on 
the cells. P-gp and MRP exhibit similar multidrug resistance phenotypes, for example 
they both confer resistance to vinca alkaloids, anthracyclines and epipodophylotoxins, 
however P-gp is able to bestow greater resistance to taxanes (Kane, 1996; Leslie, 2001). 
The taxane paclitaxel is a good indicator of P-gp mediated MDR as it is not a substrate 
for MRP (Breuninger et al., 1995; Grant et al., 1994). Paclitaxel specificity for P-gp 
over MRP has been demonstrated in NIH/3T3 MRP transfectants (Breuninger et al., 
1995). In this study, MRP transfected cells displayed increased resistance to several 
lipophilic drugs, however increased resistance was not observed for paclitaxel 
(Breuninger et al., 1995).
MRP1, one of the 6 functionally characterised genes for MRP, effluxes drugs in vivo via 
a co-transporter mechanism with reduced glutathione (GSH) (Harrison, 1995; Ishikawa, 
2000). Therefore it is probable that the amount of available GSH and associated GSH- 
dependant enzymes will affect drug resistance. The overexpression of these conjugation 
enzymes, particularly glutathione S-transferase (GST), has been seen in many human 
cancers (Gekeler, 1992; Gurbuxani, 2001; Harrison, 1995). GST overexpression has 
also been associated with increased P-gp expression and it is thought that GST may 
present MRP with its substrate (Harrison, 1995).
Another possible mechanism causing MDR is qualitative or quantitative alterations to 
the enzymes targeted by cytotoxic drugs. Topoisomerases are a group of enzymes 
involved in transcription, DNA repair and cell proliferation by breaking and re-ligating 
DNA strands. Alterations in expression or function of these enzymes, for example 
topoisomerase II, have been associated with MDR (for reviews see Harrison, 1995; 
Lohri, 1997; McKenna, 1997).
Many chemotherapeutic drugs function by inducing apoptosis (programmed cell death), 
for example etoposide, VM26, m-AMSA, dexamethasone, vincristine, cisplatin, 
cyclophosphaminde, paclitaxel, 5'-fluorouracil (5-FU) and adriamycin (Hannun, 1997).
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However many cancers show intrinsic resistance to apoptosis, or acquire resistance 
upon chemotherapeutic drug treatment, thus rendering them MDR. This is thought to 
arise due to mutation or defects in cells’ apoptopic signal pathways or regulatory 
mechanisms such as the p53 tumour suppressor protein. Functional p53 acts as a 
transcription factor that regulated the expression of a large number genes involved in 
cell cycle control, the induction of apoptosis, genetic stability, DNA repair, 
differentiation control and angiogenisis (reviewed in Stewart and Kleihues, 2003; 
Vogelstein et al., 2000; Carr et al., 2000; El-Deiry et al., 1998). The p53 tumour 
suppressor gene is the most frequent gene mutated in cancer (Greenblatt et al., 1994; 
Hollstein et al., 1991) and is thought to be mutated in over 50% of human cancers 
(Hartwell et al., 1994; Shaw et al., 1992; Lane and Fischer, 1996). Its association with 
tumour development is evident in p53 knockout mice, which show a high incidence of 
tumour development at an early age (Donehower, 1996). In addition, germ line mutation 
of one p53 allele in humans gives rise to the Fi-Fraumeni cancer susceptibility 
syndrome (Donehower, 1996; Srivastava et al., 1990). The induction of apoptosis in 
cancer cells is a common mechanism of action of a number of chemotherapeutic drugs, 
consequently loss of the p53 apoptopic pathway may influence the sensitivity of cells to 
the drug. In vitro studies have reported that loss of p53 function reduced cellular 
sensitivity to 5-FU, if not abolishing it entirely (Bunz et al., 1999; Longley et al., 2002; 
Hwang et al., 2001). For example one study by Bunz et al., (1999) found that loss of 
functional p53 in colon carcinoma cells made the cells resistant to apoptosis by 5-FU 
compared to parental cells with wild type 53. In addition, p53 null mice were found to 
be resistant to apoptosis triggered by 5-FU (Pritchard et al., 1998).
Mutations or gene translocations of anti-apoptopic genes such as bcl-2 and bcl-XI, can 
lead to protein overexpression and thus resistance to apoptosis (Chresta, 1999; Clynes, 
1998; Hannun, 1997; Pan, 1997). An example of this is seen in chronic myeloid 
leukaemia whereby greater than 90% of patients demonstrate the Philadelphia 
chromosome, that is, a reciprocal chromosomal translocation of t(9:22) resulting in the 
generation of a bcr/abl translocated gene (Wu et al., 1999; Langabeer et al., 2002; 
Sonoyama et al., 2002). The abl gene encodes c-abl tyrosine kinase which induces 
apoptosis in response to DNA damage. However, the fusion protein that results from the 
bcr/abl translocation acts as an oncogene and confers apoptotic resistance to DNA 
damage (for reviews see Skorski, 2002a; Skorski, 2002b). Studies demonstrated the
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bcr/abl translocation enables the proliferation of haematopoietic cells under deprived 
conditions (Sonoyama et al., 2002) and prolongs cell cycle arrest at the G2M phase 
(Nishii et a\., 1996).
1.3 P-glycoprotein mediated MDR
Studies using in vitro drug resistant cell lines have indicated that a vast array of 
mechanisms can contribute to overall MDR. However, research has shown that a major 
contributor to drug resistance is the expression of the 170kDa transmembrane 
glycoprotein drug transporter P-glycoprotein (P-gp) (for review see Harrison, 1995; 
McKenna, 1997; Ross, 2000). P-gp belongs to the ATP-binding cassette (ABC) 
superfamily of transporters and is thought to act as an ATP-dependant membrane efflux 
pump (for review see Baggetto, 1997).
P-gp has been predicted to be composed of two homologous halves, each containing six 
putative ex helix trans-membrane domains and an ATP binding domain (Figure 1. la and 
b). These two halves of P-gp are thought to be joined by a linker region and evidence 
has shown that both nucleotide binding sites, which are contained on the C-terminus of 
each half and responsible for ATP binding and hydrolysis, are necessary for transport of 
P-gp substrates out of the cell (Ambudkar et al., 1999). The dependence P-gp activity 
on ATP was determined by mutational analysis on these C-terminus ATP binding 
domains, whereby mutations resulted in cessation of P-gp activity (Ruetz et al., 1994). 
Some controversy over the secondary structure of P-gp exists and a more recent “dual 
channel model” has been proposed by Jones and George (2000) and is shown in figure 
1.1c. This model proposes that the substrate binding site is formed from large 
intracellular loops which attach a-helix bundles to the transmembrane domain which 
consists of two (3 barrels. ATP binding sites are thought to be beneath and between 
these [3 barrels (Jones and George, 2000)
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Figure 1.1 Structure of P-gp (a) Linear representation of the human P-glycoprotein 
inserted within the cell membrane showing the twelve putative a helix transmembrane 
regions, ATP binding domains (NBD1 and NBD2), (b) Tertiary stucture model showing 
ring of helices forming a single membrane channel (taken from Jones and George, 
2000), (c) Alternative model proposed by Jones and George (2000) with double (3 barrel 
transmembrane domain.
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Two classes of P-gp, encoded by the genes MDRI and MDR2, have been identified in 
the human genome (Chin et al., 1989). However experiments where MDRI or MDR2 
cDNA have been transfected into drug sensitive cells have demonstrated that only the 
MDRI encoded P-gp bestows an MDR phenotype (Ueda et al., 1989, Roninson et al., 
1986).
Cell lines that express P-gp are able to take up cytotoxic drugs but their cellular 
accumulation is limited by the rate of their drug efflux by P-gp and hence by the level of 
expression of P-gp (Chen & Simon, 2000). P-gp is able to efflux vinca alkaloids, 
anthracyclines and epipodophylotoxins, taxoids as well as other anti-neoplastic drugs 
such as actinomycin D. Examples of some of the many different classes of compounds 
that interact with P-gp are listed in Table 1.1.
P-gp mediated drug resistance has been shown to be reversed by agents known as 
resistance modulators or chemosensitising reagents. There are several classes of 
modulators of P-gp, these include calcium channel blockers, immunosuppressive 
agents, vinca alkaloid analogues, steroidal agents, cyclosporin analogues, calmodulin 
antagonist and other miscellaneous hydrophobic agents (Clynes, 1998). P-gp 
modulation mechanisms are not fully understood and may differ for different 
compounds. However, the three main mechanisms by which modulators are thought to 
act are (i) via the blockage of drug transport by direct high affinity binding with the P­
gp binding sites through competitive or non-competitive interaction, and therefore 
inhibiting the binding of cytotoxic drugs; (ii) via inhibition of ATP binding, ATP 
hydrolysis or coupling of ATP hydrolysis to the translocation of the substrate; (iii) via 
disruption of the cells lipid membrane through interaction with the membrane 
environment or modification of drug-membrane interaction (Ambudkar, et al., 1999; 
Muller et al., 1995). The main concern with P-gp mediators is that many are toxic at 
required doses and are therefore not suitable for therapeutic use in vivo. Even some of 
the more commonly clinically used modulators such as verapamil, can cause 
detrimental side effects such as cardiac problems (Ozols, 1987).
The reversal of drug resistance by verapamil in in vitro cytotoxicity assays is useful as it 
is a good indicator that P-gp mediated drug resistance is operational in a cell line.
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Table 1.1 Representative compounds that interact with P-glycoprotein (taken from 
Ambudkar et al., 1999)
Anticancer drugs Hormones
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Although the exact mechanism of how verapamil reverses P-gp mediated MDR is not 
fully understood, it is thought that verapamil itself is a substrate for P-gp and binds with 
high affinity directly to P-gp. This binding of verapamil to P-gp inhibits the binding of 
cytotoxic drugs thus, the drugs are not excluded from the cell (Clynes et al., 1998; 
Muller et al., 1995; Gottesman and Pastan, 1989; Cano-Gauci, and Riordan, 1987). 
Verapamil is significantly less capable of reversing drug resistance in cell lines that 
overexpress MRP as, unlike P-gp, verapamil does not directly interact with MRP 
(Clynes et al., 1998; Breuninger et al., 1995; Coley et al., 1991; McGrath et al., 1989). 
McGrath et al. (1989) demonstrated this by using an 1251-labeled photoaffinity analog 
of verapamil to label proteins associated with drug resistance in the cell membranes of 
the cell lines HL60/Vinc, which overexpress P-gp, and HL60/Adr, which overexpress 
MRP. In this study it was shown that only the P-gp containing membranes of 
HL60/Vinc cells were labelled and no selective labelling occurred in the membranes of 
the HL60/Adr cells.
1.3.1 P-glycoprotein expression in normal tissues
Studies have demonstrated MDRI gene expression in many normal tissues. A high level 
has been found in the apical membrane of the intestinal epithelial cells of both the small 
and large intestines, adrenal gland, bilary canalicular membrane of hepatocytes and in 
the lumenal membrane of proximal tubular epithelial cells in the kidney (Croop, 1989; 
Goldsmith, 1993; Madden, 1993; Morrow, 1994; Thiebaut, 1987). It is also abundant in 
the luminal membrane of the endothelial cells lining the small blood capillaries in the 
brain and testes (Cordon-Cardo, 1989; Madden, 1993). Moderate levels are also seen in 
the luminal membrane of the endometrium of pregnant uterus (Arceci, 1988; Madden, 
1993) and in CD34-positive bone marrow cells, normal peripheral blood lymphocytes 
and hematopoietic stem cells (Chaudhary, 1991).
Although the precise function of the MDRI gene product, P-gp, is unknown, the pattern 
of gene expression is indicative of a physiological role in the transport of organic 
molecules, such as toxins or steroids, from normal cells and tissues. In an effort to
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confirm a physiological importance for P-gp, Schinkel et al. (1998) developed P-gp 
knockout mice. The two genes, MDRla and MDRlb, that encode P-gp in mice together 
show a combined tissue distribution similar to that of MDRI in humans. The P-gp 
knockout mice showed no obvious physiological or anatomical abnormalities and also 
appeared biochemically and haematologically normal. However when these mice were 
challenged with drugs, they demonstrated increased drug accumulation in the brain and 
central nervous system, and decreased intestinal and biliary excretion. Therefore it was 
concluded that although P-gp appeared not to be essential for basic physiological 
functions, it does play an important role in forming a barrier in the protection of 
sensitive organs, such as the brain and the intestines from toxin penetration (Schinkel, 
1998; Schinkel, 1999).
1.3.2 P-glycoprotein expression in cancer in vivo and in vitro
P-gp has been demonstrated in many human cancers. In some cases these cancers are 
derived from tissues in which MDRI is normally expressed, such as those mentioned 
above. In other cases where the cancer is derived from tissues not normally expressing 
P-gp, the cancer expresses P-gp either after exposure to chemotherapeutic drugs or 
during carcinogenesis (Gottesman and Pastan, 1993).
There is a vast quantity of literature which correlates MDRI expression and P-gp 
activity with MDR in culture model systems. A correlation between P-gp expression 
and clinical MDR has been observed, particularly for haematologica! malignancies 
(Pirker et al., 1991, Leith, 1995; te Boekhorst, 1995), and to a lesser extent solid 
tumours (Schneider et al., 1989; Cheng et al., 1993; Coley et al., 2000; Ng et al., 2000). 
There is also some suggestion of a correlation between patient prognosis and P-gp 
expression. This has been demonstrated in both haematological malignancies, such as 
acute myeloid leukaemia (Borg et al, 1998; Senent et al, 1998), promyelocytic 
leukaemia (Michieli et al, 2000), acute non-lymphocytic leukaemia (Damiani et al., 
1998), and myelodysplastic syndromes (Wattel et al, 1998) and in solid malignancies 
such as hepatocellular carcinomas (Ng et al, 2000) and soft tissue sarcomas (Coley et 
al, 2000).
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Development of MDR cancers may occur in several progressive steps, from initial 
activation of expression in the case of cancers arising from non-Pgp expressing tissues, 
to stepwise increases in MDRI activation following relapse from chemotherapy and 
progression to a more aggressive drug resistant cancer. These may involve multiple 
different activation mechanisms resulting in stable changes in phenotype. In cancer 
cells where P-gp does not appear to be expressed prior to drug treatment or is expressed 
at low levels, some event must occur that initiates or up-regulates its expression. 
Possible such events that may initiate MDRI transcription are changes in the 
methylation status of the gene’s promoter or other regulatory sequences (Desiderato, 
1997; Kantharidis et al., 1997) or by gene rearrangement, where MDRI is translocated 
downstream of an active promoter (Mickley et al., 1997). When the MDRI gene is 
already expressed, increase of P-gp expression can result from amplification of the 
MDRI gene (Morrow et al., 1994). An increase in the rate of translation or stability of 
MDRI mRNA has also been reported to cause upregulation of P-gp expression (Marino 
et al., 1990; Yague et al., 2003).
An additional phenotype that has been observed in studies of cultured cells is reversible 
induction of MDR! activation. This occurs for cultured cell lines that require continuous 
or intermittent repeated low dose exposure to the selecting drug to maintain MDR. Such 
inducible MDR mechanisms need to be distinguished from stable changes in MDRI 
activation states. For example the CEM/A7R MDR lymphoid leukaemic cell line 
exhibits decreased P-gp expression and decreased MDR when grown for an extended 
period of time in the absence of drug, however levels of P-gp expression can be induced 
and drug resistance levels restored by short term drug exposure (Hu et al., 1995; Marino 
et al., 1990; Yague et al., 2003).
A complication of studying the role of P-gp in MDR in vivo is the detection of P-gp. 
Several techniques have been employed for this purpose, including RNA and antibody 
based methods. However, while each appears to have its advantages and disadvantages 
there are conflicting views over which technique is the best or most sensitive. A further 
complication is that the definition of the level of P-gp or MDRI expression that is 
significant for the development of MDR varies among different research groups, even 
when using the same techniques (Ferry, 1998).
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Monoclonal antibodies against different epitopes of P-gp have been used for P-gp 
detection by immunohistochemistry or flow cytometry. While some believe the use of 
monoclonal antibodies to detect P-gp is a principally reliable method (Pearson and 
Cunningham, 1993), there is also evidence to suggest otherwise. One monoclonal 
antibody commonly used in P-gp detection is MRK-16. This antibody recognises an 
extracellular epitope of P-gp and it is this feature that gives it its advantage over other 
P-gp specific monoclonal antibodies. Firstly, MRK-16 can recognise P-gp on live cells 
with no fixation required and therefore can be incorporated easily into flow cytometric 
analysis (Rischin and Ling, 1993). Secondly, as the epitope detected is external it is 
thought that only functional P-gp on the surface is measured (Hamada and Tsuruo, 
1986). However, in a study whereby clinical samples from patients with chronic 
lymphocytic leukaemia were tested for P-gp expression using MRK-16 monoclonal 
antibody and by measuring the MDRI mRNA expression, 12% of the samples were 
indicated to be P-gp positive using MRK-16, whereas 53% showed increased MDR! 
mRNA (Cumber et al., 1990). The experiment was then repeated but this time the 
samples were treated with neuraminidase prior to treatment with MRK-16. The results 
from this showed 52% of samples with P-gp expression using the MRK-16 antibody, 
which is approximately equal to the percentage of samples with increased MDRI 
mRNA. From this it would appear that the addition of neuraminidase before MRK-16 
unveils epitopes that were previously masked.
Contradicting the study by Cumber et al. (1990), are the results from a series of 
experiments that were done by Ludescher et al. (1992). Here, Rhodamine 123, a 
fluorescent dye transported by P-gp, was used in flow cytometry to analyse MDR in 
samples from six acute myeloid leukaemia patients. Rhodamine 123 efflux is 
considered to indicate the presence of P-gp. Three of the six samples exhibited a marked 
decrease in accumulation of Rhodamine 123. Reverse-transcriptase PCR (RT-PCR) 
measurement of MDR! mRNA and MRK-16 staining was carried out on the three 
samples showing Rhodamine 123 efflux. Only one of the three samples showed positive 
for P-gp by detection with MRK-16, even though the method used to label the cells with 
MRK-16 was that used by Cumber et al. (1990), that is, the cells were treated with 
neuraminidase prior to MRK-16 incubation. All three samples were shown to have low 
to moderate levels of MDRI mRNA expression, thereby indicating that MRK-16 may 
not have the necessary sensitivity to detect lower levels of P-gp, and hence low level
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MDR. Thus a poor correlation between P-gp expression and MDR in vivo may result 
when MRK-16 antibody is used to detect P-gp. RT-PCR appears to be a more suitable 
method for the detection of low level MDRI expression. However according to Pearson 
and Cunningham (1993), even this may not be accurate for determining the degree of P­
gp expression, as the levels of protein in a cell do not always correspond with the 
expression of the mRNA transcript.
1.4 Mechanisms for the activation of P-gp
1.4.1 Methylation
It has been well documented that methylation of DNA plays an important role in the 
control of many genes such that methylation of specific DNA sequences can result in 
the silencing of a gene and demethylation can be associated with the activation of a 
previously transcriptionally silent gene (Bird, 1992). DNA methylation occurs on a 
cytosine in specific promoter CpG dinucleotides. In many genes CpG rich regions are 
found proximal to the promoter. These regions, known as CG islands, are not normally 
methylated with the exception of genomicaily imprinted and X-linked genes (Laird and 
Jaenisch. 1994). However, in the development of cancer, alterations to DNA 
methylation can occur (Schroeder and Mass, 1997). Studies have demonstrated a 
correlation between cancer development and tumour suppressor gene inactivation due to 
hypermethylation of the CG islands of these genes. Examples where tumour suppressor 
gene hypermethylation has been seen include the RB gene in retinoblastoma (Greger et 
al., 1989), the VHL gene in renal cell carcinoma (Herman et al., 1994) and the Mtsl 
(Merlo et ah, 1995), p 16 (Martinez-delgado et al., 1997, Baur et al., 1999) p53 genes 
(Schroeder and Mass, 1997) in many human cancers.
Evidence for a relationship between the demethylation of MDRI promoter sequences 
and initiation of MDRI expression in MDR cancer cells has also been reported. 
Kantharidis et al., (1997) demonstrated differential methylation between drug sensitive 
and drug resistant cells derived from the CCRL-CEM human T-cells leukaemia cell line 
and in clinical samples from chronic lymphoblastic leukaemia patients. Southern
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analysis was performed on MDRI restriction enzyme digestions using Hpall, a 
methylation sensitive enzyme, and MspI, a methylation insensitive enzyme, that both 
recognise the same CCGG consensus sequence. Results showed that some of the Hpall 
recognition sites were protected by methylation in the drug sensitive cells but were not 
protected in the drug resistant cells. In addition a second experiment was carried out 
where drug sensitive cells were treated and grown in 5'-azadeoxycytidine (5'-azadC), a 
drug that prevents DNA methylation. When Southern analysis of digestions were 
repeated, the Hpall sites that were originally protected became unmethylated. RT-PCR 
of these 5'-azadC treated cells also detected MDRI mRNA which was absent prior to 5'- 
azadC treatment. Thus, demethylation of the MDRI promoter correlates with activation 
of the MDRI promoter. Similarly, Desiderato et al., (1997), using a technique which 
allows detection of the methylation status of all CpGs present, has shown extensive 
hypermethylation of sites both upstream and downstream of the MDRI transcription 
start site in the drug sensitive non-P-gp expressing HL60 cell line. In contrast, P-gp 
expressing MDR HL60 sublines were completely unmethylated in these regions.
Promoter methylation may serve to directly inhibit transcription through the 
methylation of specific CpG sites within transcription factor binding sites thus 
preventing the transcription factor binding and gene transcription. However it may also 
act indirectly to inhibit gene transcription by causing conformational changes in 
chromatin. In eukaryotic cells nuclear DNA is packaged into nucleosomes by histones 
and this is further condensed into chromatin (Kornberg, 1974). As well as enabling 
packaging of DNA, this hierarchal order also enables gene regulation through 
alterations in the level of DNA condensation. In genes transcribed at a specific point in 
the cell cycle or in a certain tissue type, chromatin is maintained in an active de- 
condensed state, whereas when genes are not expressed, chromatin is coiled in a highly 
inactive condensed state. (Baylin 1997).
Transcriptional repression can result if specific transcription factors are prevented from 
the binding to their consensus sequences when sequences are hidden due to steric 
hindrance from DNA being arranged in a closed chromatin structure (Levine et al., 
1991; Boyes and Bird, 1992; Jones et al., 1998). DNA that is hypermethylated is 
associated with dense or closed chromatin organization and hence transcription 
inhibition. DNA that is hypomethylated is associated with open chromatin and active
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transcription (Jones and Wolfe, 1999). Alteration of chromatin structure can occur 
through the action of methyl-CpG binding proteins. Two such proteins are MeCPl 
(Meehan et al., 1989; Antequera et al., 1989) and MeCP2 (Pawlak et al., 1991; Jost et 
al., 1991) which bind to clusters of methylated CpG dinucleotides and single 
methylated CpG dinucleotides respectively. MeCP2 is thought to bind through its DNA 
binding domain to methylated CpG dinucleotides and silence transcription from a 
distance through its repressor domain (Nan et al., 1993; Nan et al., 1997). The repressor 
domain of MeCP2 has been shown to recruit complexes containing the Sin3A 
corepressor and histone deacetylase corepressor, these complexes direct the 
modification of chromatin into a more stable and functionally inert state (Jones et al., 
1998; Nan et al., 1998).
Histones within the nucleosome are constantly undergoing acetylation and 
deacetylation. Protruding lysine residues in the positively charged NH2-terminal tails 
are the primary target sites of acetylation. This is thought to lead to neutralisation of the 
positive charge resulting in allosteric changes in chromatin conformation and 
destabilisation and loosening of histone-DNA contacts which in turn increases 
transcription factor access to DNA (Yoshidai et al., 2001; Wolffe, 1996). When 
histones become deacetylated the affinity of the histone tail for DNA increases and thus 
histone deacetylation is correlated to a closed chromatin structure and hence 
transcriptional silencing (Wolffe, 1996). The level of acetylation of histones within the 
nucleosome is a posttranslational modification catalysed by histone acetyltranferases 
and deacetylases (for reviews see Davie, 1997; Wade et al., 1997).
1.4.2 Gene rearrangement
A further mechanism that may be involved in the activation of MDRI transcription 
resulting in P-gp expression is gene rearrangement. A study by Mickley et al., (1997) 
demonstrates MDRI activation in adriamycin-selected S48-3s cells as a result of 
juxtaposition of the MDRI gene from chromosome 7 to an active promoter of a gene on 
chromosome 4. Similarly gene rearrangements were observed in two lymphoblastic 
leukaemia samples from patients refractory to drug treatment.
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1.4.3 Gene amplification
Amplification of the MDRI gene copy number can be a factor in high MDRI expression 
(Morrow, 1994). Gene amplification frequently occurs in vitro during the selection of 
multidrug resistant cell lines. According to Kohno et al., (1994), in early stages of 
stepwise selection of in vitro cell cultures with cytotoxic drugs MDRI expression is 
increased without gene amplification. However, in late stages gene amplification is 
observed. Gene amplification is especially seen when the cells are exposed to high 
concentrations of drugs and therefore may be avoided using lower, more clinically 
relevant drug levels to treat cells (Shen et al., 1986). MDRI copy number and MDR! 
mRNA levels can be determined by Southern and Northern analysis respectively and 
comparisons of these results will demonstrate if increase in MDRI expression is due to 
gene amplification or an actual increase in MDRI mRNA (Kohno et al., 1994).
1.4.4 Transcriptional activation
The human MDRI gene reportedly contains two different promoter regions, the down 
stream or proximal promoter and the upstream or distal promoter (Ueda et al., 1987). In 
normal tissues and most tumours, the major site of MDRI transcriptional regulation has 
been found to be under the control of the proximal promoter located at -434 to +1 of the 
MDRI gene sequence (Cornwell and Smith, 1993a). A minor site of MDRI 
transcription is located within the distal promoter and is only used in a few cell lines for 
a percentage of their MDRI transcripts. The importance of this promoter is not well 
understood (Baggetto, 1997). For the purpose of this review the proximal is referred to 
as the MDR! promoter.
The structure of the human MDRI promoter, shown in Figure 1.2, does not contain a 
TATA box but has been found to contain many consensus binding sequences for 
transcription factor binding sites that might act as response elements and thus have a 
possible role in its regulation. However, despite extensive research the significance of 
many of these regulatory factors to the problem of MDR in vivo has yet to be
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determined. Moreover, the vast majority of studies on the MDRI promoter structure 
concentrate on the sequence upstream of the transcription initiation start point and very 
little work has been done downstream of this region. Several groups have used reporter 
gene systems, most commonly a chloramphenicol acetyltransferase (CAT) gene fused to 
and directed by the human MDRI promoter, to identify important transcriptional 
regulatory elements in the MDRI promoter. One such study by Miyazaki et al., (1992) 
used human cancer KB cells transfected with the CAT reporter gene fused to the MDRI 
promoter to examine the effect of heat shock on the MDRI promoter activity. By 
incubating the cells at 45°C for 90 minutes it was found that CAT activity driven by the 
MDRI promoter became induced. Varying the length of this MDRI promoter in the 
reporter gene system suggested that the human MDRI promoter contained heat shock 
response elements (HSRE) at-178 to-152 and at-136 to -76 up from the transcription 
initiation start site (Miyazaki et al., 1992).
A similar study by Tanimura et al., (1992) also using KB cells transfected with CAT- 
MDRI promoter reporter gene system, showed an increase in MDRI promoter activity 
in response to serum starvation. A series of deletions in the MDRI promoter fused to the 
CAT gene identified a serum starvation response element (SSRE) in the sequence 
between -258 and -198 upstream of the initiation site. Cornwell and Smith, (1993b) 
identified a further SSRE in the sequence between -69 to —41 of the MDRI promoter. 
Interestingly, this region (-69 to -4-1) which is known as the -55 GC box, contains 
overlapping consensus binding sites for the transcription factors Spl and Egrl 
(Cornwell and Smith, 1993a). This is one of several GC boxes found within the MDRI 
promoter, however the -55 GC box appears to be the most essential in terms of basal 
transcription (Cornwell and Smith, 1999a, Sundseth et al., 1997). Evidence for this 
comes from mutation and deletion experiments on the region containing the -55 GC 
box. In the case of both deletion and mutation, a significant reduction in promoter 
activity was observed, and in one instance a point mutation in the -55 GC box gave a 
60-70% decrease in promoter activity (Sundseth et al., 1997).
Further indication as to the importance of this area was provided by in vitro DNase 
footprinting analysis which showed that this GC-box is a protected region (Cornwell 
and Smith, 1999a). Spl is an activator of many promoters and is believed to behave as 
an activator of MDRI transcription through binding at the -55 GC box. This has been
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demonstrated by co-transfecting an A7D/?/-luciferase reporter gene with either an Spl 
cDNA construct or vector control into cells that do not express Spl. Results from this 
experiment showed that the MDRI promoter was activated 15 fold higher in the 
presence of Spl compared to the vector only control construct (Cornwell and Smith, 
1999a). High levels of Spl expression have been demonstrated in some human cancers, 
for example Kitadai et al., (1992) demonstrated increased Spl mRNA expression in 12 
out of 18 tumors at levels higher than normal mucosa. Likewise, Lietard et al., (1997) 
found increased Spl levels in human hepatocellular carcinomas.
Egr-1 is a member of a family of transcription factors known as early growth response 
(Egr) factors. Recombinant Egr-1 has been shown to bind the -55 GC box region 
(Cornwell and Smith, 1999a) and participates in MDRI regulation in some phorbol ester 
sensitive cell lines (McCoy et al., 1995). Overlapping Spl and Egr-1 motifs are found 
in a number of genes, and in the majority Egr-1 binds to the region with higher affinity 
than Spl, thus preventing Spl binding (Ebert and Wong, 1995; Khachigian, et al, 1995; 
Cui et al, 1996). The exact interaction of Egr-1 and Spl with the MDRI -55 GC box is 
not yet understood (Cornwell and Smith, 1993a). It has also been demonstrated that the 
Wilms' tumour suppressor protein, WT-1, which is a member of the Egr family, 
recognises and binds to the Egr-1 consensus sequences (Harrington et al., 1993; 
Moshier et al., 1996). In many gene promoters that are activated by Egr proteins, such 
as Egr-1, Wt-1 has been found to repress transcription (Madden et al., 1993; Madden et 
al., 1991; Wang et al., 1992). In the MDRI promoter WT-1 has been shown to down 
regulate transcription by binding to the -55GC box. McCoy et al., (1995) found that 
K562 cells showed activated MDRI transcription in response to treatment with 12-0- 
tetradecanoylphorbol-13-acetate (TPA). They then located this TPA-responsive element 
to the overlapping Spl/Egr-1 site at the -55GC box. McCoy et al., (1999) later 
demonstrated that this TPA mediated MDRI activation could be inhibited by WT-1 
binding to the Spl/Egr-1 site.
Sp3 is another member of the same family of transcription factors as Spl and is able to 
bind to the same recognition sequence as Spl. Unlike Spl, which is predominantly a 
transcriptional activator, Sp3 can act as either a represser or an activator (for review see 
Philipsen and Suske, 1999). In many genes Sp3 can compete for binding with Spl, thus 
repressing Spl mediated transcriptional activation of that gene. Therefore it is possible
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that in the case of MDRI, where Spl is essential for basal transcription, the relative 
abundance of the Spl and Sp3 may be involved in transcriptional regulation.
Another GC box located at -1 10 to -103 of the MDRI promoter sequence, relative to 
the transcription start site, is thought to act as a negative response element (NRE) and 
contain a binding site for a transcription factor that represses MDRI transcription. This 
NRE has been demonstrated experimentally by mutation of the sequence at this region 
resulting in a promoter activity increasing six fold (Cornwall and Smith, 1993a). Ando 
et al., (2000), reported that this -110 GC box was methylated in MDR K562/ADM cells 
and unmethylated in the drug sensitive parental K562 cells, and that demethylation of 
this site by treating the K562/ADM with DNA methyltransferase inhibitor 5-Aza-2- 
deoxycytidine decreased P-gp expression in these cells.
A second NRE has been isolated in the sequence between -121 to -1 11 of the MDRI 
promoter (Ogura et al., 1992). Within this, the region -1 18 to -113 has been found to 
contain a CAAT box. Ogretmen and Safa, (1999) used a luciferase reporter gene system 
to investigate the role of the CAAT box in negative regulation of MDRI promoter 
activity. A wild type 241 bp MDRI promoter DNA fragment (containing the sequence - 
198 to +43) or a corresponding mutated 237bp CAAT deleted promoter DNA fragment 
were cloned into luciferase expressing pGL3-basic vector and transfected into a drug 
sensitive MCF-7 human breast cancer cell line and its MDR subline MCF-7/Adr. From 
this it was found that MDRI promoter activity was 15 fold higher in MCF-7/Adr cells 
compared with that of MCF-7. MCF-7 cells transfected with the mutated 237bp CAAT 
deleted promoter, showed a 12 fold increase in promoter activity compared with MCF-7 
cells transfected with the wild type 241 bp promoter. However, the MCF-7/Adr cells 
transfected with the mutated 237bp CAAT deleted promoter showed only a 1.3 fold 
increase in promoter activity compared to MCF-7/Adr transfected with wild type thus 
indicating that this CAAT box is involved in downregulation of the MDRI promoter in 
this cell line.
Ogretmen and Safa, (1999) used electrophoretic mobility shift assays (EMSAs) to 
demonstrate the binding of a protein, later identified as a NF-KB/p65-cFos hybrid 
transcription factor, to this -1 18 to -1 13 CAAT box in the drug sensitive MCF-7 cells,
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but not in the MDR MCF-7/Adr cells. This evidence suggests NF-KB/p65-cFos 
produces a negative regulatory effect on the MDRI promoter activity through 
interaction with this region. NF-kB is a ubiquitous transcription factor that is usually 
maintained as a dimer in the cytoplasm under the inhibition of IkB (Bentires et al., 
2003). Many chemotherapeutic drugs can induce NF-kB activity (for review see Pahl, 
1999) through stimulating the phosphorylation of IkB thereby allowing NF-kB to be 
localised to the nucleus and induce target genes (Bentires et al., 2003). A study by 
Bentries et al., (2003) demonstrated that inhibition of NF-kB resulted in an increase in 
daumomycin sensitivity and reduced MDRI mRNA and P-gp expression in HCT15 
human carcinoma cells.
Two c-AMP response sequences (CRS) have been located around -71 and -55 of the 
MDRI promoter sequence. These CRS are identical to the consensus sequences for Spl 
and therefore it is suggested that the interaction of Spl with the CRS and the 
modulation of Spl activity by signal transduction through type 1 cAMP-dependant 
kinase (PKA) may up-regulate MDRI expression (Glazer and Rohlff, 1994, Baggetto, 
1997). PKA can phosphorylate Spl although it has not been ascertained as to whether 
phosphorylation of Spl effects its binding capabilities. Initial reports of Spl 
hyperphosphorylation, observed in monkey CV1-L cells infected with the simian virus 
40 (SV-40), found that the hyperphosphorylation only occurred once Spl had bound to 
its GC box consensus sequence and was facilitated by a DNA-dependent kinase 
(Jackson, 1990). This study did not observe any change in DNA-binding affinity of the 
phosphorylated protein or any changes in its transactivating properties (Jackson et al, 
1990).
Other studies have observed that phosphorylation altered the DNA binding affinity of 
Spl. For example it has been shown that in terminally differentiated liver cells Spl 
becomes phosphorylated which results in downregulation of its DNA binding activity 
(Leggett et al, 1995). Casein kinase Il-mediated phosphorylation of the Spl C-terminus 
region (residues around Thr-579) has also been demonstrated to closely relate to the rate 
of growth and cell cycle regulation in Balb/c 3T3 cells (Black, et al, 1999; Armstrong et 
al, 1997).
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In the case of MDRI, it is thought that hyperphosphorylated Spl inhibits 
phosphoprotein phosphatases, that dephosphorylate the transcription factor CREB. 
Phosphorylated CREB binds to a c-AMP regulatory element (CRE), found upstream 
from the CRS (located upstream of the transcription start site) in the MDRI promoter, 
and upon binding MDRI, transcription is increased (Baggetto, 1997; Rohlff et al., 
1993). In addition to the two CRS there are numerous other consensus binding sites for 
transcription factors that are controlled by protein kinases, for example, two AP-2 
consensus sites are located downstream of the transcription start site at +136 and +382, 
and an AP-1 consensus site is apparent around -233 from the transcription start site.
Reporter gene studies, by Uchiumi et al., (1993a), using a CAT reporter gene fused to 
the MDRI promoter revealed two stress response elements (SRE) located at -136 to -76 
and +1 to +121. By exposing human cancer KB cells transfected with the CAT-MDRI 
reporter gene constructs to ultraviolet irradiation (UV) it was found that an increase in 
CAT expression, and hence MDRI promoter activity, occurred. Similarly, an increase in 
MDRI promoter directed CAT expression also occurred in transfected KB cells in 
response to cytotoxic drug exposure of the cells to drugs such as 5-fluorouracil 
(Uchiumi et al., 1993b). Furthermore, the increase MDRI promoter activity seen after 
UV irradiation or exposure to cytotoxic drugs was inhibited in the presence of a protein 
kinase C (PKC) inhibitor, thus suggesting that phosphorylation of transcription factors 
by PKC may play a role in the MDRI promoter activation in these cells (Uchiumi et al., 
1993b). This is supported by a recent study by Ratnasinghe et al., (2001). Here up- 
regulation of PKC and API subunits c-Jun and c-fos were seen in an MCF-7 drug 
resistant breast cancer cell line that over expressed MDRI, thus suggesting that 
increased levels of PKC and the transcription factor c-Jun induces MDRI up regulation.
Through a series of MDRI promoter deletions it was found that the removal of the 
sequence between -136 to -76 upstream of the transcription initiation site resulted in a 
reduction in the ability of UV to increase CAT expression, thus it was suggested that 
this region of the MDR! promoter contains a SRE that can activate the MDRI promoter 
(Uchiumi et al., 1993a). In later experiments it was suggested that contained within this 
-136 to -76 SRE is an inverted CCAAT box, also known as a Y-box, which is situated 
between -93 to -68 of this sequence (Asakuno et al., 1994). Experiments investigating 
the importance of the Y-box in MDRI promoter regulation have been performed using
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the CAT MDRI reporter gene system containing various Y-box directed deletions or 
mutations. One of these studies reported that deletion of the MDRI promoter sequence 
containing the Y-box showed wild type levels of promoter activity on KB cells 
(Cornwell, 1993) indicating the Y-box sequence is not essential for normal MDRI 
transcription in these cell lines. This however does not imply that the Y-box does not 
play a role in induction of MDRI expression in response to stress (Asakuno et al., 1994; 
Ohga et al., 1996; Ohga et al., 1998).
EMSAs on the Y-box from the MDRI promoter using nuclear proteins isolated from 
actinomycin D treated KB cells showed that this Y-box specifically bound a protein 
which was identified as the transcription factor YB-1 (Asakuno et al., 1994). The 
binding of YB-1 to a Y-box has been shown to be involved in the regulation of gene 
expression in several eukaryotic genes, for example the human major histocompatability 
complex class II genes (Makino et al., 1996; Swamynathan et al., 1998). Additional 
experiments on YB-1 have supported the possibility that it may have a role in the stress 
induction of the MDRI promoter activity in response to environmental stimuli such as 
anti-cancer agents, UV radiation, heat shock, and serum deprivation (Ohga et al., 1996, 
Ohga et al., 1998). For example, in a study by Asakuno et al., (1994) KB cells 
demonstrated a 5 fold increase in YB-1 mRNA levels after a 24hour exposure to 
actinomycin D. Furthermore, Ohga et al., (1998) demonstrated that the binding of YB-1 
to the Y-box is directly involved in genotoxic stress activation of the MDRI promoter in 
KB cells through transfection of KB cells containing various MDRI.CAT driven 
constructs with a YB-1 antisense expression plasmid. Transfection of the KB cells with 
the antisense YB-1 resulted in a decrease in cell YB-1 levels and in decreased binding 
of YB-1 to the Y-box in EMSAs.
Ohga et al., (1998) also demonstrated that an increase in MDRI promoter activity 
previously seen upon exposure of the KB cells to cytotoxic drugs or UV irradiation 
(Asakuno et al., 1994; Uchiumi et al., 1993) was decreased by transfection with 
antisense YB-1. However no effect on promoter activity was seen on transfection with 
antisense YB-1 in KB cells that had the Y-box deleted from the MDR! promoter (Ohga 
et al., 1998). Therefore this suggests that interaction of YB-1 with the Y-box in KB 
cells is important for genotoxic stress induction of MDRI but not essential for basal
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promoter activity. Moreover, Ohga et al., (1996) showed that YB-1 mRNA levels 
increase following genotoxic stress with agents such as cisplatin and UV light.
The intracellular localisation of the transcription factor YB-1 has also been shown to 
correlate with MDR. For example a study by Bargou et al., (1997) found that in drug 
sensitive MCF-7 cells, YB-1 was localised in the nucleus. In addition, transfection of 
normal P-gp negative breast epithelial HBL-100 cells with YB-1 cDNA resulted in an 
increase in YB-1 levels in the cytoplasm as well as nuclear localisation of the YB-1, 
whereas HBL-100 cells that had undergone mock transfection only demonstrated 
endogenous YB-1 in the cytoplasm. The transfected cells also expressed P-gp and 
demonstrated increased cell viability in the presence of the cytotoxic drug doxorubicin 
compared to the mock transfected cells which died rapidly upon drug exposure (Bargou 
et al., 1997). Also, in a clinical study on 27 untreated primary breast cancers, all 
patients demonstrated YB-1 in the cytoplasm while the normal breast tissue from the 
same patient showed no detectable YB-1. In 9 out of 27 of these cases, YB-1 was also 
localised in the nucleus of the breast cancer cells and these same 9 patients also 
demonstrated high P-gp levels (Bargou et al., 1997). Hence, there is a correlation 
between nuclear localisation of YB-1 and intrinsic MDR of primary breast cancers.
However, in contrast to these results, other reports have indicated that it is another Y- 
box binding factor, NF-Y, that binds to the Y-box in the MDRI promoter (Hu et al., 
2000; Jin & Scotto, 1998; Sundseth et al., 1997) and has a role in the MDRI 
transcriptional activation through genotoxic stress. For example a recent study by Hu et 
al., (2000) challenged previous work by re-investigating the Y-box binding factor 
involved in activation of MDRI by UV irradiation in KB-3-1 cells. As with the previous 
studies Hu et al., (2000) found that the CCAAT box was required for activation of 
MDRI transcription by UV light. However unlike the previous work, an anti-NF-Y 
antibody and an anti-YB-1 antibody was used in EMSAs to identify the Y-box binding 
protein interacting with a double stranded Y-box probe. Results from this indicated that 
in fact NF-Y binds to the Y-box and not YB-1. Other studies have also indicated that in 
tumour cell lines HOT 1 16, HepG2, KB3-1 and Saos2, NF-Y, and not YB-1 binds to the 
Y-box elements on the MDRI promoter (Sundseth et al., 1997). It was also shown that a 
double point mutation in the Y-box sequence between -89 and -70 reduced activity of 
the promoter by 5-10 fold. Thus in these cell lines the Y-box appeared to be essential
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for maintaining normal MDRI activity. Similar results have been found in a previous 
study on SW620 colon carcinoma cells and 2780 ovarian carcinoma cells, where 
deletion or mutation of the sequence between -89 and -70 also resulted in a decrease in 
promoter activity of around 5-10 fold (Goldsmith et al., 1993). Thus the role of the Y- 
box in MDRI regulation, though clearly important, is unclear at the present time. In 
some cells it appears to be constitutively essential to MDRI activity and in others to 
inducibly mediated up regulation of MDRI in response to genotoxic stress.
MDRI has also been reported to respond to agents that induce cytochrome P450 
(Greiner et al., 1999; Schuetz et al., 1996). Cytochrome P450s catalyse oxidative 
metabolism of many drugs and result in drug elimination (Schuetz et al., 2000). One 
cytochrome P450 enzyme CYP3A4 is thought to be responsible for degradation of 
around 50% of all pharmaceutical agents (Synold et al., 2001). Cytochrome P450s are 
regulated by hormones, for example regulation of CYP3A4 is increased by 
glucocorticoid hormones (Schuetz et al., 2000). Transcriptional regulation of CYP3A4 
has been shown to involve the orphan nuclear receptor, also known as SXR, PXR, PAR, 
PRR or N1 12 (Synold et al., 2001). Many drugs and steroids that activate the orphan 
nuclear receptor, and hence CYP3A4, are often also substrates for P-gp (Greiner et al., 
1999; Schuetz et al., 1996). The antibiotic rifampicin can induce both CYP3A4 and 
intestinal P-gp. An SXR nuclear response element, located -7852 to -7837 of the 
MDRI promoter, has been identified as essential to MDRI induction by rifampicin in 
the human colon carcinoma LS174T cell line (Geick et al., 2001).
1.4.5 Post transcriptional mechanisms
Another mechanism suggested to cause an increase in P-gp levels is an increase in the 
translation rate or stability of MDRI mRNA. The half life of mRNA can be controlled 
by many mechanisms, for example deadenylation-dependant mRNA decay where a 
poly(A)-specific deadenylasing nuclease shortens the poly(A) tail which is followed by 
removal of the methylguanosine cap and 5’ and 3’ exonucleases degrade the mRNA 
(reviewed in Bernstein and Ross., 1989; Ross., 1995; Jacobson and Peltz, 1996; Wilusz 
et al., 2001). Though not yet fully understood, it is thought that interaction with a
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poly(A)-binding protein(PABP) can inhibit mRNA degradation thus allowing
stabilisation of the mRNA and promoting translation (Wilusz et al., 2001).
A study comparing levels of MDR, P-gp expression and MDRI mRNA levels for 
different cell lines found that when selecting for a high level of vincristine resistance in 
SK VCR 2 cells (a MDR subline of the SKOV3 human ovarian carcinoma cell line) an 
increase in MDR and P-gp expression was seen without a proportionate increase in 
MDRI mRNA or gene amplification. This indicated that P-gp expression was regulated 
translationally and not transcriptionally (Bradley et al., 1989). A further study by 
Marino et al., (1990), showed that regenerating rat liver, which over expresses P-gp, 
shows a 20 fold increase in the level of MDRI mRNA compared to normal rat liver, 
which expresses P-gp at physiological levels. However nuclear run-on experiments, 
which allow the direct measurement of the rate of transcription of a specific gene, 
indicated there was no significant differences between the rate of MDRI transcription in 
regenerating rat liver compared to normal liver cells (Marino et al., 1990). These 
results suggest that MDR! overexpression can be directly linked to increases in mRNA 
stability.
1.5 The current study
In this project in order to investigate molecular mechanisms of regulation of MDR! in 
drug resistant cancer cells, K562, a human leukaemic cell line and K562 derived MDR 
sublines were used as an in vitro model of acquired MDR. K562 is a cell line derived 
from a patient with chronic myeloid leukaemia and is relatively sensitive to 
chemotherapeutic drugs (Lozzio & Lozzio, 1979). P-gp expression in K562 cells is 
generally considered to be negative (Marks et al., 1993; Marks et al., 1996) although 
some investigators believe that these cells have a very low level of expression (Hamada 
& Tsurdo, 1986, Yague et al., 2003). Several MDR sublines have previously been 
isolated by exposure of K562 cells to clinically relevant levels of drugs such as 
epirubicin (Marks et al., 1993) and daunorubicin (Hargrave et al., 1995). These MDR 
sublines express P-gp and the drug resistance is reversed by modulators of P-gp
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function, indicating that activation of P-gp expression is the cause of the MDR in these 
cell lines.
The cells lines used in this study exhibit relatively low levels of MDR mediated by P­
gp, however, each cell line was chosen so as to cover a range of resistance levels, that is 
from low to high, within this low level MDR. The K/E15B cell line was derived from 
parental K562 cell lines by multiple exposures to lOng/ml of epirubicin for 3-14 days 
over a 3 month period, then in turn exposing these cells to 15ng/ml of epirubicin for 3­
14 days over a further 3 month period (Marks et al., 1993). K/E15B cells were cloned 
by limiting dilution to obtain the K/EC32 subclone (Ishri, Honours thesis, 1997). The 
K/EC32 cell line demonstrates a very low level of MDR. K/EPR and K/DNR cells were 
developed by Hargrave et al., (1995), by intermittently exposing K562 cells to either 
20ng/ml of epirubicin (K/EPR) or 20ng/ml of daunorubicin (K/DNR) for 3 days over a 
2 month period. The K/EPR cell line was chosen to represent an intermediate level of 
MDR and the K/DNR represents a higher level of MDR. All of these K562 MDR 
sublines demonstrate a classical MDR phenotype and through flow cytometry and 
Western blotting it is also known that these cells express P-gp (Hargrave et al., 1995; 
Marks et al., 1993).
This project investigated the possible mechanisms for the activation of P-gp expression 
in the development of the K562 MDR cell lines from the sensitive K562 parental cells. 
Some in vitro cell lines in the literature require re-exposure to drug at regular intervals 
or constant exposure to low concentrations of drug in order to maintain MDR levels 
(Tohda et al., 1997; Hu et al., 1995). Others however, are able to maintain stable MDR 
levels (Geroni et al., 1993). Thus the stability of MDR in the K562 derived MDR cell 
lines and the effect of drug re-exposure on MDR levels was also investigated.
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CHAPTER 2
Characterisation of experimental cell lines
2.1 INTRODUCTION
To confirm drug resistance levels of the K562 MDR sublines used in this study, 
cytotoxicity assays with the drugs vinblastine and paclitaxel were performed. Previously 
reported Epirubicin resistance levels for the K562 MDR cells lines, relative to the 
parental K562 cells, were 1.7 fold for K/EC32 (Ishri, Honours thesis, 1997), 4-fold for 
K/EPR (Hargrave et a/., (1995) and 6.8 fold for K/DNR (Hargrave et al., (1995). MDRI 
mRNA levels were also determined by Northern blot analysis in order to see if the 
relative quantity of MDR! mRNA in the cells, correlated to their level of MDR. RNA 
isolated from the VLB 100 cell line was also used in Northern blots as a positive control 
as these cells contain amplified copies of the MDRI gene and express large amounts of 
MDR/ mRNA (Hill et al., 1988). Gene amplification can occur i/i vitro during the 
selection of multidrug resistant cell lines when the cells are exposed to high 
concentrations of drugs (Shen et al., 1986) and so to exclude MDR! gene amplification 
as the cause of differing resistance levels in the K562 MDR sublines, Southern slot blot 
analyses were also performed.
To investigate the stability of MDR in the K562 MDR sublines, cells were grown for 
varying periods of time in the absence of drug, then MDR levels re-examined. 
Inducibility of MDR was also tested by determining the effect of single short-term 
exposure of the MDR cell lines to cytotoxic drugs for varying lengths of time.
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2.2 MATERIALS AND METHODS
2.2.1 Cell lines and culture
The K562 cell line was obtained from the ATCC culture collection. The K.562 cell line 
was obtained from the ATCC culture collection. It was originally derived from a 
patient with chronic myeloid leukaemia and is relatively sensitive to chemotherapeutic 
drugs (Lozzio & Lozzio, 1979). The K562 drug resistant subline K/E15B was derived 
from parental K562 cell lines by multiple exposures to lOng/ml of epirubicin for 3-14 
days over a 3 month period, then in turn exposing these cells to 15ng/ml of epirubicin 
for 3-14 days over a further 3 month period (Marks et al., 1993). The K/EC32 cell line 
is a subclone of K/E15B isolated by cloning K/E15B cells by limiting dilution (Ishri, 
Honours thesis, 1997). The K/EPR and K/DNR cell lines were developed by Hargrave 
et al., (1995), by intermittently exposing K562 cells to either 20ng/ml of epirubicin 
(K/EPR) or 20ng/ml of daunorubicin (K/DNR) for 3 days over a 2month period. 
CEM/VLB100 cells (VLB 100) is a multidrug resistant subline originally developed 
from human leukaemia cell line CCRF-CEM (Beck et al., 1979).
Cells were cultured in RPMI-1640 medium supplemented with 20mM HEPES, 10% 
foetal calf serum and NaHC03 (0.85g/L) at 37°C with 5% C02 tension in a humidified 
incubator. The cells were maintained by passaging every 2-3 days.
2.2.2 Cytotoxicity Assays
Exponentially growing cells (4xl04 cells per well) were placed in 100/vL aliquots into 
96 well microtitre plates. 100/d of 2-fold serially diluted paclitaxel (Sigma-Aldrich) or 
vinblastine (David Bull Laboratories, Australia) was then added to cells in triplicate 
wells. The plates were incubated for 4 days at 37°C with 5% C02 tension in a 
humidified incubator, after which cell viability was assessed via an MTT assay (Marks
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et al., 1992). Control wells were treated as above except that 100/d of RPMI-1640 
media was used in place of drug dilution. For reversal of drug resistance, lOmM 
verapamil (Sigma, USA) was added to the cells in the assay. The mean cell viability and 
standard deviation of triplicate wells was determined and plotted against drug 
concentration using Graph Pad Prism Version 3. Relative resistances were determined 
by dividing the drug concentration giving 50% inhibition of growth of the MDR cell 
line with that giving 50% inhibition of growth of the drug sensitive K562 cells 
determined in the same experiment.
2.2.3 Total RNA Extraction
Total RNA was isolated from 1x10 exponentially growing cells using a method 
adapted from Chomczynski and Sacchi (1987). Cells were washed in 0.1M ice cold 
sterile PBS and centrifuged at 500xg for 5 minutes at 4°C. The cells were lysed in 1 ml a 
solution of 4M guanidinium isothiocyanate, 2.5mM sodium citrate pH7.0 at RT, 0.5% 
sarcosyl, 0.1 M (3-mercaptoethanol. Genomic DNA was sheared by dispelling the cell 
lysate at least lOx through a sterile 23 gauge needle then 0.1ml of 2M sodium acetate 
(pH 4.0), 1.0ml of water saturated phenol and 0.2ml of chloroform:isoamyl alcohol 
(49:1) was sequentially added, with mixing by inversion after each addition. This was 
then shaken vigorously for 10 seconds, incubated on ice for 15 minutes and centrifuged 
at 10, OOOxg for 20 minutes at 4°C. The upper aqueous phase containing the RNA was 
collected and mixed with an equal volume of chlorofonmisoamyl alcohol (49:1) then 
vigorously shaken for 10 seconds, incubated on ice for 15 minutes and centrifuged at 
10, OOOxg for 20 minutes at 4°C. From this the aqueous phase was collected, 1ml of 
isopropanol added and following incubation at -20°C for at least 1 hour RNA was 
collected by centrifugation at 10,000xg for 20 minutes at 4°C and the pellet resuspended 
in 300/d of solution of 4M guanidinium isothiocyanate, 2.5mM sodium citrate pH7.0 at 
RT, 0.5% sarcosyl, 0.1 M (Umercaptoethanol. 300/d of isopropanol was then added and 
following incubation at -20°C for 1 hour, the samples were spun at 10.OOOxg for 20 min 
at 4°C and the RNA pellets washed in 70% ethanol and centrifuged at 10, OOOxg for 10 
minutes at 4°C. RNA pellets were air dried and resuspended in 50/d of sterile diethylene 
pyrocarbonate treated water and stored at -80°C. The concentration of the RNA was
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determined by reading the absorbance of the samples at 260nM and 280nM. Calculation 
of the RNA concentration was performed as follows:
RNA concentration = A260nM x 40/ig/ml x dilution factor.
Where A260 is the absorbance at 260nM and 40/fg/ml is the RNA concentration 
equivalent to 1 absorbance unit.
2.2.4 RNA Transfer and Northern Hybridisation
20pig of total RNA was electrophoresed on 1% Agarose gels in lx MOPS (0.04 M 
Morpholinopropanesulfonic acid (free acid); 0.01 M Na-acetate-3 x H20; ImM EDTA; 
adjusted to pH 7.2 with NaOH) and 2% formaldehyde, then vacuum transferred onto 
Hybond N+ nylon membranes (Amersham life Sciences, Australia) for I hour in lx 
SSC (0.15 M NaCI plus 0.015 M sodium citrate), lOmM NaOH. RNA was UV cross 
linked to membranes at 70,000pJ/cnr in a UV cross-linker (Stratalinker, Australia). 
Membranes were then hybridised with a 2P- labelled MDRI cDNA probe. The MDRI 
cDNA probe was prepared by EcoRI digestion of the MDRI cDNA containing plasmid 
pMDR2000XS (Pastan et al., 1988) and isolating a 3.4kb cDNA fragment on a 1.5% 
agarose gel run in IX TAE (40mM Tris-acetate, ImM EDTA, pH 8.0) running buffer 
along with pGEM DNA markers. The 3.4kb band was excised from the gel and purified 
by the Geneclean method (GeneWork, Australia). Typically, 25-50ng of the probe was 
random primer labelled with 50//Ci of ct-l2P-dCTP (3000//Ci/mmol) using the 
Gigaprime DNA labelling kit (GeneWork, Australia) according to the supplied protocol. 
Unincorporated nucleotides were removed by column chromatography with Sephadex 
G50.
Membranes were prehybridised at 50°C for at least 1 hour in NorthernMax pre­
hybridisation/hybridisation solution (Ambion, USA). The solution was then replaced 
with fresh pre-hybridisation/hybridisation solution to which the pMDR2000xs EcoRI 
fragment probe (lOng/ml, denaturated by addition of 1/9 volumes of 4M NaOH and 
incubating for 15 min at RT) was added and membranes were hybridised overnight at 
50°C. Membranes were washed 2 times in NorthernMax wash solution #1 (Ambion, 
USA) for 5-10 min at RT, followed by 2, 15-20 min washes in NorthernMax wash
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solution #2 (Ambion, USA) at 50°C, then exposed to a BioRad phosphoimager (BI) 
screen and visualised using a BioRad phosphoimager. Membranes were subsequently 
stripped in boiling 0.1% SDS and re-probed with a 0.5//g GAPDH RNA probe. The 
GAPDH was in vitro transcribed from a linearised mouse DNA template (Ambion, 
USA) using a MAXIscript in vitro transcription kit (Ambion, USA) and labelled with 
10//Ci, 3000Ci/mmol of a-32P-dUTP according to manufacturer’s instructions. 
Membranes were prehybridised, hybridised and washed as for the pMDR2000xs EcoRI 
fragment probe except 65°C prehybridisation, hybridisation and stringent wash 
temperature was used.
2.2.5 Isolation of Genomic DNA
Genomic DNA was isolated from the K562 cell lines and each MDR sublines. Briefly, 
lxlO7 cells were pelleted at 500xg for 5 min and resuspended in 9ml of ice cold TLB 
(0.32M sucrose, 5mM MgCI2, lOmM Tris pH7.6 at RT, 1% Triton XI00). Nucleii were 
collected by centrifugation at 10, OOOxg for 5 min at 4°C. The pellet was evenly 
resuspended in 450/d of ice cold TEN (0.1M Tris pH8.0 at RT, 20mM EDTA, 0.15M 
NaCl) then 25/d of 20% SDS and 25/d of freshly prepared 2mg/ml proteinase K was 
added with mixing after each addition. This lysate was incubated at 50°C with frequent 
mixing by inversion for 2 hours, followed by incubation at 37°C overnight. An equal 
volume of Tris pH 7.0 saturated phenol was then added to the cell lysate, which was 
emulsified by repeated gentle inversions and spun at 10,OOOxg for 5 min. The upper 
phase was collected, taking care to avoid the protein containing white flocculent at the 
interface, and re-extracted with phenol until there was no white band present at the 
interface. Following this, sequential extractions, firstly with equal volumes of phenol 
and chloroform, then with an equal volume of chloroform were performed on the upper 
aqueous phase. To precipitate the DNA, 2 volumes of absolute ethanol were added. The 
DNA was then spooled on a bent sterile pasteur pipette, washed by dipping in 70% 
ethanol and air dried before being redissolved in 100/d of sterile dH20.
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2.2.6 Slot Blot Transfer and Southern hybridisation
10//g of genomic DNA was added to a transfer buffer containing 1M NaOH and lOmM 
EDTA, in a final volume of 500/d. The DNA was then denatured by heating at 95°C for 
5 min then plunged into ice. The samples were then applied to a PR600 SlotBlot 
(Hoefer Scientific Instruments, USA) in duplicate and vacuum transferred in 0.4M 
NaOH onto Hybond N+ nylon membrane (Amersham Life Sciences, Australia) 
according to manufacturer’s instructions. Slot blot membranes were prehybridised at 
65°C for at least 1 hour in 6.5ml of hybridisation solution (2x SSPE 10.36 M NaCI, 20 
mM NaP04 (pH 7.7), 1 mM EDTA|, 1% SDS, 6.5//g BSA and 320pig of sonicated fish 
testes DNA). After pre-hybridisation this solutiuon was removed and replaced with 
fresh hybridisation solution to which lOng/ml of labelled MDRI cDNA probe (prepared 
as previously described in section 2.2.4) was added along with an amount of glacial 
acetic acid equivalent to the amount of NaOH added previously. After hybridisation at 
65°C overnight the membrane was then washed sequentially with a 2x SSC rinse at RT, 
0.5x SSC and 0.1% SDS for 15 min with agitation at RT, 0.5x SSC and 1% SDS for 15 
min with agitation at 65°C and finally rinsed in ().5x SSC and 0.1% SDS before 
exposure to a BioRad phosphoimager (BI) screen and visualised using a BioRad 
phosphoimager. Image analysis was performed using the Molecular Analyst Program 
(BioRad, Australia).
After exposure, the membrane was stripped in boiling 0.1% SDS then re-probed with a 
GAPDH RNA probe (as previously described in section 2.2.4). Membranes were pre­
hybridised at 50°C for at least 1 hour in NorthernMax pre hybridisation/hybridisation 
solution (Ambion, USA). This solution was then replaced with fresh pre­
hybridisation/hybridisation solution to which the GAPDH probe was added and 
membranes were hybridised overnight at 50°C. The membrane was washed 2 times in 
NorthernMax wash solution #1 (Ambion, USA) for 5-10 min at RT, followed by 2, 15­
20 min washes in NorthernMax wash solution #2 (Ambion, USA) at 50°C. Membranes 
were exposed to a BioRad phosphoimager (BI) screen and visualised using a BioRad 
phosphoimager. Image analysis was performed using the Molecular Analyst Program 
(BioRad, Australia).
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2.2.7 Drug induction
2.2.7.1 3 day drug treatments
Cells at an initial density of 0.7x10'Vml were treated with epirubicin (David Bull 
Laboratories, Australia) at a concentration of 5ng/ml for K562, 15ng/ml for K/E15B 
subclone K/EC32 and 20ng/ml for K/EPR cells. K/DNR cells were treated with 20ng/ml 
daunorubicin (David Bull Laboratories, Australia). The cells were exposed to drug for 3 
days at 37°C with 5% C02 tension in a humidified incubator, then allowed to recover by 
culture in drug free media for 2 weeks before cytotoxicity assays were performed.
2.2.7.2 4 and 16 hour drug treatments
Four and 16 hour drug treatments were performed on the K/EPR cells using epirubicin, 
paclitaxel, cisplatin and rifampacin. K/EPR cells at an initial density of 0.7xl06/ml 
were treated with epirubicin (David Bull Laboratories, Australia) at a concentration of 
I60ng/ml, paclitaxel (Sigma-Aldrich, Australia) at 50ng/ml, cisplatin (David Bull 
Laboratories, Australia) at 500ng/ml or with rifampacin at I0//M, 30//M and 100//M. 
The cells were exposed to drug for 4 or 16 hours at 37°C with 5% C02 tension in a 
humidified incubator, then allowed to recover by culture in drug free media for 3 days 
before cytotoxicity assays were performed.
The concentration of epirubicin, paclitaxel and cisplatin chosen for the 4 and 16 hour 
drug treatments were selected on the basis of their approximate equivalence to an IC25 
caused by exposure for these times. To determine these concentrations, exponentially 
growing cells (4xl04 cells per well) were placed in 100//L aliquots into 96 well 
microtitre plates and 100//1 of 2-fold serially diluted drug was then added to the cells in 
triplicate wells. The plates were incubated for 4 or 16 hours at 37°C with 5% C02 
tension in a humidified incubator, after which cell viability was assessed via an MTT 
assay (Marks et al., 1992). Control wells were treated as above except that 100/d of 
RPML1640 media was used in place of drug dilution. The IC25 caused by either a 4 or 
16 hour drug exposure was similar. A range of concentrations of rifampacin was used 
for the 4 and 16 hour treatments.
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2.2.8 Trichostatin A treatment of cells
Exponentially growing K562 and K/EPR cells were incubated with a range of 
Trichostatin A (TSA) (Sigma-Aldrich) concentrations (0, 50, 200, 500, lOOOnM) for 16 
hours at 37°C with 5% CO, tension in a humidified incubator. As TSA was dissolved in 
ethanol, cell growth was assessed and ethanol controls were carried out for all assays. 
After TSA exposure, cells were washed in RPMI and used in an epirubicin cytotoxicity 
assay as previously described in section 2.2.2. The effect of TSA on cell growth was 
determined by preforming cell counts on cells exposed to the various TSA 
concentrations for 16 hours, then allowed to recover for three days in drug free medium.
2.3 RESULTS
2.3.1 Drug Resistance Levels of K562 MDR Cell Lines
To confirm MDR levels of the model cell lines, cytotoxicity assays were performed on 
K562, K/EC32, K/EPR, K/DNR and the parental K562 cells using either of the 
chemotherapeutic drugs vinblastine or paclitaxel. To confirm that the mechanism of 
drug resistance in the K562 MDR cell lines was P-gp mediated, cytotoxicity assays 
were performed on each of the cell lines in the presence and absence of the 
chemosensitising agent verapamil. As well as verapamil, paclitaxel itself is a good 
indicator of P-gp mediated MDR as it is not a substrate for multidrug resistance protein 
(MRP), the other main efflux means for cytotoxic drugs (Grant et al., 1994).
Figures 2.1(a) and (b) respectively show results for a vinblastine and a paclitaxel 
cytotoxicity assay for the K/EC32 subline. The results indicate that K/EC32 cells were
2.4 fold resistant to vinblastine (Figure 2.1(a)) and 3.9 fold resistant to paclitaxel 
(Figure 2.1(b)) relative to the parental K562 cell line. These assays were performed at
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Vinblastine (nM)
Paclitaxel (nM)
Figure 2.1 Resistance levels of K/EC32 cells. The K/EC32 (O) cell line was assayed 
for its resistance to (a) vinblastine and (b) paclitaxel compared to the resistance of the 
parental K562 cell line (□). These assays were performed in the presence (•) and 
absence (O) of the chemosensitising agent verapamil. Points are the mean of triplicate 
wells and bars are the standard deviation.
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least five times with similar results. The resistance demonstrated by the K/EC32 cells 
was completely reversed in the presence of verapamil. The reversal of K/EC32 
resistance with vinblastine was performed three times reproducibly. Vinblastine and 
paclitaxel cytotoxicity assays were also performed on the K/EPR cell line and the 
results of one of these assays are shown in Figures 2.2(a) and (b) respectively. In these 
assays K/EPR cells demonstrated 6.9 fold resistance to vinblastine (Figure 2.2(a)) and 
an 8.8 fold resistance to paclitaxel (Figure 2.2(b)) relative to the parental K562 cell line. 
K/EPR vinblastine cytotoxicity assays were performed three times and the paclitaxel 
cytotoxicity assays five times with similar results. Like the K/EC32 cell line, the 
resistance of the K/EPR cells was completely reversed in the presence of verapamil. 
This reversal of K/EPR resistance was repeated in a subsequent experiment.
Figures 2.3(a) and (b) show the corresponding results for one of the cytotoxicity assays 
carried out on the K/DNR cell line. These results indicate that, relative to K562 cells, 
the K/DNR cells were 16.7 fold resistant to vinblastine (Figure 2.3(a)) and 21.0 fold 
resistant to paclitaxel (Figure 2.3(b)). K/DNR vinblastine cytotoxicity assays were 
performed three times and the paclitaxel cytotoxicity assays five times with similar 
results. Once again all resistance was reversed in the presence of verapamil. This 
reversal of K/DNR resistance was repeated in a subsequent experiment.
fhe results of these cytotoxicity assays indicate that a range of low (K/EC32), medium 
(K/EPR) and high (K/DNR) state, albeit generally low level MDR cell lines are being 
used in the current study.
2.3.2 MDRl mRNA Levels in K562 and MDR Cell Lines
The cells used in this study were derived from the same K562 parental cell line and yet 
all exhibit different levels of MDR. In order to determine if the relative quantity of 
MDRl mRNA in the cells correlated to level of MDR displayed by the sublines 
Northern Blots were performed on total RNA extracted from K562 and MDR sublines 
at the same time the paclitaxel sensitivity assay was conducted. RNA extracted from 
the highly MDR! expressing VLB 100 cell line (Beck et a!., 1979) was used as a 
positive control. After hybridisation with the MDRl probe (representative blots shown




Figure 2.2 Resistance levels of K/EPR cells. The K/EPR ((}) cell line was assayed for 
its resistance to (a) vinblastine and (b) paclitaxel compared to the resistance of the 
parental K562 cell line (□). These assays were performed in the presence (♦) and 
absence (0) of the chemosensitising agent verapamil. Points are the mean of triplicate 
wells and bars are the standard deviation.






Figure 2.3 Resistance levels of K/DNR cells. The K/DNR (T) cell line was assayed for 
their resistance to (a) vinblastine and (b) paclitaxel compared to the resistance of the 
parental K562 cell line (□). These assays were performed in the presence (#) and 
absence (T) of the chemosensitising agent verapamil. Points are the mean of triplicate 
wells and bars are the standard deviation.
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ill Figure 2.4a) the membrane was then stripped and re-hybridised with a GAPDH RNA 
probe to normalise RNA loadings (representative blot shown Figure 2.4b). MDRl 
mRNA was detected in each of the MDR cell lines but not in the drug sensitive K562 
cells. Normalised levels of MDRl mRNA were determined by preforming densitometry 
using the Molecular Analyst program (BioRad, Australia). Table 2.1 shows the 
normalised levels of MDRl mRNA in the cells lines and also correlates these levels 
with the levels of paclitaxel relative resistance determined at the time the RNA was 
extracted. Examination of this data shows a positive relationship between the level of 
MDRl mRNA present in the cells and the levels of MDR displayed by the cells at that 
time. These results were reproduced three times with similar results.
2.3.3 MDRl gene copy number
To investigate the possibility that Pgp up-regulation was due to amplification of the 
MDRl gene copy number genomic DNA was extracted from each cell lines and used in 
slot blot Southern hybridisation with a 32P-labelled pMDR2000XS EcoRI fragment
DNA probe (refer to section 2.2.4) (Figure 2.5(a)). The amount of DNA loaded on the 
membrane was normalised for each cell line by stripping then re-probing the membrane 
with a 2P- labelled GAPDH RNA probe (Figure 2.5(b)). From these results and the 
densitometry results shown in Table 2.2, it is evident that each of the cell lines contains 
equivalent copy numbers of the MDRl gene, which in turn is equivalent to the number 
of copies present in the parental K562 cell line. This results was reproduced in a 
subsequent experiment. Therefore in the K562 derived MDR sublines MDRl 
upregulation is due to a factor other then MDRl gene amplification.
2.3.4 Stability of MDR in K562 MDR sublines
The stability of MDR was investigated by repeated cytotoxicity determination over an 
extended period of time in drug free culture following establishment from frozen stocks. 
Figure 2.6 shows a summary of the paclitaxel resistance levels (relative to K562) of the 
MDR sublines determined after various periods of time in drug free culture.
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Figure 2.4 Northern blot for the determination of MDRl mRNA levels in K562 MDR 
cell lines. Total RNA from K562, and MDR sublines before, and after drug treatment, 
was hybridised with (a) an MDRl DNA probe, before stripping and re-hybridisation 
with (b) a GAPDH RNA probe. VLB 100 RNA was used as a positive control.
Table 2.1 Normalised MDRl mRNA levels in K562 MDR cell lines and thei 











K/EC32 2.5 2.4 3.9
K/EPR 3.6 6.9 8.8
K/DNR 6.6 16.7 21.0
* MDRl mRNA levels normalised to GAPDH mRNA levels.
# resistance levels shown are relative to that of untreated K562 cells and refer to the 
individual IC50 drug concentrations.
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Figure 2.5 Comparison of the MDRl gene copy number in K562 MDR cell lines. DNA 
from K562, K/EC32, K/DNR and K/EPR was used in duplicate in a slot blot Southern 
Hybridisation with (a) an MDRl DNA probe before stripping and re-hybridising with 
(b) a GAPDH RNA probe to normalise loadings.
Table 2.2 MDR! gene copy number normalised to GAPDH gene copy numbers in K562 
MDR cell lines
K562 K/EC32 K/DNR K/EPR
Normalised1
level
1.17 1.08 1.00 0.92
1 shows the average of duplicate MDRT1 slot blot intensities divided by average of 
duplicate GAPDH slot blot intensities






















Weeks in drug free culture
Figure 2.6 Stability of MDR. (a) Relative paclitaxel resistance of K/EC32 after culture 
for 17 or 28 weeks in the absence of drug ( ) (b) Relative paclitaxel resistance of 
K/EPR ( ) and K/DNR (■) cells were determined after being maintained for 5 or 17 
weeks in drug free culture.
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Examination of this data indicates that the resistance levels of the non-drug treated cell 
lines decreases with time in culture. From Figure 2.6a it can be seen that K/EC32 cells 
maintained for 17 weeks in drug free culture were 3.9-fold resistant to paclitaxel 
relative to K562, but after 28 weeks of drug free culture paclitaxel resistance in K/EC32 
cells had decreased to 2.3-fold. This assay was repeated six times with similar results.
Figure 2.6b shows the corresponding results for the K/EPR and K/DNR sublines. As 
was seen in the K/EC32 cells, the K/EPR and K/DNR sublines also demonstrated 
decreased resistance with culture in drug free media. The K/EPR decreased from an 8.8 
fold resistance (relative to K562) after 5 weeks in drug free culture to 4.0 fold after 17 
weeks. Similarly, K/DNR showed a 21.2 fold resistance at week 5, decreasing to 16.7 
fold after 17 weeks in drug free culture. These assays were performed three times with 
similar results.
2.3.5 Effect of 3 Day Re-exposure to Drug
As the K562 MDR sublines did not appear to be stable in long term drug free culture, 
cells were re-exposed to drugs to determine if MDR levels could be re-stimulated. Cells 
were treated for 3 days with the original selecting drug concentration and then 
cytotoxicity to paclitaxel was assessed following a short period of recovery. The drug 
concentration used typically produces less than 50% inhibition of cell viability in a 
standard 4 day cytotoxicity assay (data not shown).
Figure 2.7 shows the result obtained following a 3 day exposure to 15ng/ml of 
epirubicin of the K/EC32 subline after 17 weeks in drug free medium. The untreated 
control cells K/EC32 and drug treated cells, designated K/EC32T, were found to be 3.9- 
fold and 14.1-fold respectively, more resistant to paclitaxel than the K562 cells 
(cytotoxicity assays were performed six times with similar results). Thus, short term 
drug exposure of the K/EC32 subclone was able to increase the level of drug resistance 
displayed by these cells. The induction of drug resistance by 3 day epirubicin exposure 
of the K/EC32 cell line was also tested after a further 1 1 weeks in drug free medium 
(week 28). In order to allow distinction of the previously treated K/EC32T cells and the 
newly treated cells in these experiments, newly drug exposed cells were named by the 
addition of the suffix T*. The effect on the previously treated K/EC32T cells of a
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Figure 2.7 The effect of 3 day drug exposure on the K/EC32 cell line. K/EC32 cells 
were grown in drug free culture for 17 weeks then treated with 15ng/ml epirubicin for 3 
days. Drug treated K/EC32T (•) and untreated K/EC32 cells (O) were then assayed for 
their resistance to paclitaxel and compared to the resistance of parental K562 cells (□). 
Points are the mean of triplicate wells and bars are the standard deviation.
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second round of drug exposure at week 28, (designated K/EC32TT cells) was also 
examined. As seen previously drug treatment of the K/EC32 cell line again resulted in 
the induction of MDR (Figure 2.8). Thus the relative resistance to paclitaxel of the 
K/EC32T* cells was 5.6-fold compared to 2.3-fokl in K/EC32 cells, that is an increase 
of 2.4-fold. The previously drug treated K/EC32T cells maintained a level of resistance 
equivalent to that of the freshly treated K/EC32T* cells. However the K/EC32TT cells 
which had undergone 2 drug treatments demonstrated a slightly further increase in 
relative resistance to 7.7-fold (Figure 2.8) (assays at week 28 were repeated three times 
with similar results).
A 3 day exposure of the K/EPR cells to 20ng/ml of epirubicin following 17 weeks in 
drug free culture also resulted in the induction of MDR. The resulting K/EPRT* cell 
line demonstrated 16.7 fold relative resistance to paclitaxel, which was a 4.2 fold 
increase compared to the untreated K/EPR cells (Figure 2.9). In contrast, 3 day 
exposure of the K/DNR cells to 20ng/ml of daunorubicin did not result in a large 
difference in relative resistance between the untreated K/DNR cells, (16.7-fold) 
compared to the 20 fold resistance in the treated K/DNRT* cells (Figure 2.10). These 
assays on K/EPR and K/DNR cells were repeated three times with similar results. These 
cells were at a high level of resistance prior to drug treatment and it may not be possible 
for the MDR levels to increase much higher.
The parental K562 cells were also treated with 5ng/ml of epirubicin, a concentration 
which gives a similar degree of cytotoxicity as does 15ng/ml to K/EC32 cell lines (data 
not shown). As shown in Figure 2.11, exposure of the parental K562 cells to drug 
resulted in no apparent difference in resistance between the K562 and K562T* cells 
(repeated three times with similar results). It is possible that an irreversible change 
occurs to produce the K562 MDR cell lines from the K562 cells and once this change 
having been effected, the MDR cell lines are also reversibly inducible.
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Figure 2.8 The effect of short-term drug exposure on the K/EC32 and K/EC32T cell 
lines. K/EC32 cells (O) were grown in drug free culture for 28 weeks before Paclitaxel 
cytotoxicity assay. K/EC32T cells (•) were grown in drug free culture for 17 weeks 
then treated with 15ng/ml epirubicin for 3 days, then assayed after a further 1 I weeks in 
drug free culture. K/EC32T* (A) were grown in drug free media for 28 weeks then 
treated with 15ng/ml epirubicin for 3 days. K/EC32TT (T) cells were treated with 
15ng/ml epirubicin for 3 days after 17 weeks in drug free culture and re-treated with 
15ng/ml epirubicin for 3 days after 1 1 weeks in drug free culture. Paclitaxel cytotoxicity 
assays were performed on the cell lines and compared to the resistance of parental K562 
cells (□) to examine the induction of drug resistance by drug treatment of the cells. 
Points are the mean of triplicate wells and bars are the standard deviation.










Figure 2.9 The effect of 3 day drug exposure on the K/EPR cell line. K/EPR cells were 
grown in drug free culture for 17 weeks then treated with 20ng/ml epirubicin for 3 days. 
Cytotoxicity assays to paclitaxel were performed for K/EPR (^) and drug treated 
K/EPRT* (♦) and compared to the resistance of parental K562 cells (O) to examine the 
induction of drug resistance by drug treatment of the cells. Points are the mean of 
triplicate wells and bars are the standard deviation.










Figure 2.10 The effect of 3 day drug exposure on the K/DNR cell line. K/DNR cells 
were grown in drug free culture for 17 weeks then treated with 20ng/ml daunorubicin 
for 3 days. Cytotoxicity assays to paclitaxel were performed for K/DNR (T) and 
K/DNRT* (#) and compared to the resistance of parental K562 cells (□) to examine 
the induction of drug resistance by drug treatment of the cells. Points are the mean of 
triplicate wells and bars are the standard deviation.
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Figure 2.11 The effect of 3 day drug exposure on the K562 cell line. K562 cells grown 
in drug free culture treated with 5ng/ml epirubicin for 3 days. Cytotoxicity assays to 
paclitaxel were performed for K562 (□) and K562T* (■) cells to examine the induction 
of drug resistance by drug treatment of the cells. Points are the mean of triplicate wells 
and bars are the standard deviation.
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2.3.6 MDRl mRNA levels in re-stimulated K562 MDR sublines
Northern Blots were performed on total RNA extracted from K562, non-drug treated 
MDR sublines and drug treated MDR sublines isolated at the same time the paclitaxel 
sensitivity was conducted, after 28 weeks for K/EC32, and 17 weeks for K/EPR and 
K/DNR (Figure 2.12). Table 2.3 shows the normalised levels of MDRl mRNA (relative 
to GAPDH) in the treated and untreated cell lines and also correlates these levels with 
the levels of paclitaxel relative resistance, determined at the time the RNA was 
extracted. Examination of this data shows a positive relationship between the level of 
MDRl mRNA present in the cells and the levels of MDR displayed by the cells at that 
time and confirm that the drug exposure that resulted in induced MDR produced a 
corresponding increase in MDRl mRNA levels in the cells. This result was reproduced 
in a subsequent experiment.
2.3.7 Induction by short term exposure to MDRl substrate drugs
To investigate if MDR could be induced by shorter exposure times, and by P-gp 
substrate drugs different to the original selecting drug, we treated the K562 MDR cell 
line K/EPR for either 4 or 16 hours to epirubicin or paclitaxel. The concentrations of 
epirubicin (the original selecting drug) or paclitaxel used were equivalent to an IC25, as 
determined by treatment for 4 or 16 hours with serial dilutions of each drug then 
performing an MTT cell viability assay. Control treatments were set up in the same 
manner as the drug treatments except for the absence of drug.
Epirubicin, an anthracycline and an epimer of doxorubicin, is a P-gp substrate drug. 
Like other anthracylines, epirubicin induces multiple intracellular effects that result in 
DNA damage in the cells (Nielsen et al., 1996). This is achieved through intercalation 
of DNA base pairs resulting in inhibition of DNA replication and by direct inhibition of 
the enzymes DNA helicase, DNA polymerase and RNA polymerase (Wilson et al., 
1999).
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Figure 2.12 Northern blot for the determination of MDR1 mRNA levels in K562 MDR 
cell lines. Total RNA from K562, and MDR sublines before and after drug treatment 
was hybridised with (a) an MDRl DNA probe before stripping and re-hybridised with 
(b) a GAPDH RNA probe. VLB 100 RNA was used as a positive control.
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Table 2.3 Correlation of MDRl mRNA and relative resistance levels in K562 MDR 
sublines following 3 day drug treatment after 28 weeks (K/EC32) or 17 weeks (K/DNR 
and K/EPR) in drug free culture.
MDRl mRNA Drug Resistance
Cell Normalised Relative RelativePaclitaxel
Resistance
Relative
















1. MDRl mRNA levels normalised to GAPDH mRNA levels.
2. Paclitaxel resistance levels shown are relative to that of untreated K562 cells and 
refer to the individual IC50 drug concentrations.
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Paclitaxel is also a P-gp substrate drug but its mode of action is quite different from that 
of epirubicin. It is a natural product drug obtained from the bark of Taxus brevifola, a 
pacific yew tree (Niethammer et al., 2001). Paclitaxel was the first taxane to be 
routinely used clinically (Luck et al., 1997) and has applications including breast, lung 
and ovarian cancers (Niethammer et al., 2001). Paclitaxel binds to microtubules causing 
formation of microtubulin bundles in interphase cells and spindle asters during mitosis. 
This results in increased polymer mass and stabilisation of microtubules leading to 
mitotic arrest and failure of chromosomes to segregate (Blagosklonny and Fojo, 1999, 
Reinecke et al., 2000).
Short term exposure to epirubicin caused a temporary growth block and so the treated 
cells were allowed to recover for 3 days in drug free medium, before assaying MDR 
levels in a standard 4 day paclitaxel cytotoxicity assay. From these results it can be 
seen that treatment of K/EPR cells for as little as 4 or 16 hours with epirubicin (Figure 
2.13) induced higher levels of MDR in these MDR cells (treatments performed four 
times with similar results). Cells pre-treated with paclitaxel, for 4 or 16 hours at 
concentrations giving similar inhibition to epirubicin also resulted in an increase in 
subsequent resistance to paclitaxel (Figure 2.14) ((treatments performed four times with 
similar results). In contrast to epirubicin, short term exposure to paclitaxel at these 
concentrations did not block growth after removal (data not shown), but paclitaxel 
exposed cells were also assayed following a 3 day drug free recovery period. The effect 
of 4 or 16 hours exposure to epirubicin or paclitaxel on subsequent sensitivity to 
paclitaxel is summarised in Table 2.4, from which it can be seen that both induction 
treatments resulted in a similar induction of MDR level.
2.3.8 Induction by Short Term Exposure to Cisplatin
To investigate if MDR could be induced by cytotoxic agents that are not P-gp substrate 
drugs, we treated the K/EPR cells for either 4 or 16 hours with cisplatin. The 
concentration of cisplatin used for treatments (500ng/ml) was equivalent to an IC25, as 
determined by treatment for 4 or 16 hours with serial dilutions of cisplatin, then












Figure 2.13 The effect of short-term epirubicin exposure on the K/EPR cell line. K/EPR 
were exposed to epirubicin for (a) 4 hours and (b) 16 hours then cytotoxicity to 
paclitaxel was assessed. Resistance of epriubicin treated cells (□) was compared to the 
resistance of control untreated K/EPR cells (■). Points are the mean of triplicate wells 
and bars are the standard deviation.





Figure 2.14 The effect of short-term paclitaxel exposure on the K/EPR cell line. K/EPR 
were exposed to paclitaxel for (a) 4 hours and (b) 16 hours then cytotoxicity to 
paclitaxel was assessed. Resistance of pacitaxel treated cells (□) was compared to the 
resistance of control untreated K/EPR cells (■). Points are the mean of triplicate wells 
and bars are the standard deviation.
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Table 2.4 Comparison of K/EPR cell paclitaxel IC50’s before and after 4 or 
16 hour epirubicin or paclitaxel treatment.







epirubicin 24 120 5.0
4 hours 
paclitaxel 25 98 3.9
16 hours 
epirubicin 40 220 5.5
16 hours 
paclitaxel 40 140 3.5
# resistance levels shown are relative to that of untreated K/EPR cells and refer to the 
individual IC50 drug concentrations.
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performing an MTT cell viability assay. Control treatments were set up in the same 
manner as the drug treatments except for the absence of drug.
Unlike epirubicin or paclitaxel, cisplatin is a non-P-gp substrate drug. The exact 
mechanism of cisplatin action is unknown, however it is thought that cisplatin causes 
DNA damage through the formation of a variety of covalent DNA adducts that result in 
DNA crosslinks (Ise et al., 1999, Cohen, 2001). These cisplatin adducts are thought to 
deform the conformation of the DNA and thus inhibit or eradicate DNA replication and 
RNA transcription in the effected cell (Brabec and Kasparkova 2002). The reason for 
inclusion of cisplatin in the current induction studies even though, as previously stated, 
it is not a P-gp substrate drug, was because previous studies by other groups have 
indicated that cisplatin has induced P-gp levels both in vitro (Ohga et al., 1998, 
Chaudhary and Roninson, 1993) and in vivo (Demeule et al., 1999).
Like paclitaxel, short term exposure to cisplatin at similar cytotoxic concentrations did 
not block growth after removal, but cells exposed to these drugs were also assayed 
following a 3 day drug free recovery period. Results for cisplatin (Figure 2.15) indicate 
no induction of MDR has occurred (treatments performed four times with similar 
results). As was done previously with paclitaxel, for cells pre-treated with cisplatin, 
assay of MDR level in a standard 4 day paclitaxel cytotoxicity assay performed 
immediately after the 4 or 16 hour drug exposures gave the same result (data not 
shown).
Recent reports have indicated that in some cell lines pre-exposure to cisplatin can 
sensitise the cells to paclitaxel (Yamamoto et al., 2000). In this study paclitaxel is being 
used to assess resistance levels after cisplatin treatment, thus an increase in resistance 
after cisplatin treatment may be masked. To overcome this, the resistance levels of 
cisplatin exposed cells were also assessed with vinblastine, however these results also 
indicated that no induction of drug resistance had occurred (Figure 2.16) (this result was 
reproduced in a subsequent experiment). Thus both of the P-gp substrates epirubicin and 
paclitaxel induced MDR levels, but the non-P-gp substrate cisplatin at similar inhibitory 
concentration had no inducing effect. Moreover treatment of the K/EPR cells with







Figure 2.15 The effect of short-term cisplatin exposure on the K/EPR cell line. K/EPR 
were exposed to cisplatin for (a) 4 hours and (b) 16 hours then cytotoxicity to paclitaxel 
assessed. Resistance of drug treated cells (□) was compared to the resistance of control 
untreated K/EPR cells (■). Points are the mean of triplicate wells and bars are the 
standard deviation.







Figure 2.16 The effect of short-term cisplatin exposure on the K/EPR cell iine. K/EPR 
were exposed to cisplatin for (a) 4 hours and (b) 16 hours then cytotoxicity to 
vinblastine assessed. Resistance of drug treated cells (□) was compared to the 
resistance of control untreated K/EPR cells (■). Points are the mean of triplicate wells 
and bars are the standard deviation.
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cisplatin prior to paclitaxel exposure in the cytotoxicity assay resulted in a slight 
decrease in the paclitaxel resistance and this is consistent with the previous observations 
of Yammamoto et al., (2000).
2.3.9 Induction by short term exposure to rifampacin
Rifampacin, also known as rifampin, is a semi synthetic antibiotic derived from 
rifamycin B which is produced by the fermentation of a strain of Streptomyces 
mediterranei (reviewed in Sensi, 1983). Rifampacin acts by binding to the B-sub-unit of 
bacterial DNA-dependent RNA polymerase thus preventing the initiation of DNA 
transcription (Fahr et al., 1985). Previous studies have indicted that rifampacin 
treatment can induce intestinal P-gp (Greiner et al., 1999, Westphal et al., 2000, Geick 
et al., 2001).
As rifampacin was found not to be cytotoxic to the K/EPR cell line, three concentrations 
of rifampacin were chosen to both cover and exceed the concentrations used in the 
literature. Chosen rifampacin concentrations were 1 Dpim, 30/nn and 100/mi. Control 
treatments were set up in the same manner as the drug treatments except for the absence 
of drug. However as shown in Figure 2.17, as for cisplatin, short term exposure of the 
K/EPR cells to rifampacin at a variety of concentrations also did not induce MDR levels 
(this result was reproduced in a subsequent experiment).
2.3.10 Effect of short term exposure to the histone deacetylase 
inhibitor TSA
A previous study by Jin and Scotto, (1998) demonstrated that the MDR! promoter could 
be induced in SW620 colon carcinoma cells by exposure to the histone deacetylase 
inhibitor TSA. Other published studies using TSA to activate genes use concentrations




Figure 2.17 The effect of short-term rifampacin exposure on the K/EPR cell line. 
K/EPR cells were exposed to rifampacin for (a) 4 hours and (b) 16 hours at 10//M (O), 
30//M (O), 100//M (A), then cytotoxicity to paclitaxel was assessed and resistance 
compared to control untreated cells (■) to examine the induction of drug resistance by 
the drug treatment of the cells. Points are the mean of triplicate wells and bars are the 
standard deviation.
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of TSA from 3nM to 500nM for 16-24 hours (Jin and Scotto, 1998; Jones et al., 1998; 
Cameron et al., 1999). Therefore K562 and K/EPR cells were incubated for 16 hours in 
concentrations of TSA varying from 0 to lOOOnM. To determine the effects TSA had on 
the growth of the cells, TSA treated cells were counted after a three day recovery period 
in normal growth medium. To determine the effect TSA exposure has on K562 and 
K/EPR MDR levels, the sensitivity of the TSA treated cells to epirubicin was assessed.
As shown in Figure 2.18a TSA slightly inhibits the growth of the K562 cells, with 
viability decreasing from 100% to 85% at 50nM TSA, then remaining approximately 
constant to 500nM TSA. From Figure 2.18b it can be seen that the IC50s obtained by 
treatment with epirubicin of untreated K562, ethanol control, 500nM and lOOOnM TSA 
treated cells were all approximately llnM, whereas the cells treated with 50nM or 
200nM TSA had a 2.2 fold higher IC50 of 24nM epirubicin. These experiments were 
repeated 3 times with similar results. The results indicate an induction of MDR levels 
by pre-treatment with low inhibitory TSA concentrations, which is extinguished at high 
concentrations.
Figures 2.19a and 2.19b show the corresponding results for K/EPR cells. TSA has less 
inhibitory effect on the growth of K/EPR cells (Figure 2.19a) than on the K562 cells, 
requiring 500nM to lOOOnM to reduce growth by 10 to 15%. As shown in Figure 2.19b, 
TSA concentrations up to 500nM had no effect on MDR levels (IC50 of 35nM 
epirubicin). Treatment with lOOOnM TSA slightly decreased the IC50 to 18nM. This 
experiment has been performed 3 times with similar results. Thus these results suggest 
that while TSA does not appear to upregulate MDR levels in the K/EPR cell line, it may 
increase drug resistance levels slightly in the more drug sensitive K562 cells.
2.4 SUMMARY OF RESULTS
The relative resistance levels of the cell lines to be used was confirmed. Initial testing of 
the cytotoxicity levels of the K562 MDR cell lines showed that K/EC32 cells displayed 
very low level drug resistance, the K/EPR cells demonstrated medium drug resistance 
and K/DNR cells had a higher drug resistance. These cell lines demonstrated resistance 
to the specific P-gp substrate paclitaxel, which was reversible by verapamil, indicating














Figure 2.18 Effect of TSA on growth and epirubicin resistance of K562 cells. 
Exponentially growing K562 cells were treated with 0, 50, 200, 500 and lOOOnM TSA 
for 16 hours and assayed for effect on (a) cell growth (■) and (b) resistance to 
epirubicin following treatment with TSA (O = 50nM, A = 200,B3 = 500, &= lOOOnM) 
or no TSA (O = ethanol control, = media control).
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Figure 2.19 Effect of TSA on growth and epirubicin resistance of K/EPR cells. 
Exponentially growing K/EPR cells were treated with 0, 50, 200, 500 and lOOOnM TSA 
for 16 hours and assayed for effect on (a) cell growth (■) and (b) resistance to 
epirubicin following treatment with TSA (O = 50nM, A = 200, EB = 500, •$= lOOOnM) 
or no TSA (O = ethanol control, = media control).
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that MDR in these lines is P-gp mediated. The low MDR levels exhibited by these cell 
lines is consistent with the relatively low drug concentrations used for their 
development.
The levels of drug resistance displayed by the K562 MDR sublines correlated with the 
level of the MDRI mRNA in the cells. Increased amounts of MDRl mRNA in some cell 
lines can occur as a result of amplification of the MDRl gene copy number in the cells 
(Kohno et al., 1994). Gene amplification frequently occurs in vitro during selection of 
MDR cell lines, especially when the cell are exposed to high, clinically irrelevant 
concentrations of drugs (Morrow et al., 1994; Kohno et al., 1994; Shen et al., 1986). 
However gene amplification is usually avoided when low, clinically relevant 
concentrations of drug are used to isolate MDR cells (Shen et al., 1986) as was the case 
for the cell lines used for this study (Marks et al., 1993; Hargrave et al., 1995). 
Consequently, Southern hybridisations using an MDRI DNA probe performed on slot 
blots of the genomic DNA from the cells showed that the K562 MDR cell lines had an 
MDR! gene copy number equivalent to the parental K562 cells, indicating that 
amplification of the MDR! gene had not occurred in the K562 MDR cell lines.
Periodic assessment of resistance levels in the cell lines through cytotoxicity assays 
revealed that drug resistance in the MDR cell lines declined over time in drug free 
culture. However resistance levels could be restimulated in each of the MDR ceil lines 
by a single short-term treatment with the original selecting drug. Furthermore 
upregulation of resistance in the MDR sublines induced by short-term drug exposure 
was accompanied by increased expression of MDRl mRNA. In contrast to the induction 
of drug resistance in the K562 MDR sublines, treatment of the parental K562 cells with 
a dose of epirubicin that has a level of cytotoxicity equivalent to the concentrations used 
to treat the MDR cell lines, was unable to induce MDR, indicating a fundamental 
difference between the K562 cells and its derived MDR sublines.
In our experiments we found that only P-gp substrates were able to induce MDRl 
expression, with no induction seen with the non-Pgp drug cisplatin. As studies have 
shown that exposure of cells to cisplatin can sensitise cells to paclitaxel treatment 
(Yamamoto et al., 2000) it is possible that the apparent failure of MDR induction by 
cisplatin in the K/EPR cells could be due to increased paclitaxel sensitivity after
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cisplatin treatment. To overcome the possibility of an induction of MDR being masked 
in cisplatin treated cells by using paclitaxel to assay any changes in cell resistance, 
vinblastine cytotoxicity assays performed on cisplatin treated cells, however this also 
indicated no induction of drug resistance. Induction of resistance was also not seen 
when the K/EPR cells were exposed to rifampacin, a drug which binds to the SXR 
receptor which has been shown to bind to a response element approx 8kb upstream of 
the MDRl gene in the human colon carcinoma cell line LS174T cell line (Geick et al., 
2001).
Since different MDR levels in the parental K562 and drug resistant sublines may reflect 
differences in their levels of histone acetylation and chromatin structure, the effect of 
TSA, a specific inhibitor of histone deacetylase (Yoshidai et al., 2001) on MDR levels 
in K562 and K/EPR cells was investigated. The results indicated that exposure of K562 
cells to 50nM to 200nM TSA, increased the level of epirubicin resistance approx 2.2 
fold. However no corresponding increase was seen in the K/EPR cell line. This result 
may indicate that in the drug sensitive K562 cells, TSA inhibition of histone 
deacetyltransferase led to increased acetylation and subsequent activation of MDRl in 
these cells. However the absence of any similar effect in the K/EPR MDR cell line 
indicates a difference in chromatin structure in the two cell lines.
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CHAPTER 3
Investigation of Binding to Transcription Factor 
Sites in the MDRl Promoter
3.1 INTRODUCTION
The ability of the K/EPR cells to induce MDR levels after as little as 4 hours of drug 
treatment suggested that a transcriptional mechanism of induction may be involved. As 
the Y-box has previously been implicated in MDRl up-regulation (Cornwell et al., 
1993), the in vitro levels of nuclear proteins that bind to the Y-box in K562 cells and 
MDR sublines before and after drug treatment were examined using Electrophoretic 
mobility shift assays (EMSAs). The identity of the Y-box binding protein has been the 
subject of contention in much of the literature, and appears to differ in different cell 
lines. To determine the identity of the transcription factor binding to the Y-box of the 
MDR! promoter of these cells, single stranded YB-1 binding sequences and anti-NF-Y 
antibodies were used in EMSAs. Single stranded YB-1 binding sequences were also 
included as it has been shown that YB-1 binds preferentially to single stranded DNA 
(Tafuri and Wolffe, 1992).
The -55GC box appears to be essential in terms of basal MDRl transcription and 
contains a consensus binding sequence for the transcription factor Spl. Previous work 
has demonstrated the importance of this region through co-transfection of Drosophila 
cell lines, which do not constitutively express Spl, with an MD/?/-luciferase reporter 
and Spl construct (Cornwell and Smith, 1993). The cells transfected with both the
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promoter
MDRl reporter and an Spl construct showed 15 fold higher reporter expression than 
cells transfected with the MDRl reporter alone. Therefore levels of Spl binding to the - 
55GC box in K562 cells and MDR sublines were examined by EMSAs. Relative 
binding levels were also compared before and after drug induction of the K/EPR cell 
line.
To test transcriptional transactivation in a more in vivo model, K562 and K/EPR cells 
were also transfected with a Luc reporter vector containing an MDRl promoter (- 
S8/+76) relative to the transcription start site (TSS), encompassing both the -55GC box 
and the Y-box, cloned upstream of the Luc gene. The reporter activity was then 
compared with and without drug treatment. Transient transfections were also carried out 
using MDRl constructs that also contain either +283/+392 or +329/+455 regions 
(relative to the TSS) of the MDRl gene cloned into a cloning site downstream of the 
Luc gene since previous preliminary studies have indicated a possible negative 
regulatory element within this region of the MDRl gene (Byrne, 2001; Cassano, 
Honours 2000).
A region at approx -120 to -112, containing a CAAT box (-118 to-113) has been 
reported to act as a negative regulatory element (NRE) based on the demonstration in 
MDR K562/ADM cells of an increase in promoter reporter activity upon mutation of 
this region (Ogura et al., 1992). Transfection of drug sensitive MCF-7 cells with a -1 18 
CAAT box deleted promoter reporter construct also resulted in a 12 fold increase in 
MDRl promoter activity compared to wild type promoter, indicating repression of 
MDRl transcription in MCF7 cells by a CAAT binding factor to this region (Ogretmen 
and Safa, 1999). Transfection of MDR MCF-7/Adr cells with the CAAT deleted 
promoter had little effect compared to wild type, indicating that the represser was not 
active in the MDR cell line. To determine the relative levels of a possible represser 
protein binding to the NRE at approx - 120 to -1 12 of the MDRl, EMSAs were carried 
out on nuclear extracts from K562 and the multidrug resistant K/EPR cells using a 
binding probe encompassing this region.
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3.2 MATERIALS AND METHODS
3.2.1 EMSAs
EMSAs are a method of identifying possible DNA-protein interactions. They involve 
labelling DNA of a transcription factor binding sequence and incubating this with 
extracted nuclear proteins. These reactions are then run on a non-denaturing 
polyacrylamide gel and any DNA-protein complexes formed will be retarded in the gel 
whilst free DNA will migrate at a much faster pace. Appropriate protein specific 
antibodies can also be pre-incubated with the nuclear protein extract to confirm the 
identity of the DNA-protein complexes formed. Specific antibodies will bind to the 
protein, thus increasing the size of DNA-protein complexes and this will result in a shift 
in the complex on the gel.
3.2.1.1 Nuclear Extract Preparation
The nuclear extraction method was adapted from Andrews and Faller (1991). All steps 
were carried out at 4°C. 1x10 exponentially growing cells were washed in cold PBS 
then cell pellets were resuspended evenly in 400/d of cold buffer containing lOmM 
HEPES pH7.9 at 4°C, lOmM KC1, 0.1 mM EDTA, 0.1 mM EGTA, ImM DTT, 0.2mM 
PMSF (Sigma Aldrich, Australia), 0.75mM spermidine (Sigma Aldrich, Australia), 
0.15mM spermine (Sigma Aldrich, Australia), ImM benzamidine (Sigma Aldrich, 
Australia), 10//g/ml aprotinin (Sigma Aldrich, Australia) and lOug/ml leupeptin (Sigma 
Aldrich, Australia). The cells were allowed to swell on ice for 10 min, after which 25/d 
of 1% NP-40 was added drop wise with mixing to lyse cells. The cell lysate was 
vigorously vortexed for 10 seconds and spun for 10 seconds at top speed in a bench top 
microfuge. The nuclear pellet was resuspended in 50/d of buffer containing 20mM 
HEPES pH7.9 at 4°C, 25% glycerol, 1.2mM MgC12, 0.2mM EDTA, 0.5mM DTT, 
0.5mM PMSF, 2mM benzamidine, 5//g/ml aprotinin and 5//g/ml leupeptin. The volume 
of the cell lysate was determined and an equal volume of the same buffer containing 
840nM KC1 was added (to ensure a final concentration of 420nM). The samples were 
rocked for 1 hour to allow high salt extraction of the nuclear proteins, then the extracts
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were centrifuged at 15, OOOg for 5 min and the supernatent containing the nuclear 
proteins was collected. The nuclear extract was dialysed in dialysis tubing for 1.5 hours 
against 3 changes of a 100 fold excess of dialysis buffer containing 20mM HEPES 
pH7.9 at 4°C, 20% gycerol, lOOmM KC1, 0.2mM EDTA and 0.2mM EGTA. In later 
experiments the dialysis step was omitted since trials showed no difference between the 
binding of dialysed and undialysed extracts. Protein concentrations of the dialysed 
nuclear extracts were determined by the method of Bradford (1976).
3.2.1.2 Preparation of Labelled Binding DNA
Equimolar amounts of appropriate forward and reverse partially complimentary 
oligonucleotides were annealed in lx one-phorali buffer (Pharmacia, Sweden) by 
incubation at 90°C for 5 min then allowing to cool slowly. Completion of synthesis and 
^labelling was performed in 10/d reactions containing lpmol of annealed 
oligonucleotides, 1/d of one-phorall buffer, 2/d of dCTP label mix (ImM dGTP, ImM 
dATP, ImM dTTP, 50mM Tris pH 7.5, 250mM NaCl, 25mM (3-mercaptoethanol) 
2.5/d of a-32P-dCTP (lOmCi/ml, 3000//Ci/mmol) and 0.5//L of Klenow DNA 
polymerase (5U//d). After incubation at room temperature for 20 min, 1/d of cold chase 
(ImM dCTP, ImM dGTP, ImM dATP, ImM dTTP, 50mM Tris pH 7.5, 250mM NaCl, 
25mM (3-mercaptoethanol) was added and incubated at room temperature for 5 min, to 
ensure the oligonucleotides were completely end filled.
The labelled double stranded DNA fragments were separated from unincorporated 
nucleotides by electrophoresis at 100V on 12% polyacrylamide gels (20 acrylamide: 1 
bisacrylamide) with lx TBE running buffer. Labelled DNA fragments were localised by 
autoradiography, sliced from the gel and eluted from the gel slices overnight in 400/4 of 
TE at 4°C. The fragments were then ethanol precipitated by the addition of 0.1 volumes 
of 3M Sodium acetate pH6.0 and 2.5 volumes of 100% ethanol and incubated at -70°C 
for 20 min. The tubes were then centrifuged at 12, OOOxg and the pelleted labelled DNA 
washed with 100/4 of 70% ethanol and allowed to air dry before being resuspended in 
200/4 of sterile water.
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Single stranded YB-1 oligonucleotide was 32P-end labelled in 20j.il reactions containing 
lOpmoles single stranded YB-1 oligonucleotide, lx T4 polynucleotide kinase buffer, 
5//1 of y32-P-dATP (lOmCi/ml, 3000//Ci/mmol) and 10U T4 Polynucleotide Kinase. 
This was incubated at 37°C for 45min followed by 68°C for lOmin. An equal volume of 
100% formamide was added to the label reaction, which was then vortexed and heated 
to 55°C to disrupt secondary structure. The reaction was then electrophoresed on a 19% 
denaturing polyacrylamide gel at 780V at 55°C (as described in Sambrook et al., 1988), 
and the labelled oligonucleotide localised by autoradiography and excised from the gel. 
Ten volumes of H20 were added to gel fragments and rocked at room temperature for 
lOmin to remove urea. This was replaced with 10 volumes of fresh H20 and rocked 
overnight at room temperature.
Unlabelled competitor DNA molecules were prepared by annealing and end filling the 
forward and reverse oligonucleotides as described for the labelled fragments, except 
that cold chase was used in place of dCTP label mix and no a-32P-dCTP was used. The 
double stranded competitor DNA was ethanol precipitated as described above. The 
oligonucleotides used to prepare the binding sequences are shown below.
5' —TGTGGTGAGGCTGATTGG
Y_t)OX CGACTAACCGACCCGTCCTTG-5'
Single stranded YB-1 5' -GTGATTGGCCAAAG
-55GC box 5' —ACAGCGCCGGGGCGTGGGCTGAGCACAGACTCGTGT-5'
-120/-1 13 NRE 5' —ATCAGCATTCAGTCAATGTAAGTCAGTTAGGC C C G- 5'
USF 5' —GATCCGAATTCCACGTGTAAGGTGCACTGCCTCTTAAG-5'
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3.2.1.3 Binding Reactions
EMSAs were performed in 20//1 reactions containing 15fmol of labelled DNA, 50/<g 
BSA, 1 fig poly(dI-dC).po!y(dI-dC) (Sigma Aldrich, Australia) and 3-5//g of nuclear 
extract in a buffer containing 8mM HEPES (pH 7.9), 60mM KC1, 8% glycerol, 0.3mM 
EDTA, 0.3mM EGTA, 5mM MgCE, 0.05% NP-40 and 0.5mM DTT. The reactions 
were incubated at 20°C for 30 min. For competitor reactions, 100-fold excess of 
competitor DNA was added to the reactions prior to incubation. For supershift 
reactions 1 //g anti-NF-YA antibody (Rocklands, USA) was preincubated with nuclear 
extracts for 3 hours at 4°C prior to adding the label.
The reactions were then electrophoresed at 4°C on a pre-run 6% polyacrylamide gel (80 
acrylamide: 1 bisacrylamide) at 300V with 0.25x TBE running buffer that was 
recirculated every 30 min. The gels were fixed in 10% glacial acetic acid for 10 min, 
washed in water briefly, then transferred to Whatman 3MM paper and vacuum dried. 
The dried gel was autoradiographed by exposure to X-ray film (Kodak, Australia) with 
2 intensifying screens (Dupont Quanta III) or to a Biorad phospholmager screen (Bl). 
fhe resulting images were analysed using the Molecular Analyst program (BioRad). 
Levels of binding complexes were estimated by determining the amount of specific 
complexes formed as a percentage of the total radioactivity loaded onto the gel. To 
compensate for differences in yields of factors in different nuclear extracts, the amounts 
of complexes of interest were normalised by dividing by the amount of complex formed 
with the USF binding probe by the same extract, 
i.e.
Total bound specific X complexes
Total DNA (bound+unbound)
Total bound USF complexes
Total DNA (bound+unbound)
3.2.2 Transient Transfections
K/EPR cells were treated with and without 160ng/ml epirubicin for 16 hrs, then washed 
in serum free RPMI-1640 medium and transfected with MDR-Z+/C constructs. The Luc/
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construct contains an MDRl promoter comprising the sequence between -88 and +76 of 
the MDRl gene, cloned upstream of the luc gene in the pGL3 basic vector (Promega). 
The LucAAB and Luc3BC constructs contain the Luc 1 MDRl promoter plus MDRl 
gene sequences +283/+392 and +329/+455 bp downstream of the transcription start site 
respectively, cloned downstream of the luc gene. Cells were co-transfected with a 
CMV-(3-galactosidase control reporter vector (generously provided by Dr Merlin 
Crossley, University of Sydney) for normalization purposes. Transfections were carried 
out in 24 well plates in triplicate. Serum Free RPMI-1640 (98/d) and DMR1E-C (Life 
Technologies) (2/d) was added to each well and mixed with 100/d media containing 
0.4//g of Lucl, Luc3AB, or Luc3BC constructs and 0.5//g of CMV-(3-galactosidase 
reporter vector DNA. Control (empty vector) transfections containing 0.4//g of pGL3- 
Basic vector (Promega) were also carried out. The reaction mixes were incubated at 
room temperature for 45 minutes. Cells (2.4 x 104) suspended in 40/d of serum free 
media were then added each well and incubated for 4-5 hours at 37°C, 5% COz after 
which 400pi of RPMI-1640/15% FCS was added to each well and plates incubated for a 
further 48 hours.
3.2.2.1 Reporter Assays
Transfected cells were removed to microcentrifuge tubes and collected by 
centrifugation at 500g for 5 minutes to remove the media, then washed in 150//1 PBS 
and re-centrifuged as above. Cells were then lysed by addition of 150/d of IX Reporter
Lysis Buffer (Promega) and frozen at -80°C until ready to be assayed. When ready to
assay, tubes were thawed and centrifuged at 9000g for 5 minutes, to clear the 
supernatant to be assayed.
Galactosidase Activity
Using 96 well plates, 50/d of each sample was combined with 50/d of 2X Assay buffer 
(Promega, Australia) containing 120mM Na2HP04, 80mM NaH2P04, 2mM MgCl2, 
lOOmM (3-Mecarptoethanol and 1.33mg/ml O-nitrophenyl-beta-D-galactopyranoside 
(ONPG) and incubated for between 30 minutes and 3 hours to allow the colour reaction
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to develop. Following the incubation period, (3- Galactosidase activity was measured 
using a microplate reader (Biorad 3550-UV) to determine the absorbance of each 
sample at 405nm.
Luciferase Activity
Immediately following the addition of 100 pi\ of Luciferase Assay Reagent (Promega, 
Australia) to 20/d of sample, luminescence was read using a Turner Designs TD20/20 
luminometer. For each sample, the luminometer performed a 2 second measurement 
delay followed by a luminescence measurement after 10 seconds. Background 
luminescence was also determined by measuring the luciferase activity of cell lysates 
containing no DNA.
3.2.2.2 Statistical analyses
Statistical analysis of transfection data was performed using a 2 sample T test in 
MINITAB. The difference in the data was deemed significant if the p value obtained 
was less than 0.05.
3.3 RESULTS
3.3.1 Preparation of Nuclear Extracts
In preliminary experiments, different methods for the preparation of cell nuclear 
extracts were examined to determine which method resulted in a better yield of nuclear 
proteins. One of these methods, derived from Schreiber et al., (1989) resulted in a total 
protein yield of 166pg from 1 x 10 cells, while a method, derived from Andrews and 
Faller (1991) resulted in a total nuclear protein yield of 260pg from the same number of 
cells. Not only was this higher than the yield from the Schreiber based method but the 
protein was recovered in a much smaller volume. It is important to have a concentrated 
nuclear protein extract for EMSA because each EMSA reaction only allowed for a 
maximum volume of 4pl of nuclear extract and typically 2-10pg of nuclear extract are
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used in each reaction. The major differences between the two methods was that in the 
Andrews and Faller based method a larger number of different protease inhibitors were 
used and the extraction buffer contained glycerol. It is important that nuclear extract 
preparations be stored at or below -70°C to prevent degradation of the proteins by 
proteases. The presence of glycerol in the extraction buffer helps prevent damage to the 
nuclear protein upon freezing. A further difference was that the nuclear extracts from 
the Andrews and Faller based method were dialysed after isolation in order to remove 
salts from the extract, which is desirable since excess salt can inhibit the binding of 
protein to the DNA in the EMSA. The method based on Andrews and Faller (1991) was 
used for the nuclear extract preparations from each of the K562 derived MDR cell lines, 
however in later experiments the dialysis step was omitted. Trial experiments 
demonstrated that there was no difference between the binding of dialysed and 
undialysed extracts and omitting the dialysis step aided the reduction of protein 
degradation in the sample.
3.3.2 Y-box binding factor levels in K562 and MDR sublines
The Y-box has previously been implicated in MDRl up-regulation, therefore 
oligonucleotides were designed to produce a 30bp double stranded radiolabelled DNA 
fragment encompassing the MDRl promoter Y-box (as shown in section 3.2.1.2) for use 
in EMSAs to investigate levels of Y box binding factors. Figure 3.1 demonstrates the 
specificity of binding to the Y-box probe as well as to a control USF binding probe used 
to normalise the levels of binding factors in different preparations of nuclear extracts. 
As shown in Figure 3.1 two major high molecular weight complexes (A and B) and 
several minor low molecular weight complexes were formed with the Y-Box. The 
binding of most of these complexes was specific as shown by the significant reduction 
in binding to labelled probe caused by the presence of competing unlabelled self probe 
(Figure 3.1a) but not by competition with a non-self (USF) competitor (Figure 3.1b). 
Two specific complexes (I and II) also bound to the USF probe but only complex I 
appeared specific (Figure 3. lc).
The levels of Y box binding factor in the various MDR cell lines before and after
induction with P-gp substrates were then examined (shown in Figure 3.2). Comparisons 
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Figure 3.1 EMSA for (a) Y-box binding probe where lane 1 contains no extract and 
lanes 2-4 contain 5pig of nuclear extract from K/DNR cells, and lanes 3 and 4 contain a 
50x and 200x fold concentration of unlabelled self competitor, (b) Y-box binding factor 
where lane 1 contains no extract and lanes 2-4 contain 5//g of nuclear extract from 
K562, and 3 and 4 contain a 50x and 200x fold concentration of unlabelled non-self 
(USF) competitor binding DNA. (c) USF binding factor where lane 1 contains no 
extract and lanes 2-4 contain l//g of nuclear extract from K562, and lanes 3 and 4 
contain 50x fold concentration of unlabelled self (USF) and non-self (Y-Box) 
competitor binding DNA respectively.




































































































































were made between cells grown in drug free culture for 28 weeks (K562 and K/EC32) 
or 17 weeks (K/DNR and K/EPR) and MDR cells whose drug resistance levels had 
been increased by treatment with their original selecting drug concentration for 3 days 
(see section 2.2.7) as well as K562 cells that had been treated with 5ng/ml epirubicin, 
albeit with no effect on drug sensitivity. Figure 3.2a shows results of an EMSA using 
nuclear extracts from the above cell lines and the Y-box probe and Figure 3.2b 
showsthe results of an EMSA performed with the same extract preparations and the 
USF binding probe. Densitometry analysis of the major specific complexes A and B 
formed with the Y-box and complexes 1 and II formed with the USF binding sequences 
was carried out and normalised levels of Y-box binding factor were expressed as a ratio 
of Y-box sequence binding to USF sequence binding (Table 3.1). As indicated there 
appeared to be no major apparent differences in box binding factor between extracts 
from K562 cells and derived MDR sublines, either before or after induction by P-gp 
substrate drug. Repeat experiments confirmed this finding, thus the increased drug 
resistance of these cell lines did not correlate with gross increases in absolute amounts 
of Y box binding protein.
3.3.3 Identification of Y-box binding factor
The identity of the Y-box binding factor is subject to some dispute with some 
investigators reporting that the factor NF-Y binds to the Y-box whilst others that the 
factor Y-Bl is the Y box binding factor. Y-Bl also reportedly binds preferentially to 
single stranded DNA (Hasegawa et al., 1991; Kolluri et al., 1992; Tafuri and Wolffe, 
1992; MacDonald et al., 1995; Bayarsaihan et al., 1996; Mertens et al., 1997; Ohmori et 
al., 1996; Kloks et al., 2002). Therefore to test for the presence of YB-1 in nuclear 
extracts from K562 derived cells a single stranded Y-box oligonucleotide was used as 
binding probe in EMSAs with nuclear extracts from K562, K/EPR, and K/EPR cells 
after 16 hour treatment with 160ng/ml epirubicin (see section 2.2.8). As shown in 
Figure 3.3i(a) a single protein:DNA complex was bound to the 14mer Y-box probe, 
however competition studies revealed this complex was non-specific. That is while its 
formation was significantly or completely reduced by the addition of 100-fold molar 
excess unlabelled self ssYB-1 oligonucleotide, it was also significantly reduced with the 
addition of either unrelated unlabelled single stranded USF binding sequence or double
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stranded USF binding sequence. These results were obtained reproducibly and thus 
suggests that the Y-Bl protein is not found in nuclear extracts from K562 and K/EPR 
cells.
To further investigate the identity of the factor binding to the Y-box in the MDR/ 
promoter in our cells, the effect of an anti-NF-YA antibody on the Y-box binding 
complex formed with K/EPR nuclear extracts was tested. As shown in Figure 3.3i(b) 
two DNA:protein complexes were formed with the Y-box probe (lane 2) and a 
supershift in the migration of both these complexes to a position near the wells of the 
gel was seen after incubation with the anti-NF-YA antibody. No shifting of complexes 
formed with USF binding sequence occurred. This result is reproducible in K562 cell 
extracts and extracts from drug treated K/EPR cells, as is seen by the shift of all specific 
DNA:protein complexes formed with the Y-box probe after incubation with the anti- 
NF-YA antibody in figure 3.3(ii). Therefore these results show that the complexes 
formed in vitro with nuclear extracts from the K562 and K562 MDR subline K/EPR and 
the Y-box are characteristic of NF-Y.
3.3.4 -55GC box binding factor levels in K562 and MDR sublines
To investigate the role of factors binding to the -55GC box of the MDRl promoter a 
binding probe encompassing this region was incubated with nuclear extracts from K562 
cells and untreated and drug treated K/EPR sublines. Figure 3.4 shows an example of 
the results of an EMSA using 3//g of nuclear extract from K562 (lane 6), K/EPR (lane 
5) and K/EPR pre-treated for 16 hours with 160ng/ml of epirubicin (lane 4). Five 
complexes were seen with the -55GC box sequence with complexes I, IV and V being 
specific since competition with a 100-fold excess of unlabelled -55GC box binding 
sequence reduced binding dramatically, whereas a 100-fold excess of unrelated USF 
binding sequence had no effect on complex binding. One major and two minor 
complexes were formed with the USF binding sequence, however only complex A and 
C were found to be specific. Densitometery analysis was carried out on specific 
complexes from the -55GC box and USF binding sequences, with USF binding used to 
normalise levels of -55GC box binding factor. Normalised levels were expressed as a
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Figure 3.3 (i) (a) EMSA using single stranded YB-1 binding oligonucleotide where 
lane 1 contains no extract and lanes 2-4 contain 3//g of nuclear extract from K562 (lane 
2), K/EPR (lane 3), K/EPR treated (lane 4). Lane 5 has a 100-fold excess of single 
stranded self competitor DNA, lane 6 a 100-fold excess of unrelated single stranded and 
lane 7 a 100-fold excess of unrelated double stranded USF competitor DNA.
(b) Supershifting of Y-box binding factor with anti-NF-YA antibody for Y-box (lanes 
1-3) and USF binding sequence (lanes 4-6), where lanes 1 and 4 contain no extract, 
lanes 2 and 5 contain 3ug K/EPR nuclear extract and lanes 3 and 6 contain 3ug K/EPR 
extract incubated with anti-NF-YA.
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Figure 3.3 (ii) EMSA for supershifting of Y-box binding factor with anti-NF-YA 
antibody for Y-box (lanes 1-9) and USF binding sequence (lanes 10-16), where lanes 1 
and 10 contain no extract, lanes 2,3 and 11 contain 3ug of K562 nuclear extract, lanes 4, 
5, 8, 9, 12, 14, 15 and 16 contain 3ug K/EPR nuclear extract and lanes 6, 7 and 13 
contain 3ug of nuclear extract from K/EPR cells treated for 16hours with 160ng/ml of 
epirubicin. The nuclear extracts in lanes 3, 5, 7 and 14 were incubated with anti-NF- 
YA. Lanes 8 and 15 have a 100-fold excess of self competitor DNA and Lanes 9 and 16 
have a 100-fold excess of unrelated competitor DNA.
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Figure 3.4 EMSA for (a) -55GC box and (b) USF where lane 1 contains no extract and 
lanes 2-6 contain 3//g of nuclear extract from K562 (lane 6), K/EPR (lane 5), K/EPR 
treated (lane 4). Lane 2 has a 100-fold excess of self competitor DNA and nuclear 
extract from K/EPR treated cells. Lane 3 had a 100-fold excess of unrelated competitor 
DNA and nuclear extract from K/EPR treated cells. For the -55CG box, binding 
complexes are labelled I, II, III, IV and V. For the USF binding sequence complexes are 
labelled A, B, and C.
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ratio of -55GC box binding factor to USF binding. As shown in Table 3.2 the levels of 
-55GC box binding factor appeared similar are in K562 and K/EPR cells. Moreover the 
drug treatment that resulted in induced MDR levels showed no effect binding levels. 
These results were reproducible in numerous subsequent experiments (n > 10).
3.3.5 Transient Transfection of MDRl Promoter
The EMSAs discussed above were used to compare absolute levels of binding factors to 
the Y-box and the -55GC box in the MDRl promoter regions in the K562 and K/EPR 
cells. However these are in vitro experiments and the binding or transactivation ability 
of transcription factors in vivo may be influenced by protein-protein interactions or 
specific modification of binding factors. Therefore in order to test the importance of 
these two regions in a more in vivo model, reporter gene studies were carried out. K562 
and K/EPR cells were transfected with a luciferase reporter gene system previously 
designed in the laboratory to contain an MDRl promoter region (-8S/+76), referred toas 
Lucl, subcloned into the upstream promoter site of the luciferase reporter vector pGL3- 
Basic (Cassano, Honours thesis, 2000).
The -88Z+76 region was chosen since previous transfection studies have shown that 
MDRl promoter activity is not increased with the inclusion of regions beyond -88, 
(Cornwell and Smith, 1993; Goldsmith et al., 1993). Further studies have indicated that 
maximum promoter activity is achieved by terminating the promoter at +76 (Lau et al., 
1998). Most importantly, this Lucl construct encompasses both the -55GC box and the 
Y-box. CMV-|3-galactosidase was co-transfected with Lucl to normalise for 
transfection efficiency. CMV- (3-galactosidase was chosen as its promoter does not 
contain any Spl binding sites, and therefore will not compete for possible Spl binding 
sites in the - 55GC box in the Lucl construct. As shown in Figure 3.5, the transfected - 
88/+76 MDRl Lucl promoter was as active in K562 cells as it was in MDR K/EPR 
cells. In fact it appeared slightly less active in the MDR K/EPR cell line, although 
statistical analysis revealed no significant difference between the activity in these two 
cell lines. Thus the absence of endogenous MDRl mRNA in K562 cells was not due to 
inactivity of, or inability to bind by essential transcription factors.
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Table 3.2 -55GC box binding factor levels* in K562, K/EPR and K/EPR drug treated 
cells
K562 K/EPR K/EPR drug treated
2.58 2.65 2.48
* levels are normalised relative to USF levels in each cell line as follows,
(Total -55GC box bound complexes I, IV and V \Total -55GC box DNA (bound+unbound) '
( Total USF binding, complex A and C \Total USF DNA (bound+unbound) *

















Figure 3.5 Relative MDR1 promoter activity in K562 ( ) and K/EPR cells (■). 
Individual MDRI promoter activities are standardised by dividing luciferase units by 
co-transfected |3-galactosidase units. Activity in K/EPR cells is expressed relative to 
that in K562 cells determined in the same experiment. The average and standard 
deviation of 9 separate determinations (triplicate wells from 3 experiments) are shown 
for each cell line.
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Previous transfection experiments in this laboratory have indicated negative regulation 
when the +283/+455 region of the MDRI promoter was cloned downstream of the Luc 
gene in the Lucl construct and transfected in an MDR cell line derived from the HL60 
cell line (Byrnes, unpublished results). In an attempt to localise further the negative 
regulatory element, the +283/+455 region was further subdivided into 2 additional 
constructs: Luc3AB and Luc3BC which contained respectively the +283/+392 and 
+329/+455 regions cloned into a site downstream of the luc gene in the Lucl construct 
(Michelle Byrne, Honours thesis 2001). To test if these regions played any role in 
MDRI induction the K/EPR cells were treated with and without 160ng/ml epirubicin for 
16 hrs, then washed and transfected with either Lucl, Luc3AB or Luc3BC, plus CMV-[3- 
Galactosidase DNA. Luciferase activity was measured after 48 hrs and normalised with 
respect to (3- galactosidase activity. Empty vector transfections were also carried using 
the pGL3-Basic vector as a control.
Figure 3.6 shows the normalised relative light units for a typical transfection of K/EPR 
cells with either the PGL3-basic vector, Lucl, Luc3AB or Luc3BC constructs before and 
after drug induction of MDR. It is clear from this that epirubicin treatment had no 
effect on MDR/ promoter activity with any of the constructs tested, (where Luc! 
p=0.613, Luc3AB p=0.742 and LucABC p=0.890 when comparing treated versus 
untreated cells). Thus the induction of MDRI mRNA produced upon exposure of the 
K/EPR cells to drug was not accompanied by a change in the activity of, or binding 
ability of any transcription factors that may bind to these putative repressor elements.
3.3.6 Repressor Binding Protein levels in K562 and K/EPR cell lines
A previous study has suggested the presence of a CAAT-containing negative response 
element (NRE) at approx - 120 to -1 12 of the MDRI promoter (Ogura et al., 1992; 
Ogretman and Safa, 1999). To determine the relative levels of a possible repressor 
protein binding to this region, nuclear extracts from K562 cells, K/EPR cells and K/EPR 
cells treated with !60ng/ml of epirubicin for 16 hours, were incubated with a DNA 
binding probe encompassing -129 to -106 bp. As shown in Figure 3.7. a single specific 
DNA protein complex was obtained for both the K562 and K/EPR untreated and 
epirubicin treated cell lines. Densitometry was performed on the binding complexes













Figure 3.6 MDRI promoter activity in K/EPR untreated (■) and K/EPR treated cells 
(■). Individual Luc 1, Lwc3AB and Luc3BC MDRI promoter activities are standardised 
by dividing luciferase units by co-transfected (3-galactosidase units. The average and 
standard deviation of 3 separate determinants are shown for each cell line.
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Figure 3.7 EMSA for (a) NRE binding factor and (b) USF using no extract (lane 1), 
3fig of nuclear extract from K562 (lane 2), K/EPR (lane 3) and K/EPR treated (lane 4). 
Lane 5 has a 100-fold excess of self competitor DNA and 3//g of K/EPR treated nuclear 
extract lane 6 has a 100-fold excess of unrelated competitor DNA and 3pig of K/EPR 
treated nuclear extract.
Table 3.3 NRE binding factor levels* in K562, K/EPR and K/EPR drug treated cells
K562 K/EPR K/EPR drug treated
0.87 1.00 0.84
* levels are normalised relative to USF levels and calculated as follows,
/ Total of NRE bound complex \
V Total NRE DNA (bound+unbound) /
/ Total of USF binding complex \
V Total USF DNA (bound+unbound) /
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and the NRE binding complex was normalised with USF binding complex (Table 3.3). 
These results indicate that the levels of the putative repressor in K562, K/EPR untreated 
and epirubicin treated MDR cells were similar in all extracts, suggesting that the 
absence of MDRI expression in K562 cells is not due to the presence of the negative 
repressor in these cells only.
3.4 SUMMARY OF RESULTS
In view of the controversy over the role of Y-box binding proteins we investigated the 
amounts and identity of proteins able to bind to the Y-box in K562 MDR cells and 
whether drug induction was mediated by changes in Y-box binding protein. Supershift 
experiments identified the Y-box binding protein in our cell lines to be NF-Y and not 
YB-1. We found similar levels of NF-Y in the MDR cells and the relatively drug 
sensitive parental K562 cells. Therefore, whilst NF-Y may be essential for MDRI 
activity, its presence is not sufficient to ensure P-gp expression in K562 cells. 
Moreover the difference between K562 and its MDR cell lines is not related to 
differences in absolute amounts of available nuclear NF-Y factor.
A single stranded YB-1 binding sequence was also included in the EMSA studies on the 
Y-box as YB-1 has been shown to preferentially bind to single stranded DNA 
(Hasegawa et al., 1991; Kolluri et al., 1992;Tafuri and Wolffe, 1992; MacDonald et al., 
1995; Bayarsaihan et al., 1996; Mertens et al., 1997; Ohmori et al., 1996; Kloks et al., 
2002). However we found no specific protein binding to the single stranded 
oligonucleotide, thus strengthening the argument for the identification of NF-Y as the 
protein binding to Y-box in the MDRI promoter of K562 derived cell lines. It was also 
questioned whether induced MDR levels and upregulation of MDRI transcription upon 
drug treatment coincided with increased NF-Y levels in the cells, however Y-box 
binding factor levels were not effected by short term drug exposure. Similar to NF-Y, 
levels of binding to the -55GC box also did not differ between K562 and the K/EPR 
MDR cell line and did not change after drug exposure. Levels of protein complex 
binding to an NRE, containing a CAAT-like motif at -1 18 to -1 13, were also found to
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be present in similar levels in both K562 and K/EPR cells suggesting that the negative 
regulation of MDRI expression in K562 cells, compared to K/EPR cells, is not caused 
by differences in absolute amounts of the factor binding to the -1 18/-1 13 NRE.
EMSAs are an in vitro experiment and thus do not take into account the possibility that 
the binding or transactivation ability of the transcription factors in vivo may be 
influenced by protein-protein interactions or specific modification of bound factors. 
However the finding that the -88/+76 MDRI promoter reporter, which contains the Y- 
box and the GC box, is equally effective in driving reporter gene expression in K562 
cells as it is in K/EPR cells, suggests that such factors are not the cause of the 
differences in resistance and MDRI mRNA levels between the K562and K/EPR MDR 
cell lines. This conclusion is supported by the finding that -88/+76 MDRI promoter 
driven reporter gene expression was not effected by drug induction of MDR in the 
K/EPR cell line. Transfection of the K/EPR cell line with constructs encompassing 
+283/+392 or +329/+455 regions of the MDRI promoter, confirmed the presence of a 
possible negative regulatory element in this region. However, repression by these 
regions was also not effected by drug induction of K/EPR cells.
Thus our finding suggest that changes in the availability of factors binding to the -55GC 
box, Y-box and -1 I8/-1 13 NRE cannot be responsible for P-gp up-regulation in K562 
derived MDR cell lines.
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CHAPTER 4
MDRI Promoter Methylation Studies
4.1 INTRODUCTION
The results described to date indicate that increased nuclear levels of Y-box or -55GC 
box binding proteins are not responsible for the differences in MDRI activation in K562 
and derived MDR sublines.
Since repression of MDRI transcription may also result from hypermethylation of its 
promoter (Desiderato, 1997; Kantharidis et al., 1997) it was hypothesised that the 
absence of P-gp expression in the K562 cells was due to methylation. Therefore 
bisulphite genomic sequencing was used to determine the methylation status of CpG 
dinucleotides in the MDRI promoter of K562 and K/EPR cells. The technique, shown 
schematically in figure 4.1, exploits the ability of sodium bisulphate to selectively and 
efficiently deaminate cytosine residues into uracil whilst 5-methylcytosines do not react 
and thus remain unconverted as cytosines (Clarke et al., 1994). Upon subsequent 
polymerase chain reaction (PGR) using bisulphate deaminated DNA strand specific 
primers, the converted uracil residues amplify as thymines whereas 5-methylcytosines 
remain as cytosines. Products can then be subcloned and sequenced and the methylation 
status of the CpG dinucleotides can be assessed by comparison of the converted 
sequence with the original unconverted sequence. In this study, the efficiency of the 
bisulphite conversion of the DNA was increased by the addition of urea to the bisulphite 
reaction (Paulin et al., 1998).
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4.2 MATERIALS AND METHODS
4.2.1 Genomic Sequencing
4.2.1.1 Bisulphite Conversion of Genomic DNA
Genomic DNA was extracted from K562 and K/EPR cells at approximately 70% 
confluent growth as described in section 2.2.5. The DNA was restriction endonuclease 
digested with EcoRl, an enzyme which does not cut the MDRI promoter region of 
interest. EcoRl digests typically contained 1 - 10//g of genomic DNA and between 5 - 
10 units of enzyme per pig of target DNA. Digests were performed in the buffer and at 
the temperature recommended by the supplier and supplemented with 100//g/ml 
acetylated BSA. Reactions were incubated for at least 1 hour, occasionally overnight. 
After incubation, 0.2 - 1 pig of the DNA was run in a 1% agarose gel for an indication 
of digestion completion.
Bisulphite conversion of genomic DNA was based upon the method described by Clark 
et al., (1994). The procedure involves the modification of unmethylated cytosine 
residues to uracil under conditions where methylated cytosines remain unchanged. 
Briefly, \pig of EcoRl digested genomic DNA was denatured by addition of freshly 
prepared 3M NaOH to a final concentration of 0.31V1 and incubated at 37°C for 15 
minutes. The denatured DNA was then treated by addition of freshly prepared 2.01V1 
sodium bisulphite (BDH), pH5.0 (pH with 10M NaOH) to a final concentration of 1.7M 
and freshly prepared lO.OmM hydroquinone (BDH) to a final concentration of 0.5mM. 
Urea at a final concentration of 5.36M was also added in the DNA bisulphite 
conversion, as this has been shown to enhance the conversion (Paulin et al., 1998). The 
solution was overlayed with mineral oil and incubated at 55°C for 3 hours followed by 
94°C for 3 minutes and this cycle was repeated five times. Following incubation the 
DNA was purified using Bresa clean (Genesearch) and incubated at 37°C for 15 minutes 
with freshly prepared NaOH to a final concentration of 3.0M to neutralise the sample, 
and the DNA was ethanol precipitated, dried, resuspended in an appropriate volume of 
sterile water and stored at -20°C.
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4.2.1.2 PCR of converted genomic DNA
Bisulphite converted genomic DNA was amplified by the polymerase chain reaction 
(PCR). The target region was amplified by PCR using nested primers comprising the 
two forward primers :
Ml: 5’ TATTAAATAAAGGATGAATAGATGTAATTTAG 3’;
M3: 5’ TTGTTAAGTATGTTGAAGAAAGATTATTGT 3’ 
and the two reverse primers:
M2: CA ACAT AT CATTT ATTT CAA A ACT A AAA AC 3’;
M4: 5’ A A A ACA A ACT AATT ACCTTTT ATT ATT CA AT 3’ (Invitrogen).
PCR reagent concentrations were initially varied to determine optimum conditions for 
amplification. The final optimal conditions used for each sample are given below. PCR 
reactions were carried out in 25/d total volume reactions containing 37mM Tris-Cl pH 
8.8, 16.6mM (NH4)2S04, 0.45% TritonX-100, 0.2mg/ml gelatin, 1.5mM MgCI2, 200//M 
dNTPs, 1//M primers, 0.6 units Taq polymerase (Applied Biosystems) and 25-50ng 
converted DNA using the following PCR parameters {94°C /lmin, 50°C /2min, 72°C 
/3min} x 5 cycles , {94°C /0.5min, 50°C /2min, 72°C /1.5min} x 30 cycles and {72°C 
/6min} x I cycle. PCR products were run in a 1.5% agarose IX TAE gels along with 
pGEM DNA size markers (Promega), then excised and purified using the Bresa-clean 
method. Purified PCR products were ligated into T-tailed pGEM-T vector (Promega) 
using optimised vectorinsert molar ratios and subcloned into calcium competent E.coli 
DH5^c cells.
4.2.1.3 Subcloning of PCR Products
Preparation and Ligation of Insert DNA to pGEM-T Vector
PCR product obtained from the amplification of sodium bisulphite converted DNA were 
run in 1.5% agarose IX TAE gels along with pGEM DNA size markers, then excised 
and purified using the Bresa-clean method, prior to ligation to pGEM-T vector 
(Promega). Ligation reactions were performed overnight at 4°C with a vector: insert 
molar ratio of 1:1 in a 10/d reaction containing lx T4 DNA Ligase buffer (Promega)
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and 1 unit of T4 DNA Ligase (Promega). This was then subcloned into E. coll DH5a 
cells.
Preparation and Transformation of Competent Cells
E. coli (DH5a) cells were streaked from glycerol stocks onto an LB agar plate and 
incubated overnight at 37°C. A single colony was chosen, inoculated into 75mls of LB 
medium and grown overnight at 37°C, 300rpm. The following morning the culture was 
diluted 1/40 - 1/100 in LB medium and grown as before until the OD600 was 
approximately 0.15. All subsequent steps were performed on ice to ensure that 
competent cells with high transformation efficiency were obtained. The culture was 
incubated on ice 10 minutes prior to centrifugation for 7 minutes at 3000g, 4°C. Excess 
media was drained off and the pellet of cells was gently resuspended in 1/5"' volume of 
ice cold Calcium buffer (60mM CaCI2, 15%v/v glycerol/lOmM PIPES, pH 7) and re­
spun as above. The supernatant was again discarded and the cells gently resuspended in 
1/5"' volume of ice cold Calcium buffer and allowed to stand on ice for at least 30 
minutes. The cells were pelleted at 3000g, 4°C, and resuspended in l/25lh volume 
Calcium buffer. 21 OjliI aliquots were dispensed into pre-chilled microcentrifuge tubes, 
snapped frozen on dry ice and stored at -80°C until required.
The required amount of DNA was added to 0.2ml of competent cells and incubated on 
ice for 30 minutes. Competent cell/DNA mixtures were heat shocked at 42°C for 
exactly 90 seconds and immediately returned to the ice and allowed to chill for 1-2 
minutes. 800id of LB medium was added to the mixture and placed in a rotary shaker at 
300rpm, 37°C for 45 minutes to allow the bacteria to express the plasmid genes. 
Aliquots (1 OOjLil and 200ul) of the transformed cells were transferred to two agar plates 
containing ampicillin (lOOug/ml) spread evenly over the surface of the plate and 
incubated overnight at 37°C.
Identification of Recombinants
Putative recombinant clones were amplified by picking white colonies and growing 
these in 2.5mls of LB broth overnight at 37°C/300r.p.m. Cells were collected by 
centrifugation at 1 1600g for 3 minutes and lysed by the addition of 300pl of TENS 
buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 0.1 N NaOH, 0.5% SDS)
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followed by a brief vortex. The lysate was neutralised by addition of 150pl of 3.01V1 
sodium acetate (pH 5.2) and given a brief vortex. Cellular debris and nuclear DNA was 
removed by centrifugation at 1 1600g for 2 minutes. The supernatant was extracted with 
an equal volume of phenol (Tris buffered, pH 7): chloroform: isoamyl alcohol 
(25:24: l,v:v:v). The mixture was centrifuged at 1 1600g for 5 minutes at RT, then the 
aqueous phase was removed and extracted with an equal volume of chloroform: isoamyl 
alcohol mixture (24:1, v:v). This was then centrifuged at 11600g for 5 minutes at RT 
and the DNA was then ethanol precipitated from the aqueous phase by the addition of 
l/10th volume of 3M sodium acetate pH 5.2 and 2 volumes of cold 100% ethanol. 
DNA precipitation occurred for 15 minutes at -20°C and the DNA pellet recovered by 
centrifugation at 1 1600g for 30 minutes at RT.
The pellet was rinsed with 70% ethanol, dried briefly in a heating block (55°C) and 
resuspended in 30j.il of water containing 300pg/ml RNase A (Sigma-Aldrich) and 
incubated at 37°C for I hour. After RNase A treatment the plasmid DNA was further 
purified by a phenol: chloroform: isoamyl alcohol extraction (25:24:1, v:v:v) and 
recovered by ethanol precipitation and resuspended in 30j.il of water. An aliquot of 
DNA (3 pi I) was electrophoresed along with DNA purified from control blue colonies, to 
identify possible recombinants. Recombinants were identified by their slower migration 
than non-recombinants in agarose.
Sequencing reactions were carried out by the Australian Genome Research Facility 
using Ml3 sequencing primers. Sequence data was compiled using the Multisequence 
Alignment Program (ANGIS). Sequences were aligned using the ‘Pile-up’ (ANGIS) 
program, and aligned sequences were then formatted with the ‘Pretty’ (ANGIS) 
program allowing visualisation of the aligned sequences.
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4.3 RESULTS
4.3.1 Promoter Methylation status in K562 and K/EPR cells
To test the possibility that required MDRI transcription factors may be unable to access 
their sites in vivo due to chromatin condensation caused by CpG methylation, we 
performed bisulphite mediated genomic sequencing to determine the methylation status 
of the 66 CpG sites between - 462 to +782bp in the MDRI downstream promoter in 
K562 and K/EPR cells. The sequence region under investigation and the location of the 
66 CpG sites are shown in Figure 4. F Also shown in Figure 4.1 are the locations of the 
two cycle PCR nested converted strand specific primers, M1/M2 and M3/M4. Twenty 
individual clones from each of K562 and K/EPR DNA were sequenced.
As shown in Table 4.1, all CpG sites from -4-62bp to the transcription start site of the 
MDRI gene in K562 cells were unmethylated except for site 17, (-30bp) in one clone. 
The remaining CpG sites from +4 to +719bp were unmethylated in most K562 clones, 
except for CpG sites 43 and 44 (+421 and +423bp), that were methylated in all DNA 
molecules examined from K562 cell DNA. Thus methylation-mediated 
heterochromatinisation of the promoter cannot account for the absence of expression in 
K562 cells. Hypermethylation was also not observed in K/EPR clones, although a few 
individual sites were methylated in a small number of clones. Significantly, CpG sites 
1 1 and 12 located within the -110 GC box, previously suggested to be an NRE, were 
not methylated in K/EPR cells, thus binding of a represser is not prevented by 
methylation in K/EPR cells. Most noticeable however, was the absence of methylation 
at sites 43 and 44, which were completely methylated in K562 cells.
4.3.2 Protein binding levels at CpG sites 43/44
As the only highly differential site of methylation occurred at CpG sites 43 and 44, 
oligonucleotides encompassing this region were designed for use in EMSAs (3.2.1) to 
determine if specific binding of a complex to this site occurred. A radiolabelled binding
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Ml
TATTTTTTAA AACTTCCTTT TTCTTTCATT CCATTTATCA TCAAATAAAG GATGAACAGA -478
M3
TGTAACTCA^ AAACTGTCAA GCATGCTGAA GAAAGAC CT^C TGCAGAAAAA TTTCTCCTAG -418
CCTTTTCAAA GGTGTTAGGA AGC AGAAAGG TGATACAGAA TTGGAGAGGT CGGAGTTTTT
i
-358









TTGCCCTTTC TAGAGAGGTG CAACGGAAGC -178
6 7 8
CAGAACATTC CTCCTGGAAA TTCAACCTGT TTCGCAGTTT CTCGAGGAAT CAGCATTCAG -118
9 10
TCAATCCGGG CCGGGAGCAG TCATCTGTGG TGAGGCTGAT TGGCTGGGCA GGAACAGCGC -5 8
11 12 13
CGGGGCGTGG GCTGAGCACA GCCGCTTCGC TCTCTTTGCC ACAGGAAGCC TGAGCTCATT 3
14 15 16 17 TSP
CGAGTAGCGG CTCTTCCAAG CTCAAAGAAG CAGAGGCCGC TGTTCGTTTC CTTTAGGTCT 63
18 19 20 21
TTCCACTAAA GTCGGAGTAT CTTCTTCCAA AATTTCACGT CTTGGTGGCC GTTCCAAGGA 123
22 23 24
GCGCGAGGTA GGGGCACGCA AAGCTGGGAG CTACTATGGG ACAGTTCCCA AGTGTCAGGC 183
25 26 27
TTTCAGATTT CCTGAACTTG GTCTTCACGG GAGAAGGGCT TCTTGAGGCG TGGATAGTGT 243
28 29
GAAGTCCTCT GGCAAGTCCA TGGGGACCAA GTGGGGTTAG ATCTAGACTC AGGAGCTCCT 303
GGAGCAGCGC CCAAACCGTA GTGGCACTGG ACCATGTTGC CCGGAGCGCG CACAGCCCGC 363
30 31 32 3334 3536
GCGGTGCGGG GACCTGCTCT CTGAGCCCGC GGGCGGTGGG TGGGAGGAAG CATCGTCCGC 423
37 38 3940 41 42 4344
GGCGACTGGA ACCGGGAGGG AGAATCGCAC TGGCGGCGGG CAAAGTCCAG AACGCGCTGC 483
45 46 47 48 49 5051
CAGACCCCCA ACTCTGCCTT CGTGGAGATG CTGGAGACCC CGCGCACAGG AAAGCCCCTG 543
52 5354
CAGTGCCCAT CGCGGCCAGA GCAGCTGGGG CATCAACGGC GGGCGCTCCC TCTTACTGCT 603
5556 57 581 59
CTCTGGCTTC GACGGGGGAC TAGAGGTTAG TCTCACCTCC AGCGCGCCTG AGGCTCATGC 663
6C1 61 6263
ATTTGGCTAA TGAGCTGCGG TTTCTCTTCA GGTCGGGATG GATCTTGAAG GGGACCGCAA 723
64 . 65 M4 66
TGGAGGAGCA AAGAAGAAG^ ACTTTTTTAA ACTGAACAAT AAAAGGTAAC TAGCTTGTTT 783
M2
CATTTTCATA GTTTACATAG TTGCGAGATT TGAGTAATTT ATTTCTAG^C TCCAGCTCTG 843
AAATAAATGA CATGTTGTTG TTTTTAATTA TTTTTAAGAA ACGCAAGCTA GCCTTTGGAA 903
Figure 4.1 Sequence of the MDRI promoter. CpG sites are shown in blue and 
numbered below the sequence. Other cytosines are shown in red. The locations of the 
converted strand specific primers Ml, M2, M3 and M4 are located by arrows above the 
sequence. The transcription start point is highlighted in pink.
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CpG site
1-16 17 18-20 21 22 23 24-38 39 40 41-42 43 44 45-48 49 50-53 54 55-58 59 60-66
K562
- - - M
- - - M






















- MM M - M -
M M
- M - -
Table 4.1 Methylation status of CpG sites in the MDRI promoter region (- 462 to 
+782bp) in K562 and K/EPR cells. Results for 19 and 20 individual clones from K562 
and K /EPR cells respectively are shown, where M indicates a methylated CpG site and 
- indicates an unmethylated site.
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probe for this region was prepared as described earlier (3.2.1.2) using the 
complementary oligonucleotides shown below:
CpG site 43/44 binding oligo 5 ' -ggttccagtcgccgcgga
GGCGCCTGCTACGAAGGA-5'
As shown in Figure 4.2a one complex (A), was found to bind specifically to the CpG 
site 43/44 DNA probe, since competition with a 100-fold excess of unlabelled ‘self’ 
binding sequence reduced binding dramatically (lane 5), whilst a 100-fold excess of 
unrelated binding sequence (USF) had no effect on binding of this complex (lane 4). 
Normalisation of CpG site 43/44 complex A binding with that of USF complex B 
binding (shown in Figure 4.2b) demonstrated that the levels of CpG site 43/44 binding 
factor was similar in both K562 and K/EPR nuclear extracts.
Analysis of the sequence surrounding CpG sites 43 and 44 using the program Sigscan 
revealed potential binding sites for Spl, a GT box, FyF-1 and a potential inverted 
consensus sequence for the transcription factor NF-1 (shown in Figure 4.3, Table 4.2).
4.4 SUMMARY OF RESULTS
Bisulphite genomic sequencing of K562 and K/EPR cell DNA revealed that both cell 
lines were almost completely unmethylated at all CpG sites in the promoter region from 
- 462 to +782bp, thus possible changes in promoter binding site accessibility were not 
orchestrated by methylation. The only exceptions were two distant downstream sites 
that were methylated in K562 but not K/EPR DNA and are unlikely to cause wholesale 
promoter heterochromatinisation. EMSA studies on this region showed a DNA protein 
complex binds to this region in both cell lines. Although this protein is present in both 
cell lines, it may not be able to bind in vivo in the K562 cells due to the methylation in 
this region.
A study of potential transcription factor binding sites in the sequence surrounding the 
methylated CpG sites 43 and 44 was performed using a SIGSCAN analysis. This
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#Figure 4.2 EMSA for (a) binding to CpG sites 43 & 44 and (b) USF binding sequence 
using no extract (lane 1), 3ug of nuclear extract from K562 (lane 2), and K/EPR (lane 3­
5. Lane 4 has a 100-fold excess of unrelated competitor DNA and lane 5 had a 100-fold 
excess of self competitor DNA.
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Figure 4.3 Transcription factor analysis of sequence surrounding CpG sites 43 and 44. 
CpG sites are shown in blue, Spl is pink, GT box is red, LyF is highlighted green, and 
inverted NF-1 sequence is in violet.
Table 4.2 Transcription factor binding sequences.
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revealed that located near the methylation sites is a binding site for Spl and a GT box, 
which is also known to bind members of the SP/XKLF family of transcription factor, of 
which Spl is a member (Bowman and Philipsen, 2002; Fania et al., 1997). Studies 
have shown that Cytosine methylation in the Spl binding sequence does not affect 
binding of transcription factor Spl in vitro (Harrington et al., 1988). Moreover the 
differential methylation sites are not within the Spl binding sequence. A binding 
sequence for the transcription factor FyF-1 is also located near to the differential 
methylation sites, but again these are not within the FyF-1 binding sequence. FyF-1 is a 
transcriptional activator of genes but thought to be restricted to genes of B and T- 
lymphocyte linages (Lo et al., 1991; Musumoto et al., 2002). NF-1 is a family of 
transcription factors that have been implicated in the activation and repression of many 
genes and binds to DNA as dimers to the consensus sequence TTGGC(N)5GCCAA 
(Blomquist et al., 1996). Only a partial sequence was found in the sequence surrounding 
the methylated CpG sites and therefore it is not likely to be of any significance. Thus 
the significance of the differential methylation at CpG sites 43/44 is as yet unknown.
In view of the absence of any evidence for transcriptional repression of the MDR! gene 
in K562 cells, or for a mechanism mediating transcriptional activation in K562 derived 
MDR lines, it is possible that the lack of P-gp expression in K562 cells and its 
upregulation in the K562 derived MDR ceil lines may mediated by post-transcriptional 
mechanisms, as was recently reported for other K562 derived MDR cell lines (Yagiie et 
al., 2003).
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CHAPTER 5
MDRI mRNA Stability Studies
5.1 INTRODUCTION
The half-life of mRNA molecules may vary from minutes to hours to months. Long 
lived mRNAs can support multiple rounds of translation, thus producing a larger 
volume of gene product, whereas short lived mRNAs enable rapid regulatory changes in 
response to environmental signals. Thus regulation of mRNA stability is another point 
at which gene expression can be controlled (reviewed in Wilusz et al., 2001). Alteration 
of mRNA stability can be controlled by variation in the length of the poly-A tail, or by 
proteins which bind to stability or instability regulating sequences in the mRNA.
Different levels of MDRI mRNA were found in the K562, K/EPR and K/EPR drug 
treated cell lines. To investigate whether an increase in MDRI mRNA stability is 
responsible for the increased levels of MDRI mRNA and thus MDR in the K/EPR and 
K/EPR drug treated cells, the half lives of MDRI mRNA were determined following 
inhibition of transcription by actinomycin D, and compared for each cell line, before 
and after epirubicin treatment.
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5.2 MATERIALS AND METHODS
5.2.1 Determination of Inhibitory Actinomycin D concentrations
To assess mRNA stability, transcription is inhibited by the addition of Actinomycin D 
and levels of mRNA measured at various times following transcriptional inhibition. To 
determine the actinomycin D concentration required to inhibit transcription in our cell 
lines, 1 x 105 cells were plated into 24 well plates in lmL of media. Cells were 
incubated for 2 hours with serial dilutions of actinomycin D. Matching solvent only 
control treatments were also set up to assure inhibition was not due to the DMSO in 
which the actinomycin was dissolved. After 2 hours the actinomycin D was removed by 
spinning cells at 500xg for 5minutes and washing in PBS. The cells then were pulsed 
with 4/iCi/ml |3H|Uridine for 2 hours. After washing in PBS, RNA was isolated from 
the cells using Tri reagent (Sigma-Aldrich) according to the manufacturers protocol.
Total RNA was resuspended in 25//L nuclease free water and 1/d was spotted on a 
microBeta glassfibre filtermat (VVallac, Finland) and dried at 60°C for 50 mins. A 
meltilex A melt-on scintillator sheet (Wallac, Finland) was then applied to the filtermat 
by heating at 60°C. Filtermats were then placed in a microbeta sample bag (Wallac, 
Finland) and quantitated in a microbeta liquid scintillation counter (Wallac, Finland), to 
measure the levels of RNA synthesised following inhibition of transcription with 
varying levels of actinomycin D.
5.2.2 MDRI mRNA stability determination
Cells were treated for 3 days with epirubicin (David Bull Laboratories, Australia) at a 
concentration of 5ng/ml for K562 cells and 20ng/ml for K/EPR cells and assayed for 
paclitaxel cytotoxicity (as described in section 2.2.7 and 2.2.2 respectively). 
Exponentially growing cells were then plated into 6 well plates in 5ml of RPM1 and 
treated with 4//g/ml actinomycin D. After 0, 3, 10, 20 and 30 hours exposure, RNA was 
isolated using Tri reagent (Sigma-Aldrich). The concentration of the RNA samples was 
determined as described in section 2.2.3 and its integrity determined by 
electrophoresing 10//g of total RNA from each sample on 1% Agarose gels with lx
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MOPS (0.04 M Morpholinopropanesulfonic acid (free acid); 0.01 M Na-acetate-3 x 
H20; lmM EDTA; adjusted to pH 7.2 with NaOH) and 2% formaldehyde running 
buffer.
5.2.3 MDRI RT-PCR
Total RNA was converted into first strand cDNA using a Superscript II kit (Invitrogen). 
Briefly, 5//g of total RNA was mixed with 75pmoles Oligo(dT) and 0. lmM dNTPs in a 
total volume of 12/d, heated at 65°C for 5 minutes, then chilled on ice. 0.1 volumes of 
10X First strand buffer, DTT to a final concentration of lOmM and 40 units of RNasin 
(Promega) were added and reactions incubated at 42°C for 5 minutes. 200 units of 
Superscript II (Invitrogen) was then added and reactions mixed by gentle pipetting, 
before incubation at 42°C for 50 minutes, followed by a 70°C incubation for 15 minutes 
to inactivate the enzyme.
The first strand cDNA samples were amplified using a forward primer RT1 (5’ 
CAAAGAAGCAGAGGCCGCTG 3’) that is homologous to a sequence in exon I and a 
reverse primer, RT3 (5’GAAAATACACTGACAGTTGG 3’) that is complimentary to 
a sequence in exon 3. The expected product from these primers is 227bp. As an internal 
control, (3-actin cDNA was amplified in the same reaction as MDRI cDNA using the 
forward primer AF (ATGGATGATGATATCGCCGC) and the reverse primer AR 
(CGTACATGGCTGGGGTGTTG) to produce a 400bp product.
In initial optimisation experiments, primer concentration and cycle numbers were varied 
to ensure amplification was in the linear phase for both MDRI and (3-actin. However, 
final PCR reactions were carried out in 20/d total reaction volumes containing lx 
AmpliTaq, buffer (Roche), 1.5mM MgCl2, 200//M dNTPs, 1/yM RT1 and RT3 primers, 
0.25//M AF and AR primers, 0.05 units of AmpliTaq DNA polymerase (Roche) and 1/d 
of cDNA. Reactions were amplified using the following PCR parameters {94°C/2min, 
55°C/lmin, 72°C/1 min} x 1 cycle the (94°C/1 min. 55°C/1 min, 72°C/1 min} x 25 cycles 
with a final extension of 72°C for 7 minutes. Amplified reactions were run on 2% 
agarose, IX TBE gels. Densitometry was performed on gels and the amounts of MDRI
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cDNA and /3-actin PCR products were determined by image analysis. The levels in 
individual samples were normalised by the following calculation,
MDRI cDNA intensity
13-actin cDNA intensity
To determine the MDRI mRNA half life, normalised MDRI cDNA levels were 
expressed as a percentage of the zero time point, and values were plotted against time.
5.3 RESULTS
5.3.1 Optimal Actinomycin D concentration
In order to measure the MDRI mRNA half-life following actinomycin D inhibition of 
transcription, it was first necessary to measure the concentration of actinomycin D 
required to produce greater than 95% inhibition of RNA transcription in each cell line. 
This was tested by exposing the cells to serially increasing concentrations of 
actinomycin D for two hours, then pulsing cells with [3HJuridine and measuring the 
reduction in |3H|uridine incorporation due to actinomycin D treatment, compared 
against untreated controls for each cell line. As shown in Figure 5.1, pH| incorporation 
into RNA was inhibited greater than 95% by a concentration of 4/,/g/ml of actinomycin 
D in both the K562 and K/EPR cell lines.
5.3.2 MDRI mRNA half life
K562 and K/EPR cells were treated with epirubicin for 3 days, and, following a short 
recovery period, assayed for sensitivity to paclitaxel. As was seen previously, K/EPR 
cells are stimulated to a higher MDR level upon drug exposure, whereas epirubicin 
treatment had no apparent effect on sensitivity to paclitaxel in K562 cells (Figure 5.2).
The untreated and epirubicin treated K562 and K/EPR cell lines, were then exposed to 
4/,/g/ml of actinomycin for 0, 3, 10, 20 and 30 hours and RNA isolated from the cells at 
each time point (Figure 5.3a). The levels of MDRI mRNA were determined by reverse 
transcription PCR and normalisation with co-amplified [3-actin mRNA. In order to





Actinomycin D concentration (pg/ml)
Figure 5.1 Optimal actinomycin D concentration for K562 and K/EPR cells. K562 (□) 
and K/EPR (A) cells were exposed to serially increasing concentrations of actinomycin 
D for two hours then pulsed with 13HJuridine and the reduction in 13HJuridine 
incorporation due to actinomycin D treatment was compared against for each cell line 
and the 95% inhibitory concentration determined.
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Figure 5.2 The effect of short-term drug exposure on the K562 and K/EPR cell lines. 
The drug treated K562 (■) and K/EPR cells (A) were assayed for their resistance to 
paclitaxel and compared to untreated K562 (□) and K/EPR (A) cells. Points are the 
mean of triplicate wells and bars are the standard deviation.
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ensure both the MDRl cDNA and (3-actin cDNA were in the linear phase of 
amplification, several optimisation experiments were carried out whereby the 
concentration of the primers and the number of PCR cycles were varied. PCRs were 
performed using 0.25//M or 0.5//M of (3-actin primers and a constant 1/fM of MDRl 
primers, and all reactions were run at 5, 10, 15, 20, 25, 30, 35x PCR cycles. From this it 
was determined that 0.25//M of the (3-actin primers, 1//M of the MDRl primers in a 25x 
cycle PCR reaction resulted in linear amplification of both MDRl and (3-actin cDNA 
(results not shown).
The resulting RT-PCR products for MDRl and (3-actin can be seen in Figure 5.3b. No 
MDRl RT-PCR product was observed for either untreated or epirubicin treated K562 
cells, however MDRl RT-PCR product was seen in both the untreated and epirubicin 
treated K/EPR cells (Figure 5.3b). Determination of the levels of MDRl RT-PCR 
product, normalised with the (3-actin internal control reveals higher MDRl mRNA 
levels in epirubicin treated K/EPR cells compared to untreated K/EPR cells, consistent 
with the previous demonstrations of mRNA levels in Chapter 2. As shown in Table 5.1 
the relative amount of MDRl mRNA in epirubicin treated versus untreated K/EPR cells 
was similar to the relative difference in resistance to paclitaxel exhibited by these cells 
(see Figure 5.2).
However upon graphing the normalised levels of MDRl mRNA as a percentage of 
mRNA remaining against time (Figure 5.3c) no difference in MDRl mRNA half life is 
apparent between the treated and untreated cells, with the half life determined to be 
approximately 12.5 hours for both untreated and epirubicin treated K/EPR cells. The 
results of these experiments suggest that an increase in MDRl mRNA stability is not the 
mechanism for induction of a higher level of MDR and MDRl mRNA levels after drug 
exposure in the K/EPR cell line. An increase in mRNA stability could be responsible 
for the difference between K562 cells and their derived MDR subline K/EPR, however 
since the levels of MDRl mRMA in K562 cells are too low to measure, even by RT- 
PCR, it was not possible to measure the MDRl mRNA half life in K562 cells.
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Figure 5.3 MDRl mRNA half-life for K/EPR cells before and after Epirubicin 
treatment. K562 and K/EPR untreated and epirubicin treated cells were exposed to 
4/yg/ml of actinomycin D for 0, 3, 10, 20 and 30 hours, (a) Isolated RNA run on 
formamide gels to check integrity, (b) RT-PCR products for (i) pactin and (ii) MDRl. 
(c) [3-actin normalised percentages of MDRl mRNA RT-PCR products remaining after 
actinomycin D treatment of K/EPR (A) and K/EPR epirubicin treated (A) cells.
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K/EPR cells 1 1
Treated
K/EPR cells 2.6 2.9
1. MDRl mRNA RT-PCR product level relative to that of untreated K/EPR cells (taken 
from the data shown in Figure 5.3).
2. Resistance levels shown are relative to that of untreated K/EPR cells and refer to the 
individual IC50 drug concentrations (taken from the data shown in Figure 5.2).
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CHAPTER 6
Discussion
6.1 MDR and its reversible induction in K562 MDR sublines
To solve the problem of multidrug resistance in cancer chemotherapy more has to be 
understood about the underlying mechanisms that cause this phenomenon. This project 
utilised K562 drug sensitive parental cells and several K562 derived MDR sublines as 
an in vitro model of acquired MDRl mediated MDR. The K562 cell line was derived 
from a patient with chronic myeloid leukaemia and is relatively sensitive to 
chemotherapeutic drugs (Lozzio & Lozzio, 1979). P-gp expression in K562 cells is 
generally considered to be negative (Marks et al., 1993; Marks et al., 1996) although 
some investigators believe that these cells have a low level of expression (Hamada & 
Tsurdo, 1986, Yague et al., 2003). In the present study no MDR! mRNA was detected 
either by Northern analysis, or by RT-PCR, thus if MDRl is expressed it must be very 
low.
The MDR sublines used were isolated previously by exposure of K562 cells to 
relatively low levels of drugs such as epirubicin (Marks et al., 1993) and daunorubicin 
(Hargrave et al., 1995). These MDR sublines express P-gp and the drug resistance is 
reversed by modulators of P-gp function, indicating that activation of P-gp expression is 
the cause of the MDR in these cell lines. The levels of drug resistance displayed by the 
K562 MDR sublines varied, with the relative resistance lowest in the K/EC32 cells, 
higher in the K/EPR cells and highest in the K/DNR cells. The comparative levels of
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resistance correlated with the level of the MDRl mRNA in the cells, suggesting that it is 
controlled by varying MDRl transcriptional capabilities in the 3 MDR cell lines. 
However amplification of MDRl gene copy number was ruled out as a possible cause of 
variation in transcription between the MDR cell lines.
Drug resistance in the K562 MDR cell lines was found to decline over time in drug free 
culture. However resistance levels could be restimulated in each of the MDR cell lines 
by a single, short-term, low cytotoxicity, treatment with the original selecting drug or 
other P-gp substrate drug. Furthermore upregulation of resistance in the MDR sublines 
induced by short-term drug exposure was accompanied by increased expression of 
MDRl mRNA. These findings suggest that in some cancer cells, expression of P-gp, 
like that of many proteins with roles in cell detoxification such as liver enzymes, can be 
induced by toxicant substrates to a higher level when required, and decreased after an 
extended period of time without drug stimulation.
In a similar study, Hu et al. (1995) investigated induction of MDRl mRNA by short­
term drug exposure in two CEM/A7 derived cells which, like the cell lines in this study, 
exhibited a low level of drug resistance. One of these cell lines, CEM/A7, had been 
maintained in the presence of a low level of drug, whereas the other, CEM/A7R, had 
been grown for two years in the absence of drug. The CEM/A7R cell line was shown by 
flow cytometric analysis with MRK16 antibody to have decreased P-gp expression 
compared to the CEM/A7 cells, and this was accompanied by a decrease in drug 
resistance. Cells from both cell lines were then subjected to short term drug exposure 
with the anthracyclines epirubicin, daunorubicin or doxorubucin which resulted in an 
increase in drug resistance in the CEM/A7R ceil line but not in the CEM/A7 cell line, 
which had been maintained in drug.
The decline of MDR levels with time in culture in the absence of drug and re­
stimulation upon drug exposure, may also occur in clinical cancer treatment. Patients 
who at first sight appear not to be expressing P-gp may respond to an initial 
chemotherapeutic treatment. However chemotherapy failure upon subsequent relapse, 
may be due to an induction of P-gp expression, and hence MDR, in the cancer cells
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caused by the first drug treatment, thereby enabling the cancer cells to resist 
cytotoxicity from subsequent drug treatments (Hu, et al., 1995; Nooter and Herweijer, 
1991).
In this study, only P-gp substrates were able to induce MDRl expression, with no 
induction seen with the non-Pgp substrate drug cisplatin. A possibility for the apparent 
failure of MDR induction by cisplatin could be the reported sensitisation to paclitaxel of 
cisplatin resistant cells. Yamamoto et al., (2000) demonstrated that KFrl3, a cisplatin 
resistant human ovarian carcinoma cell line, acquired increased sensitivity to paclitaxel, 
compared with its cisplatin sensitive parental Kfr28 cell line, thus suggesting that 
cisplatin sensitises the Kfrl3 cells to paclitaxel. Therefore it is possible that in K562 
MDR cell lines an induction of MDR could be masked in cisplatin treated cells by using 
paclitaxel to assay any changes in cell resistance. However vinblastine cytotoxicity 
assays performed on cisplatin treated cells also indicated no induction of drug 
resistance, confirming that cisplatin did not induce MDR! activity in our model.
In contrast to the inducibility of drug resistance in the K562 MDR sublines, treatment of 
the parental K562 cells with a similarly low cytotoxicity dose of epirubicin, had no 
effect on sensitivity to the MDRl substrate paclitaxel. Thus the absence of MDRl 
mRNA, and inability to be induced by short term drug exposure, indicates a 
fundamental difference between the K562 cells and its derived MDR sublines. This 
would mimic the situation of a cancer that responded to multiple chemotherapy rounds, 
perhaps only failing after a further mutation led to the activation of MDRl expression 
and development of an MDR cancer. This is an apparent contradiction to a previous 
study by Chaudary and Roninson (1993) which indicated that transient treatment with 
the non P-gp substrate drug cisplatin, induced MDR levels and increased MDRl mRNA 
in K562 cells. However in the latter study, K562 cells were treated with a much higher 
and more cytotoxic dose (2 days with 3/^g/ml cisplatin) than we used here on K562 
derived K/EPR MDR cells (16 hours with 0.5//g/ml). De Jongh et al., (2001) 
demonstrated an average peak plasma concentration of cisplatin less than 0.7//g/ml in 
patients receiving 70mg/nr of cisplatin. Similarly, Gelderbloom et al., (2001) found a 
maximum unbound cisplatin concentration of 0.81//g/ml in patients treated for three
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hours with 70mg/m2 cisplatin. Thus it is possible that the increase of MDR after high 
level cisplatin treatment seen by Chaudary and Roninson (1993) could have resulted 
from a mutational change in the K562 cells resulting in production of an MDR cell line. 
Alternatively it may result from a general stress response mechanism that stabilises 
MDRl mRNA, rather than as a result of increased MDRl transcription. It is therefore 
possible that highly cytotoxic cisplatin treatment could activate MDRl expression in the 
normally non-expressing K562 cells, as well as K562 derived MDR cell lines.
Recent studies have demonstrated that rifampicin, which induces intestinal activity of 
cytochrome P450, can also induce MDRl. Cytochrome P450 is mainly found in human 
liver, the main organ involved in drug and toxin removal, but a large amount is also 
found in the small intestine and it is also present in pancreas, brain, lung, adrenal gland, 
kidney, bone marrow, mast cells, skin, ovary and testis (Chang and Kam, 1999). Using 
immunohistochemical staining and Western blots, Greiner et al. (1999) demonstrated 
induction of intestinal P-gp in vivo by taking duodenal biopsies in 8 healthy people 
before and after they were administered rifampicin. Westphal et al. (2000), using RT- 
PCR, showed increased MDRl mRNA expression in 6 out of 8 duodenal biopsies from 
healthy volunteers after administration of rifampicin, although all 8 of the biopsy 
samples showed increased P-gp protein levels in both immunohistochemistry and 
Western blot assays.
In a similar study Gieck et al. (2001) demonstrated rifampicin induction of MDRl in a 
time and concentration dependant manor in LS174T cells, a human intestinal cell 
model. An SXR nuclear response element located -7852 to -7837bp upstream of the 
MDRl promoter was identified as essential to MDRl induction by rifampicin (Geick et 
al., 2001). However in the current study rifampicin had no effect on resistance in the 
K/EPR cell line, thus it is possible that induction of P-gp by rifampicin is selective to 
the intestines or gut wall or to tissues of high cytochrome P450 expression.
6.2 Transcriptional regulators of MDRl
The most immediately obvious candidate for mediating reversible induction of MDRl 
mRNA upon exposure to P-gp substrates is transcriptional activation. Numerous
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studies have indicated that an inverted CCAAT box (Y-box) located in the sequence 
between -93 and -68 upstream of the transcription initiation site has an important role 
in MDRl gene transcription (Hu et al., 2000; Jin and Scotto, 1998; Ohga et al., 1998; 
Ohga et al., 1996; Sundseth et al., 1997; Goldsmith et al., 1993; Asakuno et al., 1994) 
however there are conflicting reports regarding the identification of the Y-box binding 
factor involved in regulation.
Studies of the KB cell line stably transfected with MDR1.CAT reporter constructs 
demonstrated that exposure to UV or cytotoxic drugs caused an increase in MDRl 
promoter activity (Asakuno et al., 1994; Uchiumi et al., 1993). Exposure to cytotoxic 
agents such as cisplatin and UV light also caused an increase in YB-1 mRNA levels 
(Ohga et al., 1996). In 1998 Ohga and colleagues demonstrated that the increases in 
MDRl promoter activity resulting from exposure of the MDRECAT transfected KB 
cells to cytotoxic drugs or UV irradiation was decreased by transfection with a YB-1 
antisense expression plasmid. However no effect on promoter activity was seen on 
transfection with antisense YB-1 in KB cells that had the Y-box deleted from the MDRl 
promoter (Ohga et al., 1998) suggesting that interaction of YB-1 with the Y-box in KB 
cells is important for genotoxic stress induction of MDRl. A previous report that 
deletion of the Y-box from an MDRl promoter construct had no effect on promoter 
activity on KB cells Cornwell (1993), indicated that the Y-box sequence is not essential 
for normal MDRl transcription in these cell lines.
However, in contrast to these results, other reports have indicated that the Y-box is 
essential for normal transcription and that the factor, NF-Y, binds to the Y-box in the 
MDRl promoter (Hu et al., 2000; Jin & Scotto, 1998; Sundseth et al., 1997). For 
example Sundseth et al., (1997) reported that in tumour cell lines HCT116, HepG2, 
KB3-1 and Saos2, NF-Y, and not YB-1 binds to the Y-box elements on the MDRl 
promoter. It was also shown that a double point mutation in the Y-box sequence 
between -89 and -70 reduced activity of the promoter by 5-10 fold. Thus in these cell 
lines the Y-box appeared to be essential for maintaining normal MDRl activity. Similar 
results were found in a study on SW620 colon carcinoma cells and 2780 ovarian 
carcinoma cells, where deletion or mutation if the sequence between -89 and -70
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resulted in a decrease in promoter activity of 5-10 fold (Goldsmith et al., 1993). Thus 
the role of the Y-box in MDRl regulation, though clearly important, appears unclear. In 
some cells it appears to be constitutively essential to MDRl activity and in others to 
mediate upregulation of MDRl in response to genotoxic stress. It was therefore 
speculated by both sides that the Y-box binding factor interacting with the MDRl Y- 
box may differ in different cells lines and that inherent differences in the cell lines may 
be the reason (Ohga et al., 1998; Sundseth et al., 1997). For example the HCT116, 
HepG2, and Saos2 tumour cells used by Sundseth et al., (1997) have inherently high 
MDRl expression and the presence of the Y-Box was found to be essential in these cells 
for basal transcription of MDRl. KB cells however are induced to a higher level of 
MDRl expression as a result of genotoxic stress on the cells and thus the Y-box in KB 
cells may be important for stress induction and not basal transcription of MDRl.
However a more recent study by Hu et al., (2000) has challenged this by re­
investigating the Y-box binding factor involved in activation of MDRl by UV 
irradiation in KB-3-1 cells. As with the previous studies Hu et al., (2000) found that the 
CCAAT box was required for activation of MDRl transcription by UV light. However 
unlike the previous work, an anti-NF-Y antibody and an anti-YB-1 antibody was used 
in EMSAs to identify the Y-box binding protein interacting with a double stranded Y- 
box probe. Results from this indicated that NF-Y bound to the Y-box and not YB-1. In 
the present study it was also demonstrated by gel supershifting with anti-NF-YA 
antibody that the factor binding to the Y-box in K562 derived MDR cells is NF-Y.
YB-1 has been shown to preferentially bind to single stranded DNA (Hasegawa et al., 
1991; Kolluri et al., 1992; Tafuri and Wolffe, 1992; MacDonald et al., 1995; 
Bayarsaihan et al., 1996; Mertens et al., 1997; Ohmori et al., 1996; Kloks et al., 2002). 
However EMSAs using a single stranded YB-1 binding sequence showed no specific 
binding of nuclear factors from our K562 or K/EPR MDR subline to the single stranded 
oligonucleotide. This gives further support for the identification of NF-Y, and not YB-1 
binding to Y-box in the MDRl promoter of K562 derived cell lines. However, the 
induction of MDR levels and MDRl mRNA in the K562 derived MDR cell lines upon
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drug treatment does not correlate with increased nuclear NF-Y levels in these cells as 
measured by EMSAs performed on protein extracts isolated from drug treated cell lines.
It has been recently shown that MDRl induction in some cell lines can be inhibited by 
treatment with the novel anti-cancer drug Ecteinascidin-743 (ET-743), derived from the 
murine tunicate Ecteinascidia turinata (for review see Scotto 2002). Whilst MDRl 
activation is inhibited by ET-743. basal transcription levels of the gene appear to remain 
relatively unaffected (Jin et al., 2000). A study by Bonfanti et al. (1999) examined the 
affect of ET-743 on the binding of various transcription factors to their DNA consensus 
sequences by pre-incubating the factors of interest with ET-743 and then looking for in 
vitro binding inhibition by EMSA with the DNA consensus sequences. Both Spl and 
NF-Y were included in this investigation. Of the transcription factors assessed, the 
binding of TATA binding protein (TBP), E2F, and SRF were found to be inhibited by 
50 - 300pM ET-743. More interestingly, NF-Y was inhibited by ET-743 at a 
concentration as low as 10-30pM ET-743. Thus these results suggest NF-Y binding to 
the Y-box is a target for ET-743 inactivation of gene induction.
Spl binding however was found not to be affected by ET-743. Jin et al., (2000) 
demonstrated that SW620 colon carcinoma cells transfected with an MDRl/luciferase 
reporter construct and exposed to either TSA, sodium butyrate or UV irradiation 
showed increased MDRl promoter activity. However, this increased MDRl promoter 
activity was abolished in the presence of 50nM ET-743, which is a physiologically 
relevant concentration. This outcome was also reflected in nuclease protection assays on 
the RNA from SW620 cells exposed to MDRl inducing agents for 24 hours with, and 
without the presence of ET-743 (Jin et al., 2000). Induction of MDRl expression seen 
after treatment with TSA or sodium butyrate was abrogated in the presence of ET-743. 
Previously, MDRl induction by these agents in this cell line have been shown to be 
mediated through interaction of NF-Y and the -93 and -68 MDRl promoter Y-box (Jin 
and Scotto, 1998). However EMSAs using nuclear extract from untreated and ET-743 
treated SW620 cells showed no difference in NF-Y levels (Jin et al., 2000). A similar 
study also concluded levels of NF-Y binding to the HSP70 gene promoter, which is also 
an inducible promoter inhibited by ET-743 and has two NF-Y activated Y-boxes, was
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unchanged with ET-743 treatment (Minuzzo et al., 2000). These studies, together with 
the current study demonstrate that, whilst NF-Y binding to the Y-box may be required 
for induction, changes in NF-Y levels per se are not responsible for MDRl drug 
induction. This however does not go to say that NF-Y plays no role in MDRl up- 
regulation, it is possible that up-regulation could be mediated by changes occurring to 
factors acting either directly or indirectly on NF-Y.
6.3 GC box binding protein involvement in MDRl activation
As for NF-Y, the levels of the factor binding to the -55GC box also did not differ 
between K562 and the K/EPR MDR cell line and did not change after drug exposure. 
The -55GC box is one of several GC boxes found within the MDRl promoter, however 
it appears to be the most essential in terms of basal transcription (Cornwell and Smith, 
1999a, Sundseth et al., 1997). Evidence for this comes from mutation and deletion 
experiments on the region containing the -55 GC box. In the case of both deletion and 
mutation a significant reduction in promoter activity was observed, and in one instance 
a point mutation in the -55 GC box gave a 60-70% decrease in promoter activity 
(Sundseth et al., 1997). Spl is an activator of many promoters and is believed to 
behave as an activator of MDRl transcription through binding at the -55 GC box. This 
has been demonstrated by co-transfecting an MDRl-Iuciferase reporter gene with either 
an Spl cDNA construct or vector control into cells that do not express Spl. Results 
from this experiment showed that the MDRl promoter was activated 15 fold higher in 
the presence of Spl compared to the vector only control construct (Cornwell and Smith, 
1999a).
High levels of expression of the -55 GC box binding factor Spl have been demonstrated 
in some human cancers, for example Kitadai et al., (1992) demonstrated Spl mRNA 
expression in 12 out of 18 tumours at levels higher than normal mucosa. Likewise, 
Lietard et al., (1997) found increased Spl levels in human hepatocellular carcinomas. 
Although increased levels of Spl have not been seen in the K562 MDR cell lines in this 
study, the absolute levels of Spl in the cells may not be critical to regulation of MDRl 
transcription. For example the -55 GC box in the MDRl promoter contains overlapping
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Spl and Egrl motifs. Egrl is a member of a family of transcription factors known as 
early growth response (Egr) factors. Recombinant Egrl has been shown to bind the -55 
GC box region (Cornwell and Smith, 1999a) and participates in MDRl regulation in 
some phorbol ester sensitive cell lines (McCoy et al., 1995). Overlapping Spl and Egr-1 
motifs are found in a number of genes. In the majority of genes containing overlapping 
Spl/Egr 1 sites, Egr-1 binds with higher affinity than Spl, thus when present, inhibits 
Spl binding (Cui et al., 1996; Ebert and Wong 1995; Khachigian et al., 1995). The 
exact interaction of Egr-1 and Spl with the MDRl -55 GC box is not yet understood 
(Cornwell and Smith, 1993a). Sp3 is another member of the same family of 
transcription factors as Spl and is able to bind to the same recognition sequence as Spl. 
Unlike Spl, which is predominantly a transcriptional activator, Sp3 can act as either a 
represser or an activator (for review see Philipsen and Suske, 1999). In many genes Sp3 
can compete for binding with Spl and thus repressing Spl mediated transcriptional 
activation of that gene. Therefore it is possible that in the case of MDRl, where Spl is 
essential for basal transcription, the relative abundance of the Spl and Sp3 may be 
involved in transcriptional regulation.
6.4 NRE binding protein involvement in MDRl activation
Negative regulation of the MDRl promoter via an NRE containing a CAAT-like motif 
at - I 18 to -1 13 was identified in an MCF-7 breast cancer cell line where deletion of the 
CAAT motif resulted in a 12-fold activation of MDRl in MCF7 cells, but had little 
effect in an MDR MCF-7/Adr cell line (Ogretmen and Safa, 1999). Consistent with the 
absence of repression in the MCF-7/Adr cells the NRE binding protein, identified as a 
hybrid NF-kB/p65-cFos factor, was detected by EMSA analyses in MCF-7 cells but not 
in MCF-7/Adr cells. However results from the current study indicate that this is not the 
case in K562 derived cell lines as the protein complex binding to this NRE is present at 
similar levels in both K562 and K/EPR cells.
The finding that nuclear levels of NF-Y, SP-1 and NRE-binding complex are present at 
equivalent levels in drug sensitive K562 cells as in derived MDR sublines indicates that
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changes in levels of these factors alone is not responsible for up-regulation of MDRl 
transcription and P-gp. However, as stated previously in section 3.3.5, the binding or 
transactivation ability of transcription factors in vivo may be influenced by protein- 
protein interactions or specific modification of binding factors. Hence, reporter gene 
studies were carried out.
6.5 MDRl transfection studies
6.5.1 MDRl promoter
In transfection studies, the -88/+76 MDRl promoter reporter, which contains the Y-box 
and the GC box, was equally effective in driving reporter gene expression in K562 cells 
as it is in K/EPR cells. This indicates that differential transcription factor interactions at 
either of these two sites are not important in determining the differential expression of 
P-gp in these cell lines. Moreover differential transcription factor interactions at either 
of these two sites were not increased upon drug treatment, despite increase in MDRl 
mRNA in K/EPR cells by drug treatment.
6.5.2 Downstream region
Studies from this laboratory have indicated that the downstream region of the MDRl 
promoter may contain negative regulatory elements in the +283/+392 and +329/+455 
regions. Although the 2 constructs have a 63bp overlap, to confirm the exact location of 
this repressor element, further transfection studies using need to be performed to 
determine whether the regulatory element is present the region common to both 
constructs, or if there is more than one negative regulatory element within the 
downstream region. Previous in vitro footprinting studies have the presence of 3 
footprints within the +283/+455 region of the MDRl promoter (Desiderato, PhD thesis, 
1999). Although it is not known what proteins bind to these footprinted regions, Sigscan 
analysis of the sequence indicates that several transcription factors have consensus 
sequences within the footprinted regions and that many of these have been shown to be 
involved in negative regulation of genes. Examples of these transcription factors include 
LBP-I (Parada et al., 1995), AP-2 (Jiang et al., 2000), NF-1 (Li et al., 1997), Spl and 
Spl family members (GKLF, TIEG2, BKLF, EKLF, AP-2rep) (Lania et al., 1997;
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Philipsen and Suske, 1999) and CF-1 (Zwicker et al., 1997). When K/EPR cells were 
transfected with the constructs containing the +283/+392 or +329/+455 regions, 
promoter activity was seen to be clearly repressed compared to cells transfected with the 
promoter construct alone.
6.6 Effect of TSA on MDR levels
Differences in the levels of histone acetylation and chromatin structure in sensitive and 
drug resistant cell lines may result in increased or reduced DNA accessibility to 
important MDRl promoter transcription factors and hence levels of MDRl 
transcription. As previously outlined in section 1.3, the balance of histone 
acetyltransferases and deacetylases can determine the resulting amount of histone 
acetylation, and thus whether a gene is active or transcriptionally silent (Wolffe, 1996). 
Originally isolated as an antifugal antibiotic from Streptomyces hygroscopicus (Tsuji et 
al., 1976), TSA has been shown to induce cell differentiation, cell cycle arrest and 
reversal of transformed cell morphology (Yoshida et al., 1995). TSA is a known 
specific inhibitor of histone deacetylase (Yoshidai et al., 2001).
In the previous study by Jin and Scotto (1998), SW620 human colon carcinoma cells 
were treated with 300nM TSA. RNase protection assays using RNA extracted from 
these cells at various time points showed that increased MDRl mRNA levels were 
observed after 6 hours of TSA exposure. This study also demonstrated in SW620 cells 
stably transfected with an MDRl/luciferase reporter construct (containing sequence 
from -1202 to +1 18 of the MDRl promoter) promoter activity increased 10 to 14 fold 
after the cells were exposed to TSA. Mutation studies of MDRl promoter sequences in 
SW620 cells transiently transfected with MD/?//luciferase constructs went on to 
indicate that in this cell line, an intact Y-box and the transcription factor NF-Y was 
essential for the induction response of the MDRl promoter to TSA (Jin and Scotto, 
1998), indicating that in those cell lines, histone acetylation levels around the Y-box are 
controlling features.
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In this study, a 16 hour exposure of K562 cells to 50nM or 200nM TSA resulted in a 
two fold increase in the epirubicin drug resistance of these cells. The effect of TSA 
exposure to K562 cells suggest that, in the usually sensitive K562 cells, TSA exposure 
created an alteration in the ratio of histone acetyltransferase and histone 
deacetyltranferase, whereby inhibition of histone deacetylases lead to increased 
epirubicin resistance possibly due to increased acetylation and subsequent activation of 
MDRl in these cells. In contrast to this, there was no associated increase of epirubicin 
resistance after 16 hour TSA treatment of the MDR K/EPR cell line, possibly due to the 
cells already having a higher level of acetylation than the K562 cells.
6.7 Methylation status of the MDRl promoter
DNA methylation of key promoter sites has been implicated in transcriptional 
regulation of many genes (Bird, 1992). Bisulphite genomic sequencing of K/EPR cell 
DNA showed that this cell line was completely unmethylated at all CpG sites in the 
promoter region from - 462 to +782bp. The corresponding results for K562 cell DNA 
showed there were two distant downstream sites methylated. The presence of this small 
amount of methylation is unlikely to cause wholesale promoter heterochromatinisation. 
EMSA studies on this region showed a DNA protein complex binds to this region in 
both cell lines was present in both cell lines. It is possible that this protein may not be 
able to bind in vivo in the K562 cells due to the methylation in this region. To ascertain 
this, in vivo foot printing could be performed on both cell lines.
In a previous study it was reported that CpG sites at -1 1 1 and -106, close to the CAAT 
containing NRE (-1 18 to -1 13) and to a further possible NRE reported in KB-8-5 cells 
at -1 10 to -103 (Cornwell and Smith 1993) were methylated in MDR K562/ADM cells 
and unmethylated in the drug sensitive parental K562 cells (Ando et al., 2000). The 
authors suggested that activation of MDRl in the K562/ADM cells was due to 
methylation of these sites and hence decrease in accessibility to the -110 repressor 
binding site. However, in the latter study, only 4 of 20 K562/ADM clones sequenced 
were found to have this methylation, and these clones were reported to be methylated at
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all 28 CpG sites tested (from -389 to +231 bp) and thus will undoubtedly not express 
MDRl at all, due to chromatin condensation and inhibition of transcription factor 
binding. It appears likely that those particular four clones were revertants to methylated 
and MDRl silenced, drug sensitive clones. Cell lines in culture appear able to become 
methylated (or unmethylated according to circumstance) relatively readily and care 
must be taken to ensure they continue exhibiting the selected phenotype.
Other studies have reported partial methylation of site 8 (-184bp) in K562 DNA and 
partial methylation of sites 1 (-367bp) and 3-6 (-331 to - 220) in a K562/ADM cell line, 
however the number of clones on which this was based was not stated (Efferth et al., 
2001). Partial methylation at sites 9 (-145) 17 (-30) and heavier methylation at 
downstream sites from 28 (+21 1) to 41 (+397) were also reported in 4 to 7 clones from 
K562 cells (Frxyeli et al 1999). As stated above methylation can vary with cell line 
culture history and so patterns will not necessarily be identical in different laboratories, 
however all the data reported, including the more extensive data reported here, indicates 
there is no evidence for local, methylation directed heterochromatinisation and silencing 
of the MDRI gene in K562 cells.
6.8 Stability of MDRl mRNA in K562 MDR sublines
It was recently reported that for some K562 derived MDR cell lines, different from 
those used in the current study, P-gp regulation was mediated by post-transcriptional 
mechanisms, namely mRNA stability (Yagiie et al., 2003). Yagiie et al., (2003) reported 
that short term exposure of K562 cells to cytotoxic drugs resulted in increased levels of 
MDRl mRNA in the treated cells. Using actinomycin D to inhibit transcription, these 
authors reported that this increase in MDR! mRNA in K562 cells was due to increased 
mRNA stability and not transcriptional activation. In contrast, in our studies MDRl 
mRNA was undetectable in K562 cells, both before and after drug treatment. It is 
possible that in K562 drug treated cells the levels although increased were still too low 
to measure by RT-PCR. However, drug treatment of the K562 cells also resulted in no 
increase in MDR levels and thus, even if MDRl mRNA was stabilised, it did not result
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in significant changes in P-gp expression. Such an occurrence would be consistent with 
the results reported by Yagiie et al., (2003) since they could not demonstrate any 
increase in P-gp expression in K562 drug treated cells.
The Yagiie et al., (2003) study differs from the current study specifically in respect to 
the levels of drugs used in the induction of MDR in K562 cells. To test drug induction 
of MDRl in K562 cells Yagiie et al., (2003) exposed K562 cells for 3 days to various 
cytotoxic drugs, including vinblastine. The concentrations used for these inductions 
resulted in greater than 50% macroscopic change in cell morphology. For example 
K562 cells were exposed to 22uM vinblastine for 3 days, which is approximately 
10,000 fold higher than the vinblastine 1C50 determined in this report (section 2.3.1). 
Although we used epirubicin and not vinblastine to treat K562 cells, the concentration 
of epirubicin used was equivalent to an IC25 for a 3 day assay, which is significantly 
less cytotoxic than the treatment used by Yagiie et al., (2003). It is important to note 
that the increase in MDRl mRNA seen by Yagiie et al., was not accompanied by an 
increase in functional P-gp in these cells, as determined by flow cytometry using U1C2 
and C219 P-gp specific antibodies.
In this study, epirubicin treatment of K/EPR cells did however increase both MDR and 
MDRl mRNA levels in these cells however the rate of the MDRl mRNA decay was the 
same in both the untreated and drug treated cells lines, with the MDR! mRNA half life 
determined to be 12.5 hours. This half life is comparable to the 15-20 hour MDRl half 
life in K562 drug resistant cell lines reported by Yagiie et al., (2003). Thus, in contrary 
to Yagiie et al., (2000), we did not find increased mRNA stability in K562 MDR cells 
after short term cytotoxic exposure.
The K562 MDR sublines used by Yagiie et al., (2003) were developed by a one step 
selection with cytotoxic drugs that resulted in 99.9% cell death after 14 days in culture. 
The K/EPR cell line used here was developed through several intermittent exposures 
over a 2 month period of K562 cells to 20ng/ml (34nM) of epirubicin each for 3 days, a 
concentration which resulted in less than 50% inhibition of cell growth, (Hargrave et
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al., 1995). Unfortunately the Yagiie et al., (2003) paper did not look at induction of 
already drug resistant cell lines with further drug exposure.
The high levels of cytotoxic drugs used by Yagiie may account for the reported 
increased mRNA stability rather than an actual increase in transcription. As discussed 
previously several studies have demonstrated that the levels of the transcription factor 
YB-1 is increased in stress induced cells. Ohga et al., (1996) showed that YB-1 mRNA 
levels increase following genotoxic stress with agents such as cisplatin and UV light. 
All of these studies used relatively high levels of cytotoxic stress on the cells. It is 
possible that high levels of stress increase levels of YB-1. Stein et al., (2001) found that 
when cells were stressed with hyperthermia, YB-1 was translocated to the nucleus and 
this corresponded with an increase in MDRl and MRPl levels. Stein et al., (2001) also 
found that while YB-1 stably transfected HBL-100 cells showed increased MDRl 
promoter driven CAT expression, an increase was also seen in MRPI driven CAT 
expression and the MRPI promoter contains no Y-box motif. It is likely that the YB-1 
had a post-transcriptional involvement in MDRl up regulation. YB-1 is a multifactorial 
protein that may be involved in transcriptional activation and repression, mRNA 
binding, mRNA stabilisation and translational control (Copowski et al., 2001; Didier et 
al., 1988; Steinia et al., 2000; Ansari et al., 1999; Bouvett et al., 1995; Ranjan et al., 
1993; Chen et al., 2000). However, it is thought that YB-1 is more likely to be an RNA 
binding-protein than a double stranded DNA binding protein (Chen et al., 2000). 
Therefore exposing cells to high levels of some cytotoxic drugs may increase the levels 
of YB-1 which in turn binds to and stabilises many different mRNA transcripts.
6.9 Future directions
There are still many unanswered questions regarding the regulation of the MDRl gene 
in the K562 MDR sublines, and indeed other cell lines and cancers in vivo. 
Discrimination between transcriptional and post-transcriptional mechanism can be 
ascertained by performing nuclear run-on experiments, which allow the direct 
measurement of the rate of transcription of a specific gene. These assays work by
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radiolabelling newly synthesised RNA in isolated nucleii (Greenberg, 1987). These 
experiments were previously attempted in the K562 and K562 MDR cells lines, 
however lack of sensitivity failed to produce a reliable result and thus were not 
included. However if the sensitivity of the run-on experiments could be improved then 
these experiments could provide an invaluable insight into the mechanism of MDR! 
regulation in these cell lines.
The binding levels of various transcription factors thought to be involved in the 
regulation of the MDRl promoter were assessed in the K562 and MDR sublines by 
EMSAs. Although no variation was found between drug sensitive and drug resistant cell 
lines, EMSAs only indicate if these binding factors are present in the cell and do not 
actually reflect whether the factors are actually binding in vivo. To determine what 
intracellular DNA-protein interactions are actually occurring in whole cells in vivo 
footprinting could be carried out. In vivo footprinting not only indicates the study of 
which proteins are binding, but also can allow some indication of how protein- DNA 
conformation changes, which all give insight into the gene regulation mechanism of the 
cell (Zaret, 1997). This technique could also reveal the position of nucleosomes and 
thus the chromatin structure of the MDRl promoter. To determine if methylation is 
directly effecting protein binding to the two CpG sites 43 and 44, that are methylated 
only in the K562 cells and not the K/EPR MDR cells, EMSAs using methylated 
oligonucleotides could be performed.
RT-PCR of K562 cDNA failed to detect MDRl mRNA and therefore an MDRl half life 
could not be determined for K562. Real time PCR has far greater sensitivity than RT- 
PCR and may be used to assess mRNA decay rate in K562 and compare it to the 
stability of MDRl mRNA in drug resistant cell lines.
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6.10 Conclusions
The K562 MDR model provided an interesting model for the examination of 
mechanisms that may be a factor in the activation of the MDRl gene in cancer cells. It 
was shown that the K562 derived drug resistance cell lines showed a classical MDR 
phenotype that is due to the expression of the MDRl gene which gives rise to the 
multidrug transporter P-gp. Secondly it was shown that the level of MDR of the cells 
correlated with the level of MDRl mRNA expressed by the cells. However activation of 
MDRl expression and differences in levels of MDRl mRNA between drug resistant cell 
lines was found not to be due to the amplification of MDRl gene copy number. It was 
also demonstrated that the level of MDR and the expression of MDRl in these lines 
could be induced with exposure to P-gp substrate drugs such as epirubicin, 
daunorubicin and paclitaxel, but not non P-gp substrates such as cisplatin or rifampicin. 
Epirubicin and paclitaxel induced the MDR of the cells in as little as 4 hours, suggesting 
that transcriptional activation of the MDRl gene is likely to be occurring after drug 
treatment of the cells. Short term drug treatment with P-gp substrate drugs was not able 
to induce levels of MDR in the parental K562 cells. However, exposure of K562 cells to 
50nM or 200nM TSA increased epirubicin resistance 2-fold in these cells but not to 
K/EPR cells, possibly due to increased DNA acetylation and subsequent activation of 
MDRl in the K562 cells.
The binding of transcription factors to the consensus sequences present in the MDRl 
promoter that have been implicated in the regulation of the MDRl gene were examined 
in the K562 and MDR cell lines by EMSAs. From this it was concluded that the 
transcription factor NF-Y binds to the MDRl Y-box, however nuclear levels of NF-Y 
do not vary between drug sensitive and drug resistant cells and do not change upon 
induction of MDR through drug exposure. The same was conclusion was drawn for the 
protein binding to the -55GC box and the protein complex binding to the - 120 to -112 
NRE.
DNA methylation has long been implicated in the transcriptional regulation of many 
genes so bisulphite genomic sequencing was used to examine the methylation status of
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the MDRl promoter in the K562 and K/EPR drug resistant cell lines. All CpG sites 
tested were unmethylated in the K/EPR cells and only CpG sites 43 and 44 were 
methylated in K562 which a scan for potential transcription factor binding sites revealed 
no apparently significant binding sites were present in this region. From this it can be 
concluded that demethylation of these sites is unlikely to play a role in the activation of 
MDRl gene.
Finally the half life of MDRl mRNA was determined for the K/EPR cells before and 
after drug treatment with epirubicin that induced both MDR and MDRl mRNA levels in 
the cells. The half life was determined to be 12.5 hours for both treated and untreated 
cells thus it can be concluded that increased MDRl mRNA levels found in cells after 
drug induction are not due to post translation mRNA stabilisation.
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